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1 Summary of the Project 
Local excision (LE) of rectal cancer has been practiced as a treatment for 30 years on a highly 
selected group of patients and tumours. A method of local excision which has recently gained 
wider acceptance in the treatment of low-grade CRC (T1) is transanal endoscopic microsurgery 
(TEMS). TEMS offers advantages for operative access and oncological clearance compared to 
those of transanal resection (TAR). A number of studies have shown that TEMS can have 
almost equal results to radical surgery for early rectal cancer. Radical surgery has the 
disadvantage of an approximate mortality rate of 5% and a complication rate of around 20%, 
and it impacts on quality of life due to stomas and of sexual dysfunction. However, TEMS has 
a higher local recurrence rate, and efforts have been made to classify risk with morphological 
and histological criteria.  
Molecular biomarkers in the evaluation of CRC prognosis and treatment stratification have 
been extensively discussed in the literature. Until now, 3 pathways have been identified to 
explain the background of CRC molecular pathogenesis. Microsatellite instability (MSI) refers 
to point mutations in the DNA mismatch repair genes. MSI is currently responsible for 15−20% 
of CRC cases, and there is enough evidence to support its association with prognosis. 
Chromosomal instability (CIN) is another pathway of carcinogenesis which affects 85% of 
CRC cases and has been flagged as a poor prognostic marker. CIN encompasses any structural 
chromosomal abnormality that results in aneuploidy or polyploidy. The third pathway is related 
to aberrant hypermethylation of suppressor promoter CpG islands, commonly known as CIMP. 
v-raf murine sarcoma viral oncogene homolog B (BRAF) encodes a serine-threonine protein 
kinase that acts as a downstream effector of Kirsten rat sarcoma viral oncogene homolog 
(KRAS) pathways.  Various studies have revealed that v-raf murine sarcoma viral oncogene 
homolog B V600E (BRAF V600E) mutations appear to be valid prognostic indicators. KRAS 
is a proto-oncogene that encodes a GTPase, which is involved in facilitating cellular response 
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to extracellular stimuli. KRAS point mutations appear in 40% of CRC cases, and their presence 
is associated with poor response to anti-epidermal growth factor receptor (anti-EGFR) 
chemotherapy.    
However, to date there has been no literature linking biomarkers with stratification of risk for 
the treatment of rectal cancer following TEMS. 
 
Aim: 
The aim of this dissertation is to assess the significance of these molecular biomarkers in the 
prediction of local recurrence and prognosis of early rectal cancer following TEMS.  
 
Materials and Methods: 
Initially, we performed a narrative review of the literature to consolidate the evidence available 
for molecular biomarkers in the evaluation of CRC. We then designed a retrospective pilot 
study to identify the molecular biomarker status of 41 confirmed CRC cases among 1,446 
consecutive referrals for suspected cancer. As part of this study, we retrospectively analysed 
clinical, biochemical, and histopathological data. Gene profile analysis (KRAS, BRAF) of the 
specimens was also performed.  
Following this, we proceeded to analyse data from a series of patients who had undergone 
TEMS for Stage I rectal cancer at King’s College Hospital (KCH). Demographic, biochemical, 
histopathological, and follow-up data were prospectively collected. Molecular analysis was 
prospectively performed in the Advanced Diagnostics Laboratory of KCH to identify the status 
of BRAF, KRAS, p16 O6-methylguanine-DNA methyltransferase (MGMT), and β-catenin.  
Finally, we retrospectively collected equivalent data on a 4-year series of 135 confirmed Stage 
I−IV rectal cancer cases who underwent radical surgery +/- neoadjuvant chemoradiotherapy. 
Data on the status of the same molecular biomarkers were retrospectively collected. In both 
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cohorts of rectal cancer cases (TEMS/radical surgery +/- additional treatment), the biomarker 
status was compared with the histopathology and follow-up outcomes, including recurrence 
and overall cancer-related survival.   
 
Results:  
In our pilot study (41 cases), there was no significant correlation of presenting haemoglobin 
(Hb) levels with eventual disease staging (p>0.05 for all associations). Patients with right-sided 
tumours were found to have a lower Hb level than patients with either left-sided or rectal 
tumours. Hb levels were also significantly lower in patients with the BRAF V600E mutation, 
although this may be because all 3 patients with the mutation had right-sided tumours. Neither 
KRAS status nor lymphovascular invasion (LVI) status had a specific correlation with Hb 
levels. 
Of 29 specimens of cases who underwent TEMS, there was a statistically significant 
association between KRAS mutant status and local recurrence (n=6, p=0.037). P16 expression 
>5% (mean=10.8%, min=0, max=95) was associated with earlier recurrence within 11.70 
months (n=7, p=0.004). Membranous β-catenin expression (n=12, 48%) was also related to 
KRAS mutant (mt) status (p=0.006) but not to survival (p>0.05). BRAF gene was found to be 
wild type in all cases tested (n=23).  
With regard to the specimens of rectal cancer cases who underwent radical excision, 28 cases 
were Stage I (20.9%), n=30; Stage II (22.4%), n=45; Stage III (33.6%) and n=31 Stage IV 
(23.1. KRAS mt status was associated with female gender (n=20, p=0.021) and older age 
(69.62 vs. 62.27, p=0.005). Stage I early cancer subgroup analysis showed that KRAS mt status 
was associated with distant recurrence of disease (n=4, p=0.045). 
 
Conclusions: 
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BRAF V600E mutation seems to be associated with right-sided CRC and iron-deficiency 
anaemia. This could be used as an adjunct to diagnostic molecular tests for early diagnosis. 
KRAS, p16, and β-catenin could be used as biomarkers for prediction of local recurrence and 
stratification of the risk for further surgery in Stage I rectal cancer. Further to this, KRAS may 
be a predictor of distant recurrence in cases of early stage rectal cancer. 
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2 Introduction  
2.1 Anatomy of the rectum 
The rectum is 15–18 cm in length, anatomically extending from the third sacral vertebra to the 
dentate line. It can be divided into thirds: the upper intraperitoneal third (covered anteriorly 
and laterally by peritoneum), the middle third (covered anteriorly by peritoneum), and the 
lower extraperitoneal third. Anteriorly, Denonvilliers’ fascia separates the rectum from the 
posterior vaginal wall in females, and the bladder, the prostate, and the seminal vesicles in 
males. Posteriorly, the rectosacral Waldeyer’s fascia separates the mesorectum from the 
sacrum [1].  
The mesorectum contains blood vessels, nerves, and lymph nodes, enveloped by the fascia 
propria of the rectum. The superior rectal artery (SRA), which is a branch of the inferior 
mesenteric artery, is the main blood supply of the rectum. The SRA is divided into the superior 
haemorrhoidal arteries. The inferior haemorrhoidal arteries normally arise directly from the 
internal ileac artery or sometimes from the middle rectal artery; the venous supply follows the 
arteries. Lymphatic drainage of the rectum is via the inferior mesenteric nodes in the upper 
two-thirds; the lower third lymphatic drainage can vary along the middle rectal vessels [1]. 
In this context, local anatomy access for excision of rectal neoplasms can be challenging [2]. 
Also, the absence of serosa below the peritoneal reflection allows rectal tumours to grow in a 
deeper anatomic plane. This permits invasion towards the perirectal fat, making any attempt 
for surgical access a technical challenge. 
2.2 Rectal cancer – Is it different from colonic? 
Colon and rectal cancer combined (CRC) is the third most common malignancy, with 
approximately 30% of these tumours arising from the rectum [3]. Its incidence in the UK is 
55/100,000 for males and 34/100,000 for females, which has been reduced by almost 10% over 
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the last 25 years[1]. The relative 5-year survival is 55%, and this is inversely related to 
increasing age. 
Rectal cancer results from a complex sequence of events, which involve a step-by step 
transformation of the normal rectal epithelium initially to a dysplastic lesion, and subsequently 
to invasive carcinoma [4]. This process requires the accumulation of either somatic or germline 
mutations over a period of approximately 10–15 years.  The vast majority of CRCs are 
adenocarcinomas. These can be subdivided further as mucinous, signet ring, and medullary 
histological subtypes.  
The epidemiology, diagnosis, staging, genetic profile, and management plan of rectal cancer 
differ significantly from the rest of the CRCs. It is difficult to identify the epidemiological 
features of rectal cancer, as most studies provide information only for combined CRC. In the 
US, of 13,439 cases of CRC, approximately 39,910 (30%) are due to rectal cancer (Rca); 18% 
of Rca cases have a young onset, i.e., age <50 years.  Low socioeconomic level has a stronger 
association with Rca than with right-sided CRC [4] . 
Accurate staging of Rca is the basis of treatment selection, and this will be discussed later in 
this thesis.  Early stage Rca (cT1N0M0) can be treated with endoscopic resection, whereas 
upfront resection is applicable when the size of the lesion does not exceed the muscularis 
propria with negative lymph nodes (cT2N0M0). In the case of locally advanced rectal cancer 
(cT3–T4N0–2M0), neoadjuvant chemoradiotherapy and radical resection are the gold standard 
treatments. Adjuvant therapy can be considered in the case of pathological T3 and above, or 
where there is lymph node involvement [4].   
The distinct embryologic and postnatal development of the proximal and distal colon results in 
a series of different biological characteristics of colonic mucosa; this precipitate different 
responses to various environmental or carcinogenic factors. Further to this, recent data show 
that more than 1,000 genes are expressed differently in the adult proximal versus the distal 
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colon; surprisingly, only 87 genes show a different expression in the fetal ascending versus the 
descending colon [5]. This indicates that additional gene-regulating processes are also taking 
place at this time. As we discuss in detail in Chapter 5, the molecular biomarkers of rectal 
cancer are distinct from those of the rest of the colon. A different embryologic origin, as well 
as a different pattern of gene expression, can affect the significance of certain genes in the 
carcinogenesis pathway. The study “A Comprehensive Molecular Characterization of Human 
Colon and Rectal Cancer” [6], concluded that there are significant differences in 
hypermethylation trends between the right colon (higher trend) and the proximal colon 
including the rectum. As discussed extensively in the last chapter, hypermethylation is one of 
the fundamental events that lead to carcinogenesis. 
With regard to survival rates, recent data support that rectal cancer seems to have a similar 
prognosis to that of colon cancer. A population-based study [7] of 372,130 patients from the 
Surveillance, Epidemiology and End Results Program database (1995–2008) concluded that 
rectal and colon cancer had a similar prognosis, based on a 32-month follow-up window. 
2.3 Rectal cancer and genes 
CRC is generally classified as hereditary and sporadic. The commonest hereditary subtype is 
familial adenomatous polyposis (FAP). FAP is an autosomal dominant condition that affects 1 
in 13,500 members of the general population. FAP is defined as the presence of >100 
adenomatous polyps within the large bowel, and there is an almost 100% risk of developing 
CRC between the third and fifth decades. Lynch syndrome (LS) is another autosomal dominant 
condition associated with CRC [8]. In LS, there is an increased risk of developing synchronous 
endometrial or other types of cancers including breast, small bowel, urinary tract, ovarian, and 
brain cancer. LS is also known as hereditary nonpolyposis colorectal cancer (HNPCC) [8]. 
Other less common hereditary conditions are juvenile polyposis syndrome, Peutz-Jeghers 
syndrome, and MYH-associated polyposis. 
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Sporadic CRC is a multifactorial event in which hereditary, environmental, and other factors 
are involved [9, 10]. Sporadic CRC is more of a developed country’s disease, with North 
America, Western Europe, New Zealand, and Australia having the highest incidences of 
occurrence. Lifestyle plays an important role, with obesity and alcohol consumption being 
directly associated with increased prevalence of CRC. Consumption of 30−45 g/day of alcohol 
can increase the possibility of developing cancer by 16%, and more than 45 g/day is associated 
with a 41% increase in risk. The European Prospective Investigation into Cancer and Nutrition 
(EPIC) has advised that red-meat consumption precipitates a higher risk of CRC, whereas fish 
consumption is protective for its occurrence. Another possible contributing factor is ulcerative 
colitis (UC), which is associated with a higher risk of CRC.  It has been shown that long-term 
consumption of nonsteroidal anti-inflammatory drugs (NSAIDS), including aspirin, may 
reduce the risk of CRC; however, as of yet there is no evidence about the risks and benefits for 
commencing prophylactic aspirin for CRC.  
The progression from normal rectal epithelium to a precancerous lesion and invasive carcinoma 
is a well-recognized pathway, which results from a step-by-step accumulation of certain 
mutations [11]. Initially, the transition between normal and mild dysplastic epithelium involves 
mutations in the APC, bcl-2, and c-myc genes via aberrant hypomethylation of their genes’ 
promoters [11]. Following this, K-ras point mutations trigger a transition from mild to 
moderate dysplasia, which results in severe dysplasia due to the accumulation of SMAD-2, 
SMAD 4, DCC, and STAT3 mutations. This process can take up to 20 years (5–20 years), and 
the lesions that fall into a severe dysplastic genetic profile are still considered to be adenomas. 
Figure 1 shows the detailed transition from normal epithelium to adenoma and then to 
carcinoma. P53 gene mutation, p16 aberrant expression, and various chromosomal aneuploidy 
changes are associated with the step between severe dysplasia and cancer [11].   
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Figure 1.  Adenoma–carcinoma transition. (Imported from BJS [11]) 
 
2.4 Histopathology 
There are several histopathological factors that seem to contribute significantly to the 
evaluation of rectal cancer. Tumour classification, grade of differentiation, tumour budding, 
lymphovascular invasion (LVI), perineural invasion (PNI), and the presence of lymph nodes, 
seem to directly affect prognostic outcomes[3].  
According to a recent consensus by the World Health Organization (WHO), CRC is overall 
divided into certain histologic types, which are summarized in Table 1 [12]; adenocarcinoma 
is the most common type of CRC. 
 
Types of Colorectal Carcinoma (World Health Organization Classification) 
Adenocarcinoma 
Medullary carcinoma 
Mucinous (colloid) adenocarcinoma (>50% mucinous) 
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Signet-ring cell carcinoma (>50% signet-ring cells) 
Squamous cell (epidermoid) carcinoma 
Adenosquamous carcinoma 
Small-cell (oat cell) carcinoma 
Undifferentiated carcinoma 
Other (e.g. papillary carcinoma) 
Table 1.  Types of colorectal carcinoma (WHO classification) [12] 
 
Tumour differentiation grade has been widely used in the literature as a recognised 
histopathological prognostic marker; however, interobserver variability has been reported to 
be an issue. Several systems have been used to grade differentiation [12]; some of them use 
gland formation as a primary differentiating feature, whilst others employ a more complicated 
complex of features to determine the grade of differentiation. Either way, most systems define 
3 or 4 grades: well-differentiated (grade 1), moderately differentiated (grade 2), poorly 
differentiated (grade 3), and undifferentiated (grade 4).    
The presence of LVI in malignant tissue is considered to be an adverse prognostic feature; this 
was confirmed by a College of American Pathologists (CAP) consensus statement in 1999 [13]. 
PNI refers to a complex process in which tumour cells spread along nerve sheaths [14]. Liebig 
et al [15] concluded that PNI is an independent prognostic marker for cancer-specific and 
overall disease-free survival; the survival rate was 75% for PNI-negative tumours, versus 25% 
for PNI-positive. Figure 2 illustrates the different features that pathologists assess for PNI, LVI, 
and tumour configuration and budding.  
As discussed earlier, the mesorectum is a perirectal soft-tissue envelope which contains the 
superior rectal artery and vein, numerous lymphatics, as well as the rectal branches of the 
inferior hypogastric plexus. More importantly, since the introduction of total mesorectal 
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excision in the 1980s [16, 17], pathologists play a key role in the assessment of the mesorectum.  
This can be used as a surgical performance marker, as well as a way to assess the 
circumferential radial margin (CRM) [18]. Table 2 shows the grading of the quality of the 
mesorectum (macroscopic examination) 
 
TME Mesorectum Defects Coning Circumferential 
Radial Margin 
Complete Intact, smooth Not deeper than 
5 mm 
















Table 2 Grading of quality and completeness of the mesorectum in a total mesorectal excision. 
(Imported from [18]) 
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Figure 2: Tumour grade, tumour border configuration, lymphovascular and perineural 
invasion, and tumour budding, (Imported from 
http://atlasgeneticsoncology.org/Tumors/colonID5006.html) 
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2.5 Role of lymph nodes in rectal cancer is unimportant: An argument for MRI 
evaluation of extramural vascular invasion 
Ever since the Dukes era, the presence of lymph node metastasis has been considered an 
adverse prognostic marker in colorectal cancer.  However, this seems to have started to change 
rapidly. A recent review from Nagtegaal et al. has explained the rationale behind this 
statement[19], which is based mainly on the fact that most clones which metastasize in liver or 
lungs are different from those found in LN. This delineates a new perspective for the 
functionality of LN; basically, this argument converts the function of LN to that of “sponges” 
rather than “seeds” of cancer cells.  
Nagtegaal et al. based their critical reconsideration of LN functionality on a recent study. 
Naxerova et al. [20] examined the evolutionary relationship between the primary tumour, the 
lymph nodes, and distant metastases, based on 217 biopsy samples from 17 patients. Naxerova 
et al. used somatic variants with hypermutable DNA to reconstruct phylogenetic trees (Figure 
3). Their conclusion was that in 65% of the cases, distant liver or lung metastases arose from 
different subclones of primary cancer cells, whereas in only 35% they came from the same 
clones. Hence, this can be a robust argument for consideration of a different function of LN, 
primarily as a protective mechanism preventing lateral pelvis spread, rather than as spreading 
avenues. Based on this theory, measurement of the size of lymph nodes in the MRI preoperative 
scan would not increase the accuracy of prognosis. Further to this, the presence of large lymph 
nodes can result in a favourable outcome, especially in the case of stage I/II disease [21]. This 
strengthens the argument that lymph nodes are involved in the immune system against cancer 
cells. If this is the case, then which route is the main mechanism for disease spread? 
Although vascular spread of rectal carcinoma has been considered for a long time [22], only 
recently has it begun to be considered as the primary mechanism of rectal disease spread. 
Initially, cancer cells spread laterally from the pelvic sidewall to the mesorectal margins, 
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causing local recurrence. Then, they disseminate within the pelvis, entering the peritoneal 
cavity and metastasizing to the liver via the portal vein. Extramural vascular invasion (EMVI) 
can be detected by MRI and scored accordingly [23]. In MRI-EMVI–positive cases, the 
multivariate OR for development of liver metastases is 4.74 (2.06–11.00) [23]. This statement 
supports the hypothesis of vascular spread mechanism of cancer cells and is also a potential 
indirect argument for the protective role of LN. On the MRI scan, detection of EMVI post 
chemoradiotherapy (CRT) can be a more accurate prognostic marker than that of other 
histopathological parameters [24, 25]. Based on this, downgrading from EMVI-positive to 
EMVI-negative status post CRT predicts a favourable survival outcome [25], Despite this 
promising theory, identifying EMVI status on MRI scan or pathology specimens still requires 
expertise and education to improve sensitivity and specificity. 
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Figure 3.  Sixty-five percent of the distant (liver/lungs) and lymph node metastases arose from 
different subclones of primary cancer cells, whereas only 35% of the metastases arose from the 
same clone. [20] 
 
 
2.6 Classification of early rectal cancer 
Prior to focusing on the classification of rectal cancer, it is essential to define what we refer to 
as “early rectal cancer” (ERC). According to the clinical consensus conference of the European 
Association for Endoscopic Surgery (EASES) [26], ERC is defined as a rectal cancer with good 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 35 
prognostic features, that can be safely removed with tissue-sparing techniques and can provide 
good overall survival with limited risk for relapse after surgery.  
Tumour node metastasis (TNM) staging is the current gold standard for staging protocols. 
Although Dukes classification has been used in the past, TNM has gained wider acceptance 
during the last year. Table 3 shows the TNM and Dukes classification systems, and Table 4 the 
relevant expected survival rate per stage. For the purposes of this dissertation, we will focus on 
Stage I rectal cancer. The American Society of Clinical Oncology recommends routine 
carcinoembryonic serum (CEA) levels and highlights that any increase above 5 ng/ml can be 
an adverse outcome factor for CRC [27]. Staging computer tomography (CT) of thorax, 
abdomen, and pelvis is standard practice in most of the cancer units in the UK.  
Recently, Kikuchi et al. introduced a new classification for rectal cancer based on the depth of 
submucosal invasion of the rectal neoplasm [28, 29].Kikuchi classification is widely used in 
rectal endoscopy. It is based on dividing the submucosa into thirds, and within the uppermost 
third, there is a separate description of the horizontal spread of the tumour. Rectal neoplasms 
can be classified from sm1a (less than ¼ of the tumour invading the submucosa) up to sm3 
(muscularis propria invasion). Figure 4 illustrates the Kikuchi [29] classification, which is used 
mainly for early rectal cancer.  In a study that included T1 adenocarcinomas, 35% were Sm1, 
45% were sm2, and 20% were sm3. Further to this, sm1 lesions have a 3% overall risk for 











 ΤΝΜ   Dukes  
Stage 0 Tis N0 M0   
Stage I T1 N0 M0 A  
Stage II T2 N0 M0 A  
 T3 N0 M0 B  
Stage III Any T N1 M0 C  
 Any T N2-3 M0 C  
Stage IV Any T Any N M1   
Table 3.  TNM staging of rectal cancer 
 
 
UICC Disease at the stage of diagnosis 5-year survival rate 
 Colon Rectum Colon Rectum 
I 10−12 20 75−100 78−93 
II 35−40 25−30 50−60 40−60 
III 20−25 20−30 15−40 15−33 
IV 18−20 12−20 0−5 0−5 
Unknown 6−8 13 - - 
Table 4.  UICC 5-year survival rate of rectal cancer  
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Figure 4.  Kikuchi classification (Imported from BJS)[30]  
Haggitt et al. [31] described an alternative classification for early rectal cancer, which is less 
useful for classification of sessile tumours. Figure 5 shows the 4 levels on which Haggitt 
classification is based. Levels 1–3 refer to pedunculated lesions, whereas by definition any 
invasive carcinoma should be level 4. Therefore, the major disadvantage of the Haggitt 
classification is in the case of sessile lesions, for which Kikuchi et al. describe the grade of 
invasion in detail. 
Recently, an international group of surgeons, pathologists, and endoscopists reached a 
consensus for the endoscopic classification of superficial neoplastic lesions in the oesophagus, 
stomach, and colon. This classification is named after the city of Paris, where this meeting took 
place [32]. According to the Paris classification system, there are 2 main macroscopic types of 
lesions: superficial (type 0) and advanced cancers (types 1–5) [33]. Superficial lesions are 
further classified based on the distance from the mucosal layer.  Those lesions that are elevated 
>2.5 mm from the mucosal layer are classified as polypoid, while those that are elevated <2.5 
mm from the mucosal layer are classified as non-polypoid type lesions; the third category refers 
to mixed type.  Table 5 shows the further subdivision of polypoid, non-polypoid, and mixed 
types of type 0 lesions according to the Paris classification. 
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Polypoid/Non-Polypoid Type Paris Classification 
Polypoid type Pedunculated (0–1p) 
 Sessile (0–1s) 
 Mixed (0–1sp) 
Non-polypoid type Slightly elevated (0–IIa) 
 Flat (0-IIb) 
 Slightly depressed (0-IIc) 
Mixed types Elevated and depressed (0-IIa + 
IIc) 
 
Depressed and elevated (0–IIc + 
IIa) 
 Sessile and depressed (0–1s + IIc) 
Table 5  Paris classification of superficial colorectal lesions. (Imported from [33]) 
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2.7 Rectal cancer surgery  
2.7.1 Historical evolution of radical surgery techniques 
Current treatment options for rectal cancer include total mesorectal excision (TME) and 
transanal excision techniques, which primarily refer to local resection techniques; we will 
discuss these later in this chapter. 
For many years, TME has been accepted as the gold standard treatment option in cases of 
locally advanced rectal cancer (LAR). Abdominoperineal resection (APR), the surgical 
treatment of rectal cancer, has been marked by the concept of total mesorectal excision (TME), 
introduced by Heald et al. [16, 34]. Historically, back in the 19th century, Jacques Lisfranc was 
the first to describe a transanal approach to remove a rectal tumour (1839). Following this, in 
1885, Kraske et al. managed to remove a rectal tumour using a transsacral approach. By that 
time, colostomy was the cornerstone for treatment of rectal cancer, and symptomatic relief was 
one of the treatment’s main goals and outcomes. Later, in 1908, Ernest Miles described APR. 
The development of that (at the time) innovative technique was due to the high recurrence rate 
of rectal cancer, primarily attributed to the extended preservation of tissue, i.e., muscles or 
lymph nodes. Ernest Miles preferred to proceed with radical surgery of the anorectum, and the 
oncological outcomes were promising [35]. Despite its oncological superiority, APR holds a 
high rate of morbidity and mortality, as it is a major procedure which in many cases requires 
the use of blood products and high dependency support in the postoperative period. More 
specifically, the overall complication rate can be up to 30%; the mortality rate in the UK based 
on a recent audit is up to 4.5%. Further to this, APR can result in sexual dysfunction, the need 
for a temporary or permanent stoma, and loss of social autonomy. 
Following this novel approach, Dixon et al. introduced a new technique called anterior 
resection, which initially was implemented only for upper rectal tumours. However, due to the 
rapidly evolving technology, this technique was slightly modified for the treatment of lower 
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rectal lesions as well. This was primarily attributed to the development of specially designed 
stapling devices through which anorectal and even colorectal anastomosis became possible 
[35]. 
2.7.2 Challenges in rectal cancer treatment: TME 
As discussed previously, TME was introduced in the late 1880s and early 1890s, when Heald 
[16] was recognised as the father of this breakthrough in rectal surgery. TME was the first 
technique to allow low anastomosis with an acceptable rate of local recurrence of disease. 
Following the Report of the Tripartite Consensus Conference on Definitions for Anorectal 
Physiology and Rectal Cancer, Washington, DC, in 1999, TME was defined as complete 
mesorectal excision to the level of the levators [36]. Although it has evolved since then and has 
been modified several times, the principle of TME is based on Moynihan’s observation in 1908 
[37] that the mesorectum is involved in lymphatic spread.  Heald et al. [17] highlighted the 
important role of the mesorectum in cancer dissemination until the terminal stages.  
TME has been established as the gold standard in the case of middle and lower rectal tumours 
as it is thought to offer lower recurrence rates of around 6.6%, based on a 5,000-case series 
[37]. This evidence is primarily derived from a series of retrospective studies since a 
randomized controlled trial would be difficult to justify in terms of ethical approval. 
However, TME is associated with a series of adverse effects.  The incidence of anastomotic 
leaks is estimated at around 20%, although this can be reduced given the better experience that 
surgeons have these days with TME [37]. A solution to anastomotic leaks could be a routine 
synchronous diversion, which tends to be performed more in cases of male pelvis. TME has 
also been associated with gastrointestinal dysfunction, i.e., incontinence; this can be limited to 
20% with nerve-sparing approach techniques, which are practiced by the vast majority of 
surgeons [37]. Finally, in some cases urinary and sexual dysfunction has been attributed to 
TME, although evidence for this is still inconclusive. Enker et al. [38] supported the fact that 
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sexual functionality can be maintained in up to 80% of the cases, depending on patient age and 
surgical approach. 
 
2.7.3 Local excision options for early rectal cancer    
 
The definition of ERC has been discussed previously. Local excision (LE) of rectal tumours 
has been practiced globally for more than 30 years [39] [40], which follows the overall concept 
of a tissue-sparing surgical choice, if possible.  
The choice between radical surgery and local excision has been extensively discussed in the 
literature, although it can still be controversial. Currently, treatment stratification is facilitated 
in an MDT environment. Improved staging techniques including CT, MRI, and high-frequency 
ERUS have facilitated more accurate staging and potentially better treatment options. Optimal 
staging techniques are truly important, as they allow better prediction of ERC prognosis and 
hence, optimal treatment stratification (local versus radical excision). LE is a broader term 
encompassing several different surgical techniques, which reflects the relevant evolutionary 
process. LE is considered as a safe alternative in the case of ERC. Transanal excision (TAR) 
is an example of an older local resection option which has been practiced for some time [41]. 
Traditional full-thickness TAR is limited to tumours <4 cm in diameter that are within 5 cm 
[41] from the anal verge; this has recently been extended to 6–8 cm from the anal verge [42]. 
Access to lesions is facilitated by anal retractors, and local anaesthetic infiltration helps in 
minimizing blood loss intraoperatively. The main disadvantage of TAR is that it is suitable for 
excision of only a very small number of lower rectum adenomas. 
First described in 2010, transanal minimally invasive surgery (TAMIS) [43, 44] is practiced in 
several hospitals across the world. The TAMIS surgical platform, which is based on a single-
port transanal platform combined with the usual laparoscopic equipment, is designed to bring 
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access to proximal rectal tumours. In the US, 2 FDA-approved devices have been used: the 
Gel-POINT and the SILS Port [44]. As with every other LE technique, TAMIS has strict patient 
selection criteria, which in most cases are limited to well-differentiated adenocarcinomas, pT1 
stage without PNI or LVI, and size <4 cm. 
Transanal endoscopic microsurgery (TEMS) is a widely used local excision technique that 
seems to be gaining more and more ground in the treatment of early rectal cancer. TEMS is 
described in detail in a later chapter.  For the scope of this thesis, we based our observations 
on patients who underwent TEMS. 
2.7.4 LE advantages and disadvantages 
There are several advantages in favor of LE techniques. A recent meta-analysis [45] concludes 
that LE offers a better quality of life with fewer postoperative complications. According to this 
study, the perioperative mortality RR is 0.31 (0.14–0.71); the major post-operative 
complication RR is 0.20 (0.10–0.41); and the need for a permanent stoma RR is 0.17 (0.09–
0.30). In total, this supports a better quality of life following LE. 
The main disadvantage of LE is a higher rate of local recurrence; in general, most of the 
prospective and retrospective studies across the literature report higher recurrence rates 
associated with LE. According to a recent meta-analysis, the RR is 1.90 (0.57–6.32), which 
overlaps the line of no effect [46]. However, in a meta-analysis by Kidane et al. [45], which 
included 2,855 patients in 12 observational studies and 1 randomized controlled trial, a 
significantly higher mortality rate (72 more deaths per 1,000 patients, CI: 30–120) was 
reported.  A sub-group analysis focused on patients who underwent TEMS yielded a similar 
mortality rate with radical resection. In the same meta-analysis, the RR for overall recurrence 
following LE was 2.23 (1.52–3.25); this was based on 1,062 patients who underwent LE versus 
1,399 patients who had radical excision. The RR for local recurrence after 5 years based on 13 
observational studies varied between 1.48–36.56 [45]. 
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Finally, many authors stress patient selection as a vital parameter in LE practice, and most of 
the studies consider LE as an option only in cases of early cancer, or for patients unfit for major 
surgery. With regard to TEMS as a LE option, in cases of early rectal cancer it offers similar 
oncological outcomes with less morbidity and mortality[41], which we will discuss in detail in 
the next section. 
On the other hand, TME generally runs the risk of development of intraoperative and 
postoperative complications, with an expected mortality of approximately 2−3% [47]. There 
have been several references in the literature which conclude that the complication rate of 
radical surgery is estimated to be around 20−30%. Complications include sexual impotence, 
decreased fecundity in females, as well as change in bowel habits and the possibility of the 
need for a permanent stoma, which were discussed previously [48]. 
2.7.5 Transanal endoscopic microsurgery (TEMS) – Technique and advantages 
 
The method of local excision that has recently gained wider acceptance for early CRC is 
TEMS, which generally offers advantages for operative access and oncological clearance 
compared to those of TAR [41]. 
TEMS is a minimally invasive technique which was introduced by Buess in the early 1980s 
[49]. With the use of the novel (for that time) rectoscope, which offers 3D binocular optic, and 
the use of laparoscopic instruments, TEMS offers better access to proximal lesions with lower 
margin positivity and fragmentation, as well as magnification of the operative field [50, 51]. 
One of the main advantages of this technique is the fact that it does not impair anorectal 
function [52]. Multiple studies suggest that TEMS is the gold standard technique for rectal 
adenomas [50, 51] and retrorectal and submucosal rectal lesions [53]. Enthusiasts like the 
Italian team of Lezoche et al. [54] published one of the first randomised trials of TEMS vs. 
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TME for T1−T3 rectal tumours (negative lymph nodes) with additional neoadjuvant CRT [54]. 
The results were impressive: the local recurrence rate for TEMS was 5.8% vs. 2.8% for TME, 
and both techniques had 1 distant recurrence each (2.8%).  
As discussed previously, radical surgery has the disadvantage of a mortality rate of around 5% 
and a complication rate of around 20%, with an effect on quality of life from stomas and sexual 
dysfunction [55] [56, 57]. TEMS is increasingly being supported as the gold standard in early 
stage rectal cancer [58] and is suitable for surgical treatment of broad-based adenomas [59-61]. 
In a retrospective study, Christoforidis et al. reviewed information on pT1 and pT2 rectal 
adenocarcinomas from 1997 through mid-2006. This study included 42 TEMS and 129 TAE 
patients and concluded that TEMS offers a better quality of resection compared to TAE [62].  
2.8 TEMS – Indications and patient selection 
During the last decade, a new era of research has evolved which has essentially converted 
TEMS into a legitimate option for selected patients with early rectal cancer, regardless of the 
operative risk. The National Institute for Health and Care Excellence (NICE) has incorporated 
TEMS as a treatment option in such cases [63]. 
TEMS is an accepted method provided there are no positive lymph nodes present (TNM 
classification N0). TEMS is indicated as a curative treatment for malignant neoplasms that are 
histologically confirmed as pT1, sm1 carcinomas. On the other hand, TEMS treatment for T1, 
sm2–3, and T2 lesions is still controversial  [56]. A prospective study by Puia et al.  suggests 
that TEMS is a safe technique for benign early rectal tumours and selected malignant 
neoplasms [64]. With regard to the previous data, another retrospective study[65] concludes 
that TEMS is an effective minimally invasive technique for early neoplasms, and when 
compared to TAR, it has a broader operative range and a better therapeutic effect.  
In the case of T3 tumours treated with TEMS, there remains an unacceptably high recurrence 
rate of approximately 50%. T1N0M0 tumours are currently the gold standard indicators, and 
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the reported recurrence rate in the literature varies from 5−12%. According to the ESMO 
guidelines [66], because T2N0M0 tumours are confined within the rectal wall, they can also 
be candidates for TEMS.  
Potentially adverse histological features, as well as the fitness and perioperative risk of the 
patient are factors taken into consideration. Close follow-up of patients is crucial for early 
recognition of recurrence, as well as for improvement of their survival outcomes.  
Either way, strict patient selection, close follow-up, and the surgeon’s level of experience are 
vital factors that determine TEMS outcomes. 
 
2.9 Oncological outcomes of TEMS  
Studies across the literature support the superior oncological outcomes of TEMS compared to 
those of other local resection surgical techniques [62]. Sajid et al [47] in their meta-analysis, 
included all published trials to compare the outcomes (morbidity and recurrence) of TEMS 
versus radical resection for ERC.  There was a trend toward higher risk of local recurrence [OR 
2.78 (1.42-5.44)] and overall recurrence (p<0.001). However, the risk of overall survival and 
mortality [OR 0.90 (0.49-1.66)] was similar for both TEMS and radical resection. As a 
limitation for this meta-analysis was reported the significant variation in the design of the 
included trials. 
 
Studies which contained more than 10% of pT3 tumours and provided neo+/-adjuvant 
treatment in more than 35% of cases, had improved OR for survival [32.2 (95%CI=16.3-63.5, 
p=0.001, Q=8.4, p=0.21)]. Studies with more than 10% of pT3 tumours and neo+/-adjuvant 
treatment in more than 20% of the cases had recurrence-free benefit [OR 20.23 (95%CI=13.84-
29.57, p=0.000, Q=2.18, p=0.54)] [67]. 
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A big dilemma in LE is completion surgery in the case of non-complete excision. Hahnloser et 
al [68] in their study examined the impact of completion surgery within a month. 52 T1N0 or 
T1N1 rectal cancers were excised locally followed by radical surgery and TME. Further 
surgery was decided on the basis of unexpected cancer, high risk histology, positive margins, 
or T3 stage. 29% showed residual cancer in specimen. 21% (mostly in lower rectum) had 
positive lymph nodes. In conclusion this study showed similar local recurrence after 
completion TME compared to primary radical resection with TME. 
In conclusion, TEMS is associated with higher recurrence rate for T1 and T2; compared though 
with other LE techniques, it has better oncological outcomes. However, no literature to date 
has linked biomarkers with risk stratification for the treatment of rectal cancer with TEMS.    
 
2.10 Molecular prognostic and predictive biomarkers – Where are we now? 
Currently, treatment strategies and decision-making in the treatment of rectal cancer are 
primarily based on the latest TNM classification. The rationale behind treatment stratification 
includes local tumour invasion, spread to lymph nodes or other organs, and is further 
characterised by the histology (grade of tumour, LVI, differentiation, etc.). Although TNM 
seems to be the cornerstone for the way rectal cancer treatment is perceived, new data from 
molecular biology have generated hope and demand for a new era. In general, a biomarker is 
defined as an objectively measurable characteristic which can describe progression of a 
biological process or pharmacological response to treatment [69, 70]. Biomarkers are further 
divided into prognostic or predictive. Prognostic biomarkers refer to measurable characteristics 
that predict survival, whereas predictive biomarkers focus on response to pharmacological 
treatment [71, 72]. The identification of molecular biomarkers in the management of CRC has 
been extensively studied in the literature [73-79]. Researchers have focused on developing 
classification models based on those biomarkers in order to direct CRC management on the 
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basis of molecular events. These classification models [80-82] are based on grouping molecular 
events based on common features which could potentially define certain pathways of 
carcinogenesis. The starting point in most cases is the progression from healthy epithelium to 
adenoma and then to carcinoma, which happens in a sequence of events [83, 84]. 
The current molecular classification models divide CRC into 3 main mechanisms of 
carcinogenesis. CIN is thought to be involved in 80−85% of CRC  and simply refers to any 
structural abnormality of the chromosomes that can cause aneuploidy and lead to cancer 
development [73]. MSI affects 10−20% [73, 78] of cases of CRC. The mechanism behind MSI 
is mismatch defects on the gene repair system, which normally affects repetitive, small DNA 
sequences called microsatellites. In the vast majority of cases, MSI and CIN cannot coexist 
together, as this would lead to lethal accumulation of mutations. CIMP is the hypermethylation 
of CpG islands in various oncogenes or regions of tumour suppressor promoters, which causes 
upregulation of the latter and therefore cancer progression. CIMP can interfere and overlap 
with either CIN or CIMP [73, 78]. The prevalence of CIMP is around 20%, which fluctuates 
depending on the population [73]. CIN, MSI, CIMP tumours or the combinations discussed 
above can share common characteristics, which are extensively discussed in the last section of 
this dissertation. In general, CIN is associated with a poor prognosis, whereas MSI-positive 
tumours have a more favourable prognosis [73]. MSI features include mucinous and poor 
differentiation, proximal location, female gender, and greater overall 5-year survival. CIMP 
and CIN combined tumours are distally located, whereas CIMP and MSI combined are located 
more proximally. 
Other important biomarkers in CRC involve the status of KRAS and BRAF genes. KRAS is a 
proto-oncogene involved in cellular response to various extracellular stimuli. As discussed at 
length in several chapters of this dissertation, KRAS mutations lead to structural activation of 
downstream signalling pathways, including mitogen-activated protein kinase (MAPK) and 
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phosphoinositide-3-kinase/v-Akt murine thymoma viral oncogene (PI3K/AKT) [78, 85]. 
KRAS status is a well-established CRC molecular biomarker, and most of the literature up until 
early 2010 concluded that KRAS wild type status can predict favourable response to anti-
EGFR inhibitors [76, 85]. However, newer evidence associates KRAS status with prognostic 
parameters, especially in cases of metastatic or advanced-stage CRC [86-92]. BRAF plays a 
similar role in intercellular signalling by encoding a serine-threonine kinase that acts as a 
downstream activator of MAPK pathways [82, 93, 94]. BRAF is thought to be a poor 
prognostic marker which is primarily found mutated in cases of proximal tumours [93] and can 
be associated with MSI status. The most common mutation is BRAF V600E, which has also 
been extensively discussed in cases of skin cancer. More recently, references in the literature 
discuss a predictive role of BRAF in anti-EGFR response to chemotherapy [95], claiming that 
BRAF V600E mutation can predict poor response to chemotherapy, regardless of KRAS 
maintaining wild type status. A recent meta-analysis concluded that BRAF V600E can 
supplement standard clinical and pathological staging for more individualised management of 
CRC [93].  
On performing a review of the literature [78], we identified biomarkers that are thought to be 
involved in the molecular classification of CRC. Although there have been several high-quality 
studies, the complexity and diversity in molecular events have led to limited consensus of their 
role, including their prognostic or predictive value. Moreover, the initial objective to define a 
classification model is still in progress, and a recent systematic review [96] concluded that 
more research is needed to achieve this goal. Consequently, based on the literature evidence 
we focused our research on those biomarkers that seem to be important in CRC prognosis and 
framed our questions on outcomes that have not been previously associated with those 
biomarkers. For instance, there is very limited evidence on the association with biomarkers 
with recurrence, as well as their association with several histopathological features including 
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tumour mass, LVI, and PNI. Moreover, looking back to the embryologic origin of rectum, the 
proximal and distal colon tend to have different biological behaviours, suggesting the potential 
for different biomarkers. This is why most of the biomarkers tend to be positive (or mutated) 
in the right colon (i.e. BRAF V600E mutation) but not in the rectum. Looking at the literature, 
there have been many studies that have investigated the different gene expressions in cancers 
of the left colon, including the rectum and the right colon [5, 97, 98]. 
In the context of identifying several biomarkers that have been studied in CRC and identifying 
which of those can be important to rectal cancer, we have to incorporate an additional 
challenge. Most of these biomarkers have been studied in more advanced stage (stage II and 
above CRC. The diagnosis of early rectal cancer is still a controversial topic and is less studied 
compared to advanced or metastatic CRC. Additionally, newly implemented screening 
strategies have increased the proportion of cancers that are caught at an early stage. It is 
important to consider early cancer as a different subgroup that has a complex biological 
activity, as it can involve several different cancer pathways before advancing to further stages. 
Tissue-sparing surgery like TEMS in the complex context of early rectal cancer would be 
effectively optimised if treatment stratification were based on individualised molecular 
biomarkers. This can provide a paradigm shift in the early prediction of recurrence and the 
optimisation of treatment options to ensure that high-risk groups are receiving the necessary 
additional treatment, i.e., neoadjuvant or adjuvant radiotherapy. Based on this statement, 
oncological outcomes will be equal to those of radical surgery options, whilst achieving 
dramatically reduced rates of morbidity and mortality. Hence, we focused our research on  
determining the significance of molecular biomarkers commonly applied in CRC, specifically 
in the subgroup of early rectal cancer following transanal endoscopic microsurgery. 
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2.11 Personalised Medicine in colorectal cancer biology: future endeavours 
 
Personalised Medicine is an evolving field which aims to tailor therapy to individualised 
characteristics of each patient, and, primarily their genetic profile [99]. The general vision of 
personalised medicine is to offer the right treatment to the right patient at the right time [ref 
JS]. Treatment of cancer is an eminent example of personalised medicine, and prognostic 
and/or predictive biomarkers can serve as a fundamental tool for this scope. The hallmarks of 
cancer as described by Hanahan & Weinberg [100] provide the biological basis explaining why 
many cancer therapies fail.  The wide variation in mutations support the notion of focusing on 
the individual patients’ characteristics in the prevention, diagnosis, prognostic stratification 
and treatment of cancer; molecular biomarkers have been the stepping stone to achieve this 
goal. 
A classic example of cancer prevention strategy based on genetic features has been inherited 
from breast cancer biology. Identification of females with BRCA 1 or BRCA 2 mutation and 
subsequent high risk for future breast cancer development (45-65%, [101]) by the age of 70, 
has result in establishment led into application of screening programs to identify high risk 
individuals. Genetic screening for women with relevant risk factors is available in most 
developed countries’ health care services. BRCA 1 and 2 have been associated with high risk 
for future development of ovarian, colon or prostate cancer. Further to screening protocols, 
preventive strategies consider removal of breast tissue, or prophylactic oophorectomy or 
chemical deprivation of oestrogens [99]. 
In the case of CRC, screening programs have been drastically improved over the last years. As 
discussed earlier, CRC is a complex event attributed, in most cases to an accumulation of a 
series of mutations. Around 1% of CRC are caused by FAP which preserves a certain genetic 
profile; in most cases this affects the APC gene which results in down-regulation of wnt 
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signalling pathway. Identification of such mutations in high risk individuals with family 
history, has led to preventive treatment options, which include prophylactic bowel resection. 
Given that FAP has almost 100% risk of future CRC, such preventive strategies have decreased 
the risk for future CRC by 55%, an example of the benefits of personalised medicine. 
Additionally, personalised medicine has shaped the management of breast cancer. The 
Herceptin-2 (HER-2) gene regulates cell proliferation and is overexpressed in 20-25% of breast 
tumours [99]. HER-2 positive tumours have a poorer prognosis compared to HER-2 negative, 
however they respond better to Transtuzumab, a humanised IgG1 monoclonal antibody 
chemotherapy.  
In the case of CRC, as previously discussed, KRAS is a proto-oncogene involved in cellular 
response to extracellular stimuli. KRAS mutations can downregulate the MAPK or PI3K/AKT 
pathways, which are protein chains that connect the EGFR receptors with nucleic transcription. 
This means that KRAS mutant tumours will not respond to anti-GFR chemotherapy. 
Cetuximab is a monoclonal antibody which acts against EGFR inhibitor and has been widely 
used as chemotherapy agent in CRC; hence KRAS mutant tumours will not respond in such 
treatment [78]. In chapter 4 we discuss in detail this pathway and its importance in CRC.     
The vision of personalised medicine is to create therapeutic protocols tailored and adapted to 
certain distinct molecular characteristics of each tumour. This would optimise prognosis 
stratification, as well as treatment plan; in simple words to avoid undertreating an aggressive 
tumour, but at the same time to eliminate drug-related toxicity in the case of unnecessary 
administration (overtreatment). There have been many efforts which attempted to develop a 
molecular classification model of CRC, which would essentially take over the traditional TNM 
classification, and achieve a more individualised approach for each case. As we discuss later 
on in detail (Chapter 4), Simons et. al (2014) [82] suggested a novel classification model based 
on MSI, CIN, and CIMP; this incorporates further point mutations including KRAS or BRAF 
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genes, and stratifies prognosis based on those features. Similarly, Domingo et al. (2014) [80] 
developed a mutual concept which goes into a more detailed description of 7 distinct molecular 
subtypes of CRC. In both cases there is common ground, however there is still a long way to 
reach consensus and subsequently clinical applicability. Despite being discussed for more than 
a decade, personalised medicine, especially in the case of CRC prognosis and treatment has yet 
to reach the clinical applicability and the consensus that most enthusiastic researchers would 
expect. 
Nevertheless, personalised medicine follows a rapid evolution, and newer evidence, along with 
advanced technology based on artificial intelligence becomes available [102]. Therefore, there 
is hope that increasing of the understanding CRC biology with implementation of novel 
technology (artificial intelligence) will soon revolutionise the existing knowledge to a 
powerful, and clinically applicable, molecular classification model of CRC; this would allow 
individualised approach for each case. 
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3 Our Research Question: Can Oncogenes Predict Recurrence After 
TEMS?   
 
Our research question is whether the aforementioned panel of molecular biomarkers can predict 
local or distant recurrence of early rectal cancer following Transanal Endoscopic 
Microsurgery; we also explored the association between those biomarkers and cancer-related 
death. Finally, we aimed to define the association of those biomarkers with several clinical and 
pathological features that are generally known to play a role in the prognosis of rectal cancer. 
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4 Material and Methods 
 
As this dissertation is based on a “thesis by publication” template, the materials and methods 
of each study are extensively described in dedicated chapters, which have been previously 
published. In this chapter, we provide a synopsis of the basic characteristics of the cohorts that 
were used to produce our results. Also, we explain the rationale behind each study, and finally 
proceed to briefly describe the standard operational procedures followed by the Advanced 
Diagnostics Laboratory at KCH.  
 
4.1 Molecular Biomarkers and Classification Model in the evaluation of the 
prognosis Colorectal Cancer [78] 
 
Initially, we performed an extensive narrative review of the literature. The aim was to collect 
all the available evidence across the literature and define those biomarkers that could be 
applicable to our research question. As part of the same review, we divided all available 
biomarkers into those that were prognostic and those that were predictive, the definition of 
which has been discussed in the Introduction section. Further, we additionally delineated and 
summarised the accepted molecular mechanism by which each of the biomarkers was 
associated with prognosis or response to therapy. Although by definition this was a narrative 
review, a systematic approach to evaluate the literature was followed to ensure all available 
studies were analysed. The keywords used included “colorectal cancer,” “molecular 
biomarkers,” “MSI,” “CIMP,” “CIN,” “KRAS,” “BRAF,” “miRNA,” and “review.” The 
keyword strategy was based on previous narrative reviews and aimed to include any biomarker 
previously discussed in the literature as an essential element of CRC molecular biology. 
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Careful selection and appraisal of the studies were performed to select those that were suitable 
and applicable to our review, with sample size taken into account to maintain quality of 
analysis. We also manually searched each study, methodically appraising the relevant studies 
that were cited and discussed. Our analysis focused on a 5-year period from 2009−2013, with 
extensive involvement of papers derived from a basic science background that had been the 
basis for large multinational studies.  
This manuscript was published in the journal “Anticancer Research” [34: 2061-2068(2014)]. 
 
4.2 BRAF V600E mutation in colorectal cancer is associated with right-sided 
tumours and iron deficiency anaemia [103]. 
 
This is a pilot study based on some of the biomarker panels discussed in our review. The cohort 
of the population consisted of suspected CRC cases referred by general practitioners to KCH 
via the 2-week-wait pathway. Suspected CRC cases are primarily screened by GPs using a 
form specially designed to include all the possible CRC symptoms, as well as demographics 
and family history (FH) of CRC. Although this form is not standardised across the UK, it 
appears to include similar criteria across the country.   
We retrospectively identified 1,446 regional referrals of suspected CRC within a 4-year period 
(2011-2014). We identified 41 confirmed CRC cases, of which 21 were male and 20 were 
female (mean age 67.99, SD= 13.5). 
Data were retrospectively collected in a predesigned Microsoft Excel spreadsheet and 
classified for demographics; symptoms at referral (based on the standardised referral form); 
outcome of investigations performed including imaging and scoping; histopathological 
features; as well as biochemistry results, including Hgb levels. The presentation profile 
(symptoms at presentation) included “changes in bowel habits−CIBH;” “weight loss;” “rectal 
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bleeding;” “unexplained iron deficiency anaemia-IDA;” “abdominal mass on examination by 
GP;” and “family history of CRC.” All data were collected from the electronic patient record 
(EPR), which included all the above-mentioned information, as well as scanned GP referral 
forms and clinic letters. Molecular biomarker data were available, including KRAS and BRAF 
status, which were collected from the EPR and from WinPath (the KCH pathology database), 
which imports data from the Advanced Diagnostics Lab at KCH. All the cases were managed 
in an MDT environment and discussed in the relevant MDT meeting prior to any decision being 
reached.  Data were analysed with IBM SPSS for Macintosh, version 22.0 (IBM Corp., 
Armonk, NY, USA) using the t-test and ANOVA test. Finally, cross-referencing of our results 
was performed using existing data in the literature.  
The aims of this pilot study were to explore the association of KRAS and BRAF status with 
the presentation profile, and to explore the association of KRAS/BRAF with histopathological 
features and biochemistry profile at presentation. Finally, we explored the difference in the 
expression of KRAS and BRAF across different stages of CRC and location of cancer.  
This study was published in the journal “Anticancer Research” [35: 2345-2350 (2015)], and 
was an invited submission following presentation of the concept at the relevant international 
conference. Results are presented in the relevant chapter. 
 
4.3 KRAS mutant status, p16 and β-catenin expression may predict local 
recurrence in patients who underwent transanal endoscopic microsurgery 
for stage I rectal cancer [104]. 
 
This is the main cohort based upon which we studied our biomarkers. Primarily, this is a case-
control study in which we explored the difference between recurrent and non-recurrent early 
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rectal cancer (Stage I) following TEMS. Our institution performs TEMS for early-stage rectal 
cancer according to national UK guidelines. All decisions are taken in the MDT meeting which 
takes place on a weekly basis, and there are dedicated slots for early rectal cancer cases. All 
the cases were operated on by the same surgeon (SP), who is the first supervisor of this 
dissertation. Preoperative staging of the specimens was based on ERUS and magnetic 
resonance tomography (MRI) with a special pelvic protocol. The diagnostic accuracy and 
rationale behind this is discussed extensively in the Introduction. A particular follow-up 
protocol was in place for 5-year surveillance for early diagnosis of recurrence. This included 
6-monthly endoscopy, CEA levels, MRI pelvis, and CT abdomen/pelvis. This schedule was 
reduced to annually after the fourth year. 
From a 10-year cohort at KCH, we selected Stage I cases with the aim of achieving an average 
3-year follow-up window. Of the selected cases, 19 were non-recurrent and 10 were recurrent. 
This was to ensure that adequate samples of recurrent and non-recurrent lesions were available 
for comparison purposes. Given the limitations of the number of the entire KCH TEMS cohort 
at that time (48 cases in total), this was a relatively good sample size. 
Radiological staging took place before and after neoadjuvant radiotherapy where applicable. 
Decision for neoadjuvant or adjuvant radiotherapy was taken on the basis of patients’ fitness 
for surgery as well as on the basis of the patients’ choice. The option for completion surgery 
was offered in individualised cases, but this was declined by the patients and hence it was not 
performed. Demographics and follow-up outcomes of MRI, endoscopy, and blood results were 
prospectively collected.  Histopathological features from endoscopic biopsies and theatre 
samples were also prospectively collected.  
The molecular biomarker panel, including KRAS, BRAF, p16, β-catenin, MGMT, and 
mismatch repair (MMR)/MSI were retrospectively analysed by the research student (MS), who 
was directly supervised by staff from the KCH Advanced Diagnostics Laboratory. The 
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majority of the samples were directly analysed by Dr Jane Moorhead (JM), the laboratory 
director, with MS being present for familiarisation with the relevant standard operational 
protocols (SOPs). Original photos from the microscope were obtained of various aspects of the 
immunohistochemistry (IHC) in order to supplement this manuscript. The methodology for the 
molecular techniques (pyrosequencing, PCR, and IHC) is discussed in detail later on in this 
chapter.  
As a general cohort description, 18 patients were male and 11 were females. Mean age at 
diagnosis was 67.93 years (28.25 - 86.87). All the specimens were deliberately chosen as Stage 
I, which represents the vast majority of the entire TEMS cohort at KCH.  
Statistical analysis of the results was performed by MS under supervision, using IBM SPSS 
for Macintosh, version 22 (IBM Corp., Armonk, NY, USA). We performed bivariate 
correlations (Pearson’s and Spearman’s rho, as well as chi-square associations) to identify any 
potential links between the follow-up parameters and KRAS, BRAF, p16, β-catenin or MGMT. 
Logistic regression analysis and Kaplan-Meier curves were not possible due to limitations in 
the sample size. 
Our primary aim was to compare the association of the panel of biomarkers, including KRAS, 
BRAF, p16, β-catenin, and MMR/MSI, with the survival outcomes including recurrence and 
cancer-related deaths. As part of this study, we explored the association of the status of 
biomarkers against the time-to-recurrence. Also, we aimed to compare the status of our 
biomarker panel against histopathological features and demographics.  
 
4.4 KRAS mutant status may be associated with distant recurrence in early-
stage rectal cancer [77].   
A recommendation from the mid-term Viva review was to include a rectal cancer series from 
KCH in order to compare the significance of the already studied panel of biomarkers. One 
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hundred and thirty-five consecutive rectal cancer cases, from 2011−2014, along with 
prospective collection of clinical and pathological data were included in the study cohort. 
Prospective collection of data was part of a UK National Bowel Cancer Audit.  
All the cases were discussed in the cancer MDT, which is held on a weekly basis at KCH, for 
treatment stratification. Intense follow-up on a 6-monthly basis according to the local 
guidelines included 6-monthly endoscopy, CEA, CT abdomen pelvis and thorax, and 
occasionally MRI pelvis and ERUS. 
Data were collected on demographics, preoperative staging including imaging, MDT 
outcomes, preoperative biopsy where applicable, and theatre specimen histopathology. 
Biochemistry profile and treatment stratification (neoadjuvant/adjuvant chemo/radiotherapy) 
data were also collected.  All data were stored on the EPR and accessed online from hospital-
based computers.  
Analysis of biomarkers was performed using the same SOP protocol, led by Dr S Diaz-Cano 
and Dr Jane Moorhead. A description of processing of the sample is given in the next  Methods 
section. Selection of biomarker panels was based on the same selection criteria as those for the 
TEMS cohort.  
The primary aim of the study was to explore the prognostic significance—against cancer- 
related survival and local or distant recurrence—of the same biomarkers studied in the TEMS 
cohort, in cases of a cohort of patients who underwent radical surgery. Also, we aimed to 
further compare the significance of those biomarkers in the particular subgroup population of 
Stage I rectal cancer specimens and to identify any associations between those biomarkers and 
histopathological features including LVI, PNI, stage of disease, etc. 
A total of 135 cancer cases were identified in our cohort (mean age at diagnosis was 64.67 
years, range=22−89 years, SD=13.32); 87 cases were males and 48 were females. The mean 
follow-up time was 39.21 months (range=5−83 months, SD=21.34). Twenty-one cases were 
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ASA grade I, 72 ASA grade II, 35 ASA grade III, and 1 was ASA grade IV. With regard to the 
preoperative MDT stage, 28  cases were Stage I, 30 were Stage II, 45 were Stage III, and 31 
were Stage IV. The stage was defined during the MDT meeting based on either radiological or 
preoperative biopsy results, if available. Neoadjuvant/adjuvant therapy details are given in the 
relevant chapter section. 
Statistical analysis of our results was performed using IBM SPSS for Macintosh version 22 
(IBM Corp., Armonk, NY, USA). Univariate correlations (Pearson’s and Spearman’s rho as 
well as chi-square crosstabs) were used to identify any potential links between various 
parameters and KRAS, BRAF, p16, β-catenin, or MGMT. Independent t-test associations were 
used to compare the means of different groups. The statistical significance level was set at 
p=0.05. Subgroup analysis of the Stage I rectal cancer cohort was undertaken to evaluate and 
compare the significance of the panel of biomarkers with the TEMS cohort. 
This study was published in the journal “Anticancer Research” [37 1349-1358 (2017)]. 
 
4.5 Biomarker analysis - Synopsis  
 
All biomarkers were assessed on formalin-fixed, paraffin-embedded (FFPE) samples. Βeta-
catenin, MMRs, MGMT, and p16 assays were performed using IHC. Four-μM sections of the 
tumour were cut onto coated slides, and IHC was performed using standardised protocols for 
each antibody. The final step was visualisation of antigen-antibody complexes by the addition 
of the chromogen, diaminobenzidine. The slides were then assessed (by SDC and JM) and 
scored for percentage of tumour cells and protein location figures 13-19.  
KRAS mutation analysis was performed on the same tumour samples. HH&E-stained sections 
of the tumour were assessed and marked for tumour content, and the tumour was then 
macrodissected using serial, unstained sections from the non-tumour components, allowing for 
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enrichment of tumour cells. DNA was then extracted from these samples using standardised 
protocols and quantified by Qubit analysis. Polymerase chain reaction (PCR) was performed 
using primers on either side of the regions of interest: codons 12 (35G>A, 35G>T, 34G>T), 13 
(38G>A), and codon 61 (182A>T).  After immobilisation of the resulting amplicons, single-
stranded DNA was prepared and the sequencing primer for each region was annealed. The 
samples were then analysed on a Qiagen Q24 pyrosequencer©, using the appropriate software 
(PyroMark Q24 software, version 2.07). The mutation status of each tumour was reported 
according to standard protocols (by SDC and JM). Appropriate positive and negative controls 
were included for all assays.  
Photos were obtained by JM with the relevant permission of the Advanced Diagnostics 
Laboratory (King’s College Hospital NH Foundation Trust, London, Denmark Hill, UK).  
 
4.5.1 Immunohistochemistry (IHC) on FFPE samples (p16, MGMT, β-catenin, MMRs) 
 
Immunohistochemistry is a technique used to identify [105] and analyse protein expression in 
the context of tissue morphology. The basic concept of IHC is based on the principle of  
antibodies that bind into their target epitope and at the same time are identifiable via a 
chromogenic or fluorescent readout. The steps followed for IHC in the Advanced Diagnostics 
Laboratory at KCH are based on those provided by the commercial supplier and can be 
summarised as follows [106]:  
• preparation of solutions and reagents 
• sample preparation 
• deparaffinazation/rehydration 
• antigen unmasking 
• staining 
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• dehydrating and mounting sections 
  
Preparation of solutions and agents: This is to ensure that the following are available: ethanol, 
anhydrous denatured; xylene; hematoxylin; wash buffer; antibody diluent options 
(SignalStain, TBST/5%, PBST/5%); antigen unmasking options (EDTA, citrate, TE, pepsin); 
3% hydrogen peroxide; blocking solution (TBST/5% normal goat serum); detection system 
(SignalStain); and substrate (SignalStain DAB Substrate Kit 8059). 
Sample preparation: Paraffin-infiltrated tissue is briefly cooled in a mold with liquid paraffin 
in order to immobilise the tissue. The base of a cassette is placed on top of the mold, then  filled 
with liquid paraffin and cooled. Four-mm slices from the microtome are baptised in a water 
bath. Mount sections are left to dry overnight onto the charged slides. 
Deparaffinization/rehydration (figure 6): Prior to antibody masking, paraffin has to be 
removed by putting the sections on 3 containers of xylene, 5 minutes each. The sample needs 
to be rehydrated using 2 containers of 95% ethanol, and finally the sections are washed twice 
in dH2O for 5 minutes each. 
 
Figure 6- Deparaffinization/ Rehydration 
 
Antigen unmasking: Prior to antibody staining, we have to break the cross-links formed by 
formalin fixation using either citrate, EDTA, TE, or pepsin. 
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Staining: We performed chromogenic staining using SignalStain diaminobenzidine (DAB) 
solution. The sections were washed in dH20 3 times for 5 minutes. Sections were placed in 3% 
hydrogen peroxide for 10 minutes. Then, sections are washed initially in dH2O for 5 minutes 
each and in wash buffer for 5 minutes. 100−400 μL of blocking solution were used to prevent 
nonspecific blocking. The blocking solution is then removed and 400 μl of the primary 
antibody solution is used for each section. The sections are rested overnight at 4°C in a 
humidified chamber. The next step includes equilibration with SignalStain boost detection 
reagent. The antibody solutions are removed and the sections are washed in wash buffers 3 
times. Three drops of SignalStain Boost detection reagent are used to cover the section and 
then rested for 30 minutes in a humidified chamber; 100−400 μl of SignalStain DAB for 10 
minutes on each section is enough for acceptable staining intensity. The slides are then washed 
with dH20. 
Dehydration and mounting of sections: Either ethanol or xylene is used for this purpose. 
The slides are assessed by Dr Jane Moorhead or Dr Salvador Diaz-Cano with MS to score for 
percentage of tumour cells and protein location. The original (electron microscope) pictures 
are available below.  
 
4.5.2 Polymerase chain reaction (PCR) – KRAS and BRAF mutation status 
KRAS and BRAF mutation analysis was performed on the same tumour samples. The 
HH&E−stained sections of the tumour were assessed and marked for tumour content, and the 
tumour was then macrodissected using serial unstained sections from the non-tumour 
components, allowing for enrichment of tumour cells. DNA was then extracted from these 
samples using standardised protocols and quantified by Qubit analysis. 
Reagents and equipment: [107] 
• DNA extraction buffer 
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• isopropanol 
• 70% (v/v) ethanol 
• table-top microcentrifuge 
The tumour microdissected material with unstained sections of the non-tumour components 
were placed into sterile Eppendorf tubes and mixed with 400 μl of DNA extraction buffer using 
the vortex (13.000 rpm for 1 min). The supernatant was transferred to a new Eppendorf tube 
and mixed with isopropanol using the vortex (13.000 rpm for 1 min). The supernatant was 
discarded, and the DNA pellet was washed with 70% (v/v) ethanol using the vortex (13.000 
rpm for 1 min). The pellet (DNA) was inverted onto a paper towel and then air-dried to remove 
remaining ethanol. Finally, the DNA was dissolved in 100 μl ddH2O and stored at 4°C for 
immediate use. 
DNA amplification and sequencing reaction [107]: 
Thermal cycling took place in 0.2 ml thin-walled PCR tubes with 50 μl reaction volume. 
Contents of the reaction solution were: 1μl of 10 pmol universal barcode primers [108]; 1μl 
template DNA; 5μl 10x PCR buffer; and 0.4 μl Thermus aquaticus polymerase. We used the 
following conditions as described by Margam et al. [107]:  95°C/2min, then 5 cycles (95°C/30 
sec each cycle), 45°C for 45 sec, 72°C for 1.5 min, and then followed by 31 cycles (95°C, 30 
sec), 50°C for 45 sec, 72°C for 45 sec, and a final cycle of 72°C (8 min).  
 
4.5.3 Pyrosequencing Qiagen Q24 Advanced Technology (Qiagen Q24® - qiagen.com) 
 
Pyrosequencing was performed using Qiagen Q24® [109], following the local standard 
operational procedures to identify KRAS codon 12 (35G>A, 35G>T, 34G>T), 13 (38G>A), 
and codon 61 (182A>T) [104] mutations, as well as BRAF (c.f. 1799 T>A) [76, 95, 103] 
V600E mutation. 
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The essential pyrosequencing workstation is presented in figure 7. Reagents; vacuum 
preparation workstation; instrument (Pyromark Q24 Instrument) [110] (figure 8); and 
application software (PyroMark Q24 software) are essential for further processing of 
identification of KRAS and BRAF mutations. PyroMark Q24 Technology [109] (figure 8) 
allows 1−24 gene specimens to be analysed in 15 minutes.  
The first step is sample preparation, which is taken over by PCR amplification. PCR products 
are cleaned to remove any remaining primers or nucleotides, and DNA is quantified by Qubit 
analysis. The vacuum preparation workstation is essential for cleaning the PCR DNA in order 
to end up with a single-stranded DNA. 
 
Figure 7 - Pyrosequencing Preparation Workstation 
 
A bottle with Sepharose beads is essential for immobilizing the PCR product to beads. A 2 
μl/sample of Sepharose beads solution, 40 μl/sample of binding buffer solution, and Milli-Q 
18.2 MΩ x cm or equivalent (18−28μl/sample) are mixed with 10−20 μl of PCR product in a 
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cubicle (80 μl in total). The solution is agitated constantly for 5−10 minutes at 1.400 rpm. The 
final solution is processed according to the steps on the vacuum preparation workstation (figure 
3) in order to separate DNA strands into a single-strand product ready for pyrosequencing.  
 
Figure 8 - PyroMark Q24 Instrument 
 
The pyrosequencing principle uses sequencing by synthesis for accurate and quantitative 
analysis of DNA. The principal algorithm of pyrosequencing consists of 9 steps. The 
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description below is based on the manufacturer’s principal manual of the device which we used 
for our specimens [111]. Initially, a sequencing primer is hybridised to a single-stranded, PCR-
amplified product template (process described previously). Then, the template is incubated 
with enzymes and substrates, and the first of the 4 nucleotides are added into the reaction. The 
nucleotides are incorporated into the complementary bases of the template strand. Each 
incorporation is a chemical reaction which releases pyrophosphate (PPi) based on the following 
reaction: (DNA)n + dNTP → (DNA)n+1  + PPI (facilitated by DNA polymerase). The released 
PPI is converted to ATP by the ATP sulfurylase in the presence of adenosine 5’ 
phosphosulphate. ATP is essential for converting the luciferin into oxyluciferin by the enzyme 
luciferase, which is the principle behind pyrosequencing. Conversion of luciferin to 
oxyluciferin produces light that is picked by charge-coupled devices (CCD), which is seen as 
a peak in the pyrogram (figure 9).   
 
Figure 9: Conversion of luciferin to oxyluciferin produces light which is picked by CCD 
  
Apyrase is responsible for continuously degrading unincorporated nucleotides (dNTP) → 
dNDP + dNMP + phosphate. Apyrase also degrades ATP to ADP + AMP + phosphate. 
Nucleotides are added one at a time, and as the process continues, the nucleotide sequence of 
the complementary strand is determined by the peak in the pyrogram (figure 10).  
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Figure 10: Nucleotide Sequence (dNTP sequence) 
 
PyroMark Q24 [109] software is used for visualisation of the nucleotide sequences, which 
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5.1 Abstract  
Colorectal cancer (CRC) is the second leading cause of cancer-related death. Despite the 
progress that has been made towards the identification of the molecular mechanisms involved 
in CRC, there are many unclear points. The current opinion is that microsatellite instability 
(MSI), CpG island methylator phenotype (CIMP) and chromosomal instability (CIN) seem to 
play a significant role. MSI is related to point mutations in defect mismatch repair system of 
DNA. There are two well-established MSI phenotypes: MSI-high (MSI-H) and MSI-low (MSI-
L or MSS). CIN refers to a different cellular event which originates from the presence of an 
abnormal chromosome complement or number. CIMP is the third most commonly involved 
event, and is defined by widespread methylation of CpG islands of suppressor promoters, with 
two phenotypes: CIMP-high and CIMP-low which interact with MSI or CIN status 
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V-raf murine sarcoma viral oncogene homolog B (BRAF) is a serine-threonine protein kinase 
that acts as a downstream effector of the Kirsten rat sarcoma viral oncogene homolog (KRAS) 
pathway.  Various studies have revealed that BRAF V600E mutations appear to be a valid 
indicator of poor prognosis. KRAS is a proto- oncogene which encodes a GTP-ase involved in 
cellular response to extracellular stimuli. Its prognostic value is still controversial. However, 
wild-type KRAS is associated with better response to Endothelial Growth Factor Receptor 
inhibitors combined with standard chemotherapy. Loss of Heterozygosity, especially involving 
18q, is a well-known potential mechanism for tumorigenesis that has been studied in CRC. 
Vascular Endothelial Growth Factor is a proangiogenic factor linked with the aggressiveness 
of CRC. Emerging data show that Cycloxygenase 2 overexpression is significantly associated 
with worse outcomes in CRC. Recent studies highlight microRNAs as promising prognostic 
biomarkers. More specifically, the down-regulation of miR-451, miR-625, miR-29c, miR-126, 
miR-129 and miR133 is purported to be a poor prognostic factor, while miR-224 was 
overexpressed in CRC.  
 
Key Words: CRC biomarkers, CIMP, CIN, MSI, KRAS, BRAF, miRNA, review. 
  





Currently, treatment strategies and clinical outcomes in colorectal cancer (CRC) are 
determined by cancer stage as defined by TNM or relevant staging protocols [112], based on 
local tumor’s penetration and spread to lymph nodes or other organs. The cornerstone of non-
metastatic CRC treatment remains the surgical resection. In patients with higher stage disease, 
(III or high risk II) there is a significant risk of reoccurrence. Although certain histological 
factors such as differentiation, Grade, lymphovascular invasions have been identified as 
exposing to higher risk there is still lack of understanding of molecular factors which may 
affect the risk of metastasis and recurrence.  
In recent years, molecular biomarkers have generated interest as prognostic markers or in the 
case or as in the case of KRAS, as factors involved in the treatment choice. Generally, a 
biomarker is defined as a characteristic that can be objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological response to 
a specified therapeutic intervention. Biomarkers can be either prognostic or predictive [69, 70, 
113, 114] . Prognostic values are defined by the estimated life expectancy post diagnosis and 
treatment whereas predictive biomarkers are related to the response of a patient to a relevant 
treatment strategy. 
The purpose of a molecular classification is to identify similar characteristics among individual 
tumors, and then predict empirically the pathogenesis and biological behavior of a particular 
tumor [71, 72, 115-117]  [71]. The most accepted way of creating a classification model is to 
identify and correlate single cellular events that have been statistically proven to play a role in 
the tumor genesis. 
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The starting point of these efforts was the identification of significant stages in the progression 
from healthy epithelium to cancer [83]. Currently some theories exist which explain the 
transition from adenoma, the first pre-cancerous type of lesion, to carcinoma and then invasion 
to other the tissues. In this way, commonly involved events in CRC were identified and 
highlighted as the guiding points for a classification model. Subsequently, the first efforts to 
summarize and correlate these events were published, but none was actually adequately 
evidence-based to achieve translation to clinical practice 
Most of the current molecular classification models are based on MSI, CIN and CIMP and they 
correlate these event with other significant mutations i.e. KRAS, and BRAF [84, 118]. 
In this review article, we summarize what is currently believed in terms of all the popular 
potential biomarkers in CRC and we are going to set the parameters up for further discussion 
and points of interest for further research 
5.3 MSI 
Microsatellite disorders are established as frequent event in CRC, occurring in around 22% of 
cases [56, 119]. There are many reports supporting the effect of MSI CRC prognosis [70, 80, 
114, 120] [121-124] [72, 116, 117, 125, 126]  
Microsatellites are short repetitive DNA nucleotide sequences which are prone to frame-shift 
mutations and base-pair substitutions during DNA replication  [70, 114]. They are involved in 
the DNA repair system and their mutations were initially associated with Lynch Syndrome 
(LS), which is an autosomal dominant disorder, highly associated with 3% of multiple CRC 
types. MMR genes involved in Lynch Syndrome are MLH-1, MSH2, NSH6 and PMS2 [81] . 
Loss of these genes results in defective MMR, which in turn results in MSI. 
Sporadic CRC is more likely to be associated with hMLH-1 mutation. In terms of MSI status 
classification most of the studies divide it into three categories: MSI-high (MSI-H) at ≥30%, 
MSI-low (MSI-L) at 10-30% and microsatellite stable (MSS)[70, 81, 114] . Some other studies 
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aim to simplify MSI status as being positive or negative[80, 82, 127]. It been questioned 
whether MSI-L exists or falls in the same category as MSS [128].  
Most of the studies aiming to establish a classification model in CRC, consider MSI status as 
one of the primary criteria for categorization [80, 127] (Table 6). A recent multivariate analysis 
identified MSI alterations in 119/892 CRC samples and highlights MSI status as one of the 
major prognostic biomarkers [80] . Another interesting study (Simons et al. 2013) suggested a 
model which is mainly based on MSI status and its relationship with CIMP and CIN. In the 
same study, it was noted that APC and KRAS mutations were less frequent in MSI tumors 
(13.3% and 10.9% respectively) whereas BRAF V600E mutation is most often seen in MSI 
tumors (58.7%)  [82]  
There are many clinicopathological variables associated with MSI status. For instance, patents 
with MSI-H tumors have in general greater 5-year overall survival irrespective of stage 
compared to those with MSI-L and MSS tumors. The PETACC III trial has confirmed these 
retrospective findings and suggested that MSI-H is a strong prognostic factor for relapse-free 
and overall survival in patients with stage II and III [70, 114]. Moreover, MSI-H tumors have 
been classified as proximally located, poorly differentiated with a higher incidence in female 
gender. They are also characterized by mucinous differentiation, increased age at onset and 
round and vesicular nuclei with a prominent nucleolus[69, 80-82, 113, 127]  
MSI Summary of basic features 
  
appears in around 22% of CRC cases [80, 119] 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 75 
 
However, contrary to the promising results in terms of the prognostic value of MSI status, no 
clear relationship between MSI status and response to neoadjuvant chemotherapy has yet been 
proven. However, Ribic et al.[119] study concluded that MSI-H status can be associated with 
poor response to 5 FU based chemotherapy compared to MSI-L and MSS tumors[69, 113]. 
Nevertheless there are multiple studies with conflicting results in terms of the predictive value 




Greater 5-year survival, proximal location, poor differentiation, 
female gender, mucinous differentiation [69, 70, 80-82, 127] 





MSI in LS 
Association with hMLH-1 [70, 81] 
 






BRAF V600E is associated in 58.7% with MSI +ve CRC [82] 
 
KRAS mutations appear in 10.9% of MSI +ve CRC [80] 
Predictive value Predictive value is still controversial [69, 127] 
Table 6: Baseline characteristics of MSI tumors. This table provides a summary of the baseline characteristics of MSI tumors and 
their correlation with KRAS and BRAF mutations 
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5.4 CIMP  
Most studies develop the CRC classification model based on CIMP status and its correlation 
to CIN and MSI[72, 81, 82, 115-117, 127, 129] . CIMP is defined as hypermethylation of CpG 
island promoter. CIMP results in transcriptional silencing of specific tumor-suppressor and 
DNA repair genes, including MLH-1[82] .Some studies describe CIMP status as CIMP-high, 
CIMP-low and CIMP negative [81] . There is a discussion about whether CIMP low and CIMP 
negative fall into the same category[129], resulting in two categories, CIMP positive and CIMP 
negative; we use this for simplicity here.  
There have been some reasonable studies which associate MSI and CIMP status along with 
Chromosomal Instability (CIN), resulting in a classification model which attempts to identify 
and link macroscopic variables to molecular features [82] . A recent study, Simons et al. 2013, 
suggests a classification based on MSI, CIMP and CIN. According to that, MSI and CIMP-
positive  tumors were more proximally located (85.7% and 51.9 % respectively), whereas 
CIMP-positive and CIN or CIN-only tumors were distally located (distal colon to rectum 
52.3% and 82.1% respectively). Triple negative tumors were located both in distal and 
proximal colon and in 89% of them BRAF V600E mutation was present. 
Regarding CIMP-only tumors (Simons et al. 2013) the average age at diagnosis was 67.6 years, 
51.9% was located proximally and the differentiation grade was II at the stage of data analysis. 
BRAF V600E mutation was present only in 18.5% and p53 over expression was  noted in 66.7 
% [82].  
5.5 CIN 
Tumors with CIN have chromosomal gains and losses, with or without structural 
rearrangements possibly reflecting an increased mutation rate and this is called aneuploidy 
and/or polyploidy respectively [80, 130, 131]  and occurs in around 60% of CRC cases [69, 
113] The mechanism underlying CIN is not yet understood. Most studies tend by definition to 
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differentiate MSI positive tumors from CIN, as CIN reflects to a separate mechanism of 
carcinogenesis  [82, 127]. MSI positive and CIN positive tumours have been described, but 
they tend macroscopically to appear more likely MSI positive[80] . The overlap between CIN 
and MSI is not clear [82] . CIN positive tumors are generally associated with poor prognosis 
and they tend to be well or moderately differentiated [80] Simons et al, hold that CIN only 
tumors are more frquent in men (54.7%), 76.5% at the stage of diagnosis are grade 2 and there 
is subsequent p53 over expression [82]. However, BRAF V600E mutation tends not to be 
involved in such a mechanism of tumorigenesis [80, 82], but several studies do link KRAS 
mutations with this molecular phenotype [127] . CIN tumors are located more often distally. 
CIMP-negative and CIN positive tumors have been described [82] 
Domingo et al., have described 3% of MSI-H and CIN positive tumors tending to have 
characteristics closer to MSI-H CIN negative tumors i.e. right-sided location and increased 
BRAF mutations, while p53 mutation and 17p LOH was not increased significantly, and thus 
there was no association [80].  
5.6 KRAS mutations  
KRAS is a proto-oncogene which is involved in cellular response to extracellural stimuli [70, 
114, 132]. In cases of KRAS mutations there is a structural activation of downstream signaling 
pathways i.e. MAPK and PI3KAKT pathways[69, 113] , and through this mechanism tumour 
cells are more resistant to inhibition of surface receptors of tyrosine kinase such as EGFR. The 
MAPK pathway was recently found to be one of the fundamental mechanisms that get involved 
in the sequence of tumorigenesis [56, 119] 
Point mutations in codons 12, 13 and 61 of KRAS gene are noted in about 30-40% of CRC[69, 
113] and in total there have been identified around 85 KRAS mutations have been 
described[56, 119]. These different molecular phenotypes of KRAS may result in different 
pathways of carcinogenesis which could alter the macroscopic phenotype. 
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However, it is still controversial whether KRAS can be considered as a valid biomarker or not, 
as recent studies suggest there are no clinicopathological feature to support this [56, 70, 114, 
119]. There are some controversial data emerging that link KRAS mutation with poor 
prognosis. Phipps et al. found KRAS mutation to be associated with poorer prognosis 
compared to wild-type KRAS [90] . Most studies link KRAS mutation with certain molecular 
phenotypes i.e. CIN whereas they are less likely to be noted in MSI positive tumors[70, 80, 82, 
114, 127]  
An interesting study in Moroccan patients with advanced CRC showed that [133] 76.09% of 
patients had wild type KRAS genotype, whereas 23.91% were KRAS mutants, The majority 
of KRAS mutations referred to an amino acid substitution of glycine by aspartic acid (68.2%) 
On the other hand, despite the debating prognostic value of KRAS, it has been established that 
wild-type KRAS is associated with better response to EGFR inhibitors in terms of adjuvant 
chemotherapy setting i.e. cetuximab [56, 70, 76, 112, 114, 119, 134-136]. An interesting study 
by DiBartolomeo et al. in 2013 concluded that patients with KRAS/NRAS, BRAF and TP53 
wild-type tumours could had the maximum benefit from treatment with cetuximab, oxaliplatin 
and UFT[137]  Nevertheless, Selcukbirik et al. 2013 found that BRAF and KRAS mutations 
do not seem to be a potential biomarkers in the treatment of metastatic CRC (mCRC) with 
bevacizumab therapy [138]. Also, Bruera et al. also noted a worse prognosis in patients with 
metastatic CRC and KRAS (c35  G) / BRAF mutations [139],  and a similar hypothesis is 
supported by Loupakis et al. 2013 where EGFR ligand was significantly modulated by 
cetuximab plus irinotecan therapy[140]   
Tian et al 2013 states that a combined signature of KRAS/BRAF and PI3KCA could offer an 
optimized source of information for cetuximab responsiveness of the tumour[141]. Saridaki et 
al 2011, concluded that KRAS-BRAF mutations and EREG expression can be used as 
biomarkers to further select patients undergoing anti-EGFR therapy[142] 
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5.7 BRAF mutation 
BRAF gene encodes a serine-threonine kinase that acts as an inhibitor of the RAS/MAPK 
intracellular signaling pathway. Mutations of BRAF occur at early stage of colorectal 
carcinogenesis[94] .   
In terms of correlations of BRAF with the main cellular events, most studies associate BRAF 
V600E activating mutation with sporadic MSI-H CRCs [69, 113] [56, 70, 80, 82, 114, 119]  
and it is linked with poor prognosis [143] (table 7). What is more, no association between 
BRAF mutations and CIN has yet been noted [69, 80, 82, 113]. According to Doming et al., 
BRAF alterations occur in 10% of CRC cases and there is a negative association with KRAS 
mutations[80], whereas there is primary positive association with MSI and CIMP-high [115, 
117, 136] .  
In a recent study (Lochhead et al. 2013) BRAF mutation, occured in 10% to 20% of CRC and 
there was associated with MSI-high through its relationship to CIMP-high [122] . The same 
study concludes that BRAF mutations are associated with inferior prognosis. Eklof et al. 
analyzing the mutation status in KRAS and BRAF and PIK3CA and PTEN expression in two 
separate CRC cohorts, state that KRAS and BRAF status are important in the establishment of 
the prognosis in CRC and should always be considered[144] . Similarly, Yokota et al.  conclude 
that mutated BRAF is one of the most powerful prognostic markers in CRC[145] .    
Nevertheless, BRAF as a predictive marker is still under discussion [76, 114]. There are some 
studies which tend to use a signature of BRAF/KRAS as a predictive factor for the response to 
EGFR inhibitors [137-142]. Another interesting meta-analysis, [146] , taking into 
consideration 21 trials including 5229 patients, conclude that BRAF mutation is a predictive 
biomarker for poor prognosis in patients with metastatic CRC undergoing therapy with anti-
EGFR monoclonal antibody, especially in those with wild type KRAS.  
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Finally Mesteri et al., concluded that BRAF V600 mutation can be used as a classification 
criterion for the evaluation of serrated lesions and progression to sessile/serrated adenoma 
polyps and CRC.  
 













Most likely at codons 12,13,61 [69] 
In total 85 kRAS mutation have been identified and occupy 








Predictive value is still under discussion [70, 76] 
BRAF mutations are related with 10-20% of CRC (Lockhead et 
al.)  and they are associated with inferior prognosis [122] 
V600E mutation is associated with sporadic MSI + tumours [69, 
70, 80, 82, 119]  
Table 7: KRAS and BRAF gene mutations baseline characteristics. This table describes the baseline characteristics of KRAS and 
BRAF mutations regarding predictive value and common mutation patterns 
5.8 VEGF  
VEGF is a proangiogenic factor which is involved in endothelial cell proliferation, migration 
and vascular permeability [114]. Increase in its expression levels is associated with poor 
prognosis, low response to preoperative radiotherapy, and more likelihood for recurrence 
[147].  
Angiogenesis plays a significant role in CRC as neovascularization markers are overexpressed 
in most of the cancer cells [148]. VEGFA is involved in early tumour stages i.e. adenoma 
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formation. According to the same study, VEGFA was associated with advanced cancer stage 
and metastatic disease via a angio-lymphatic invasion pathway. 
Moreover, there has been noted a relationship between VEGF-C and collagen triple helix 
containing 1 has been noted in terms of prognostic value in rectal cancer [149]. VEGFC 
activates the tyrosine-kinase-linked receptor of the VEGFR-3 pathway and induces the 
lymphagiogenesis. [148] This means that the overexpression of VEGF-C could be a valid 
molecular biomarker for lymphagiogenic metastasis.  
5.9 COX -2 cycloxygenase 2 enzyme related pathway 
Several prospective studies have shown that COX-2 overexpression could be interpreted as an 
adverse prognostic factor for CRC[150].  
There are some studies which support that use of COX-2 inhibitors i.e. aspirin can be associated 
with lower risk of CRC, especially with patients who have been diagnosed with CRC in which 
COX2 is overexpressed[117]  
There is another study [122, 123] evaluates the correlation between aspirin intake and 
colorectal cancer according to BRAF mutation status using biennial questionnaire on aspirin 
and collected data from 1986 to 2006. The study concluded that regular aspirin use was 
associated with lower risk of wild-type BRAF CRC but not of BRAF-mutated cancer risk.  
Finally, a recent study noted [151]  that positivity for COX2 and VEGF was strongly correlated 
with decreased DFS (p=0.007), whereas combinations of positivity for RAF kinase inhibitor 
protein with COX2- and VEGF was strong correlated with improved DFS. 
5.10 LOH 18q 
LOH especially in 18q is a well-known potential mechanism for tumorigenesis that has been 
studied in CRC. LOH is being an important mechanism of inactivation of tumor suppressor’s 
genes [114] . There have been several studies trying to interpret the potential prognostic effect 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 82 
of LOH 18q in CRC, however there have been inversely associated with MSI.  There are many 
tumor suppressor genes in 18q, e.g. DCC, SMAD4 (DPC4), SMAD2, and CABLES1 [72, 116, 
117]  which might interfere with and subsequently explain the prognostic value of LOH 18q . 
Nevertheless, in the same study it is clear in 555 non–MSI-high tumor samples with 
informative 18q LOH data, LOH was present in at least one 18q marker in 362 tumors (65%; 
). There was an association between LOH 18q and obesity (BMI ≥ 30 kg/m2; p =0.018), distal 
colon location (p =0.025), low tumor grade (p =0.0060), low-level LINE1 methylation (p=0 
.040), wild-type KRAS (p=0.015), and JCVT (p=0.0004). The same study concluded that there 
is no association with LOH 18q and prognosis as yet. 
5.11 MiRNA – Developing New Promising Biomarkers  
miRNAs are short, 18-25 nucleotide non-coding single-stranded RNA sequences which are 
involved in regulation of gene expression on post-transcriptional level, through binding to their 
target protein-encoding mRNA [152]. (Michocova et al. ) They are believed to play an 
important role in the pathogenesis of colorectal cancer [153]. There are numerous studies which 
identify the presence of various miRNAs as predictive or prognostic biomarkers. In the study 
of Svoboda et al., [153], miR-215, miR-99a*, miR-196b, miR-450b-5p and LET-7e were 
associated with expression of thymidylate synthetase and radioresistance or chemoresistance 
to its inhibitors. 
miRNAs are also involved in the regulation of the EGFR signalling pathway as well and thus 
they may have essential value in predicting the response to EGFR inhibitors. Another study 
[154] identified that miR-451 inhibits cell growth through down-regulating the P13K/AKT 
pathway and thus it potentially has a repressive role. Lou et al., [83]  claimed that miR-625 
may have a prognostic and predictive role in CRC as decreased levels of the latter are 
associated with high incidence of metastasis and poor prognosis. [155] Yang et al., identified 
that miR-29c as having an antitumorigenic role and preoperatively decreased levels of miR-
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29c were associated with CRC relapse. miRNA-126 can have anticarcinogenic properties 
through inhibitition of neovascularization via blocking the 3- UTR’ of VEGF [156] 
Karaayvaz et al. [157] highlighted that miR-129 could potentially have a tumour-suppressor 
role and might be a novel target for anti CRC therapies. Dong et al., [156, 158, 159]  claim 
that, miR-133a serves as a functional tumor suppressor in CRC via enhancing apoptosis and 
inhibiting cell proliferation. According to the same study miRNA 133a iincreased p53 protein 
and induced p21 transcription and it can serve as sensitizer to doxorubicin and oxaliplatin. One 
potential mechanism of the anticancer properties of miRNA 133a is the fact that it can repress 
RFFL-3'UTR reporter activity and reduce its protein level.Finally Liao et al. [122, 123, 158]  
noted that miRNA 224 can induce tumour expansion and cell proliferation through via 
repressing PHLPP1 and PHLPP2 genes. miRNAs seem to be an interesting field of research 
with promising results (table 8).   
5.12 Conclusion 
CRC is the second most frequent cancer in Europe and despite progress in the understanding 
of the molecular background of CRC, effective molecular classification remains a challenge. 
Facing these difficulties in the establishment of a key model, researchers have started to try 
different, more innovative approaches, in which gene signatures dominate. In fact, the idea of 
gene signatures is very promising (59, 60), but there are still several issues of reproducibility 
and possible overlap (61, 62). Metabolomics is a new and promising field which tends to utilise 
simple products from cellular metabolism in order to identify differential and pathognomonic 
features of cancer[160-163] . The main advantage of this approach is the easy access; however, 
the low specificity for CRC remains a great challenge. Nevertheless, there is much to be looked 
at in this field, as metabolomics could potentially be a new concept in the investigation and 
classification of CRC. 
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Thus, molecular classification of CRC still remains a challenge that researchers have to 
overcome in the coming years. Creating an effective classification of CRC biomarkers based 
on their prognostic and predictive value will generate an effective decision-making tool in 












                                   Mechanism of action 
 










Anti-cancerous action via blocking the 3-UTR’ of VEGR and 








Anti-cancerous properties via increase of the expression of p53 and 
p21 gene products [156] 
 
miRNA 224 
   








Can induce tumour expansion via repressing PHLPP1 and PHLPP2 
[158] 
Table 8: MicroRNAs involved in CRC mechanisms. This table describes the main microRNAS that are involved in potential CRC 
pathways. Each might have different mechanisms of action by which it could result in inhibition or acceleration of tumorigenesis 
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Background: BRAF gene encodes a serine-threonine kinase that inhibits the RAS/MAPK 
intracellular pathway. BRAF mutations occur at an early stage of colorectal cancer and their 
presence, 10-20% of Colorectal Cancer (CRC), is usually associated with inferior prognosis. 
Materials and Methods: From 41 consecutive CRC confirmed referrals from 1,446 suspected 
cancer cases (mean age=67.99+13.45, Male=21, Female=20), we retrospectively analyzed 
collected data from haemoglobin (Hb) and symptoms at presentation, location of tumor 
and stage of the disease, including lymphovascular invasion (LVI). Gene profile analysis data 
(KRAS, BRAF) were retrospectively collected and associated with the presentation profile 
above. Results: There was no significant correlation in presentation Hb levels and eventual 
disease staging (P>0.05 for all associations). Patients with right-sided tumours were found to 
have a lower Hb level than patients with either left-sided colonic or rectal tumours. Hb levels 
were also significantly lower in patients with the BRAF V600E mutation. KRAS status or LVI 
status did not have a specific correlation with Hb levels. Conclusion: BRAF V600E mutation 
could be associated with right-sided tumors and subsequently related unexplained iron-
deficiency anaemia (IDA) at the stage of presentation. This finding may affect the choice of 
clinical strategy for investigation of unexplained IDA. Further research should be conducted 
in order to identify and support the potential biological explanation of the findings above. 
 









Colorectal cancer is the third most common cancer worldwide and, during the last decades, 
there has been a significant progress in understanding its pathogenesis [166]. Currently, there 
are three distinct molecular pathways to explain its complex pathogenesis [166-168]. The first 
one is chromosomal instability (CIN) where the aetiology is attributed to numerical 
(aneuploidy) or structural loss of chromosomes, whereas loss of heterozygosity (LOH) is a 
classic component of this theory. CIN is linked with several point mutations in genes, which 
are thought to be involved in the CRC pathway (APC, KRAS, BRAF, etc.) [166, 169]. The 
second pathway consists of a fault of the mismatch repair (MMR) system of the DNA  and this 
is defined as microsatellite instability pathway (MSI) [8, 166, 170]. MSI is a unique feature of 
Lynch syndrome (LS), though it could be found in sporadic cancer as well [8]. Lastly, a newer 
theory is this of C-phosphate-G (CpG) island methylation (CIMP), which can result into CIMP-
high and CIMP-low phenotypes. BRAF tends to be associated with CIMP high tumour 
phenotype [82, 117, 166]. 
V-raf murine sarcoma viral oncogene homolog B (BRAF) gene is involved as an inhibitor in 
the RAS/RAF/MAPK pathway [94, 171]. Somatic mutations in BRAF gene are found in 10-
20% of colorectal cancer  cases [122] and result in activation of BRAF serine-threonine kinase 
and subsequent up regulation of the RAS/RAF/MAPK signalling pathway [94, 172]. This can 
result in abnormal cellular growth, invasion and metastasis [167].  
BRAF V600 E mutation is the most well studied mutation and occurs in 90% of BRAF 
mutations [172-174]. It refers to a substitution of the amino acid glutamic acid for a valine at 
amino acid position 600 (c.f. 1799T>A) [76, 95].  
In terms of BRAF mutations and their relationship to other genetic events in CRC pathogenesis, 
there has been documented an association between BRAF mutant status and sporadic MSI-high 
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tumours [80, 122, 175, 176]. Lochhead et al. [122, 123] states that combined BRAF is related 
with MSI profile through its association with high level CpG methylator profile (CIMP) and 
MLH1 promoter methylation. The same study concludes that BRAF/MSI status could be used 
as a prognostic tool [122, 123]. 
There are existing data on the literature, which associate BRAF status with certain macroscopic 
features. Roth et al. [177, 178] concludes that BRAF mutations are significantly associated with 
female sex, right-sided location, older age, high grade and MSI-high tumours. A recent 
metanalysis [93] concludes that BRAF V600E is linked with advanced TNM stage, poor 
differentiation, mucinous histology, MSI, CIMP, as well as female gender, older age, proximal 
location and mutL homolog 1 (MLH1) methylation. 
There has been a long discussion about the prognostic and predictive value of BRAF mutational 
profile [146, 179, 180]. Recent studies associate BRAF mutations with poorer prognosis [122, 
146] and support their role in the response to chemotherapy [76, 95, 142].  
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6.3 Materials and Methods 
All our data derive from the urgent referral (“2 week-wait” or “2WW”) Cancer Database. 2WW 
is a pathway where general practitioners (GP) refer suspected colorectal cancer cases to a 
specialized unit in the UK. We used as a source of information the original GP referral letter, 
as well as the Colorectal Clinic letters in order to identify the presenting symptoms of each 
patient. Biochemistry profile information (haemoglobin (Hb)), histology reports and molecular 
diagnostics were kept online on Electronic Patients’ Records (EPR) database. 
We retrospectively identified 41 confirmed CRC cases from 1,446 consecutive referrals for 
suspected cancer. From those patients, 21 were male (51.2%), 20 females (48.8%). Mean age 
was 67.99 years and standard deviation (SD) 13.451 (Figure 11).  
Data were collected on clinical presentation profile, i.e. changes in bowel habit (CIBH), rectal 
bleeding (RB), unexplained iron-deficiency anaemia (IDA), weight loss, abdominal mass and 
family history (FH). Moreover, we have focused on the Hb levels at presentation, as well as 
tumour location and staging profile including lymphovascular invasion (LVI).  
KRAS and BRAF mutations ware defined using the pyrosequencing technique from extracted 
tumour DNA. The whole series of those were performed in our Advanced Diagnostics Lab.   
Data were analysed on IBM SPSS Statistics for Macintoshversion 22.0 Armonk, NY) using t-
test and ANOVA test. Finally, cross-reference of our results was performed using existing data 
in the literature. 
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Figure 11: Age distribution. 
6.4 Results 
The mean overall initial Hb level was 115.8 g/dl (SD=20.4), with 10 patients being referred 
with a diagnosis of IDA (24.4%). Amongst those referred with IDA, the mean Hb was 95.3 
g/dl, significantly lower than those not identified as IDA who had a mean Hb of 124.3 g/dl (t-
test, P<0.0001). Twenty patients were referred with rectal bleeding (48.8%), 26 (63.4%) with 
a change in CIBH, 6 (14.6%) with weight loss and 1 (2.4%) with a significant family history.    
Hb levels were significantly lower in patients referred with rectal bleeding (107.1 g/dl with and 
126.3 g/dl without, P=0.002). There was no significant difference in Hb level between patients 
according to CIBH (119.6 g/dl with CIBH and 111.5 g/dl without, P=0.245) or abdominal mass 
(109.3 g/dl with a mass, 118.3 g/dl without, P=0.323).  
All patients had a confirmed diagnosis of CRC: 10 right-sided (24.4%), 31 left-sided (75.6%) 
– comprised of 16 patients with left-sided colonic (39.0%) and 15 with rectal tumours (36.6%). 
Overall, there were 26 patients with a colonic primary (63.4%) and 15 (36.6%) with a rectal 
primary.  
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There were 8 patients (19.5%) with stage I disease, 12 stage II (29.3%), 15 Stage III (36.6%) 
and 6 stage IV (14.6%).  There was an uneven distribution of patients by stage, with relatively 
more patients with stage II and III disease than I and IV disease (see Table 9 and Figure 12, 
P=0.003), which was not altered significantly between those with colonic or rectal primaries 
(Table 6, P=0.212). The presence of LVI was available in 36 patients of whom 25 had no LVI 
(69.4%) and 11 with LVI (30.6%).  
 
Stage Colonic (N, %) Rectal (N, %) Total (N, %) 
Stage I 4 (15.4%) 4 (26.7%) 8 (19.5%) 
Stage II 9 (34.6%) 3 (20.0%) 12 (29.3%) 
Stage III 10 (38.5%) 5 (33.3%) 15 (36.6%) 
Stage IV 3 (11.5%) 3 (20.0%) 6 (14.6%) 
Total 26 (100.0%) 15 (100.0%) 41 (100.0%) 
Table 9: Cancer stage. 
 
Figure 12: Cancer Stage. 
 
Of the 41 patients, KRAS status was available in 40 of whom 28 were wild type (wt, 70.0%), 7 
mutation 12 (17.5%) and 5 mutation 13 (12.5%). BRAF was available in 24 patients of whom 
14 were wt (82.5%) and 3 with V600E mutation (17.6%).  
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There was no significant correlation in presentation Hb levels and eventual disease staging 
(P>0.05 for all associations). Patients with right-sided tumours were found to have a lower Hb 
level than patients with either left-sided (P=0.017) or rectal tumours (P=0.009). Hb levels were 
also significantly lower in patients with the BRAF V600E mutation (P=0.009). KRAS status 
was not found to be associated with Hb levels (P>0.05) (T=Table 10). LVI status as well, was 
not found to be linked with Hb levels (P>0.05).  
Feature Hb (g/dl) 
Total 115.8 
Stage I 116.0 
Stage II 114.6 
Stage III 120.6 




KRAS wt 116.6 
KRAS 12 108.1 
KRAS 13 120.4 
BRAF wt 123.5* 




Table 10: Relationship of Hb level to clinical features (ANOVA associations) 
Disease Stage P>0.05 for all associations with Hb levels; Primary location *P=0.017 (Right-
sided vs Left sided tumours’ Hb levels), +P=0.009 (Right-sided vs Rectal tumours’ Hb levels); 
KRAS status P>0.05 for all associations with Hb levels; BRAF status *P=0.009; LVI status 
P=0.456. 
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6.5 Discussion  
 
There has been a long discussion about clinical significance of BRAF V600E mutation in 
colorectal cancer [146, 177, 180]. Recent studies conclude that BRAF V600E mutation is 
associated with poorer prognosis [122, 146] and support its role in the response to 
chemotherapy [76, 144, 171]. More specifically, Mao et al. [95] state that BRAF V600E is 
associated with resistance to anti-epidermal growth factor receptor (anti-EGFR) monoclonal 
antibodies in patients with metastatic CRC and wild type KRAS. Phipps et al. [172, 181] 
conclude that BRAF mutational prognostic value can vary, depending on patient and tumour 
characteristics. Kristen et al. [182] highlight the significance of BRAF in terms of prognostic 
value, as well as a new CRC therapy target.  
However, there is also emerging data, which liaise BRAF V600E with MSI-high tumours [167]. 
In those cases, there is still a negative effect of the V600E mutation in overall survival [113], 
though some other researcher still doubt it [72, 116, 117, 183] and support that BRAF V600E 
has a negative prognostic effect only in microsatellite stable (MSS) tumours.  
BRAF V600E is generally linked in the literature with certain clinicopathological features, i.e. 
female sex and mucinous differentiation [166, 167, 184, 185]. There is a well-defined 
relationship between V600E mutation and generally poorer prognosis; however, no convincing 
explanation has been given yet.  
Our study concludes that there is a well-defined relationship between significantly lower Hb 
levels and V600E mutant neoplasms comparing to the wild type samples. There is no doubt 
that this could be attributed to the fact that all those patients present with right-sided tumours 
and also by the fact that all BRAF V600E specimens were advanced stage tumours (T3b and 
above). However, this observation could alter the significance of the presence of IDA in the 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 95 
clinical investigations pathway by demonstrating that IDA may signify a higher risk cancer. 
This may well affect the choice of treatment and would imply to look for BRAF mutation in 
unexplained IDA, where colorectal cancer is suspected. Of note is the fact that we could not 
identify any statistical significance between Hb levels and disease stage (I-IV). 
The main question that this study raises is in what stage of the carcinogenesis pathway does 
BRAF interfere. According to the literature, most of the BRAF V600E specimens appear to be 
in advanced stage [93, 177, 184]. It is, thus, quite important to establish in which time point 
BRAF interferes as it appears that this happens on a mature stage in the pathway. Taking into 
consideration the latter, it is quite important to interpret the potential link between IDA at 
presentation and BRAF V600E.   
A recent promising study [185] suggests a multitarget stool DNA test with faecal 
immunochemical test (FIT) as a noninvasive diagnostic technique for CRC screening. The 
sensitivity for detecting CRC was 92.3% with DNA testing and 73.8% with FIT detecting 
versus 42.4% with DNA testing and 23.8% with FIT in advanced precancerous lesions. This 
test does not include BRAF. The main question is whether there would be of clinical importance 
to incorporate BRAF screening in these tests, especially in those cases where IDA is noted at 
presentation. This would help in increasing the sensitivity of these methods and IDA could be 
used as an alarm point where advanced cancer with mutant BRAF is suspected. In terms of 
precancerous lesions, again, our question regarding the stage of the carcinogenesis that BRAF 
interferes, could be a crucial point in order to improve the sensitivity of this method, as well as 
stratifying the risk of potential progression to cancer. In other words, if we knew the exact point 
where V600E mutation appears, then, we would be able to tell if a precancerous lesion has a 
potential higher risk of progression to cancer.  
Moreover, we tried to liaise potential clinical presentation features with the molecular status of 
KRAS and BRAF, which are thought to play a significant role in prognosis of CRC, as well as 
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response to neoadjuvant chemotherapy. The main question was whether there would be any 
unique clinical presentation or histopathology features, which could potentially be liaised with 
a known mutation of KRAS or BRAF.  
With regards to KRAS mutational status, there was no significant relationship between disease 
stage and KRAS status (P>0.05). This keeps with what already exists in literature, as KRAS is 
not an established prognostic marker [177]. It is well known that in many centres around the 
world, KRAS can be used as a predictive tool to identify whether a patient would benefit from 
anti-EGFR chemotherapy agents [70, 76, 119, 134]. Nevertheless, despite its well known 
predictive value, there is no conclusion whether KRAS status could be used as a prognostic 
tool, with the vast majority of researchers doubting its significance in terms of defining disease-
free survival [70, 119]. An interesting point from or results is that there was no direct 
relationship between Hb levels or clinical presentation and KRAS status (P>0.05). This could 
be easily explained by the fact that CRC pathogenesis is quite complex and a single gene is 
difficult to be liaised with specific macroscopic presentation features unless there is an 
established strong relationship between certain histopathology characteristics and molecular 
status. Similarly, there was no defined statistical relationship between LVI and KRAS 
mutational status (P>0.05), which could be attributed again to its controversial prognostic 
value.  
KRAS mutations tend to appear in earlier stages of the carcinogenesis pathway [166]. Contrary 
to BRAF V600 E neoplasms, where there is an established relationship with proximal location, 
KRAS mutant tumours tend to have a bimodal distribution in the proximal-distal axis and tend 
to appear more proximally and to the caecum [85].  
On the other hand, BRAF V600E mutation is well linked with proximally located tumours 
[184]. On our sample, even though it is quite small, there was a well-defined relationship 
between right-sided neoplasms and V600E mutation.  
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Nevertheless, there was no defined statistical relationship between LVI and BRAF status 
(P>0.05) and this is difficult to comment based on the limitations of our sample. Positive LVI 
is linked with a slightly lower Hb level comparing to LVI negative (109.7 g/dl vs. 115.1 g/dl). 
In conclusion, given the complexity of the molecular pathways described, as well as the fact 
that many molecular agents are interfering one each other, it is quite difficult to establish a 
clear picture for unique partial impact of every gene in the CRC pathogenesis. Our study 
concludes to raise a question regarding the stage of the carcinogenesis pathway where BRAF 
appears to be mutant. Also, it is quite important to consider whether IDA could be used as a 
potential marker of advanced cancer and, given its relationship with proximal tumours and 
subsequently with BRAF V600E mutation, this could be used as a starting point to question 
whether V600E mutation could be incorporated in DNA screening methods that are recently 
been released. This would be indisputably useful in cases where IDA could potentially be a 
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7.1 Abstract.  
Background: Transanal endoscopic microsurgery (TEMS) is emerging as an alternative 
treatment for rectal cancer Stage I. There remains a risk of local recurrence. Aim: To study the 
effect of biomarkers in local recurrence for Stage I rectal cancer following TEMS plus or minus 
radiotherapy. Materials and Methods: This is a case control study where we compared 10 early 
rectal cancers that had recurred, with 19 cases with no recurrence, total 29 patients (age=28.25-
86.87, mean age=67.92 years, SD=14.91, Male, N=18, Female, N=11). All patients underwent 
TEMS for radiological Stage I rectal cancer (yT1N0M0 or yT2N0M0) established with 
combination of magnetic resonance imaging (MRI) and ERUS. We prospectively collected all 
data on tumour histology, morphological features, as well as follow-up parameters. Molecular 
analysis was performed to identify their status on BRAF, KRAS, p16 O6-methylguanine-DNA 
methyltransferase (MGMT) and β-catenin. Results: From 29 specimens analysed, 19 were 
KRAS wild type (65.9%) and 10 mutant (34.5%). Recurrence of the tumour was noted in 10 
cases (34.5%) from which 60% were pT1 (N=6) and 40% pT2 (N=4). There was a statistically 
significant association between KRAS mutant status and local recurrence (N=6, p=0.037). P16 
expression greater than 5% (mean=10.8%, min=0, max=95) is linked with earlier recurrence 
within 11.70 months (N=7, p=0.004). Membranous β-catenin expression (N=12, 48%) was 
also related with KRAS mutant status (p=0.006) but not with survival (p>0.05). BRAF gene 
was found wild type in all cases tested (N=23). Conclusion: KRAS/p16/β-catenin could be 
used as a combined biomarker for prediction of local recurrence and stratification of the risk 
for further surgery.    
  




The method of local excision, which has gained wider acceptance, recently, in early rectal 
cancer, is transanal endoscopic microsurgery (TEMS). TEMS generally offers advantages in 
operative access and oncological clearance over transanal resection (TAR) but recently a 
number of similar logic techniques with various rectal ports for endoscopic excision of rectal 
tumours has been invented. Those methods are collectively named transanal minimal invasive 
surgery (TAMIS) and for oncological purposes they share the same features of local excision 
as TEMS. [43, 51-53, 55, 56, 61, 64, 65, 71, 149, 186-188] 
TEMS is a minimally invasive technique that was introduced by Buess in the early 1980’s [51]. 
Through the new rectoscope with 3D binocular optic and the endoscopic instruments, it offers 
better access to proximal lesions with lower margin positivity and fragmentation and 
magnification of the operative field [51, 189]. TEMS is a safe procedure that offers low 
complications’ rate and peri-operative morbidity (10.7%) [55]. There have been multiple 
studies to suggest that TEMS is the operation of choice for rectal adenomas [186], retrorectal 
and submucosal rectal lesions [53]. Furthermore, TEMS offers the advantage of not damaging 
the anorectal function [52].  
TEMS is indicated as a curative treatment for malignant neoplasms that are histologically 
confirmed as pT1 sm1 carcinomas, whereas T1 sm2-3 and T2 lesions are still under question 
[56]. A number of studies have shown that TEMS can have comparable results with radical 
surgery [56, 64, 186, 190] for rectal cancer. 
There has been a concern about oncologic outcomes following TEMS [41]. Some studies 
support that there is potentially a higher risk of local recurrence rate with TEMS [56, 149, 191]. 
Efforts have been made to classify risk with morphological and histological criteria with better 
patients’ selection [43, 52, 56, 61, 186]; however, the risk stratification remains imperfect. 
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Molecular biomarkers have been used in prognosis of colorectal cancer (CRC) in general and 
rectal cancer seems to follow the same genetic phenotype [192]. So far, the data in the literature, 
which link biomarkers and oncologic outcomes from TEMS, are limited. 
Several biomarkers are being studied in CRC. Nevertheless, rectal cancer may have a specific 
profile of biomarkers, which is different to the rest of colonic cancer [193]. Kohonen-Corish 
et al. [193] went through and analysed a cohort of 381 rectal cancer specimens. The conclusion 
was that they identified a more aggressive subgroup arising from the KRAS-p16 pathway. This 
was explained by the fact that p16 deficiency and KRAS mutant status did promote 
carcinogenesis through the loss of oncogene-induced senescence. Therefore, p16 and KRAS 
could potentially be used as a prognostic biomarker in rectal cancer, which is against what is 
thought to be the case in sporadic colonic cancer.   
We thus, aimed to identify whether any of the biomarkers KRAS, BRAF, p16. MGMT, β-
catenin could be used as a prognostic factor to predict recurrence in early rectal cancer 
following local excision (TEMS).    
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7.3 Materials and Methods 
 
Our institution performs TEMS for early rectal cancer after discussion at the Multi-Disciplinary 
Cancer meeting (MDT) according to UK national guidelines. All cases in this study have been 
operated by the same surgeon (senior author, SP). We prospectively collected data on 
histological parameters of each lesion i.e. stage, differentiation, location, margins of resection 
and dysplasia where applicable. Preoperative staging of the tumours has been performed with 
magnetic resonance imaging (MRI) of the rectum and endorectal ultrasound (EUS), which are 
proven to have high diagnostic accuracy when combined [194-197]. We have an established 
follow-up protocol for these patients with an intensive 5-year surveillance consisting of 6 
monthly endoscopy, carcinoembryonic antigen (CEA), MRI scan and computed tomography 
(CT) scan for 3 years, which is altered to annual surveillance in years 4 and 5 (Table 11). 
We selected 10 patients who had recurrence after TEMS for early rectal cancer and we 
compared them in a case control study with 19 similar patients without recurrence. This was to 
assure we could compare the status of several biomarkers in non-recurrent vs. recurrent lesions.  
Eighteen patients (62.1%) were male and 37.8% were female (N=11). Mean age at the stage of 
diagnosis, was 67.93 years (min=28.25, max=86.87). All the specimens were Stage I rectal 
cancer. Eighteen were pT1 (62.1%) and 11 pT2 (37.9%). There were no differences between 
the two groups.     
Radiological staging has been performed both before and after radiotherapy. Neoadjuvant or 
adjuvant radiotherapy decision was based on fitness criteria, as well as patient choice. The 
option of further radical (completion) surgery has been offered in selected individualised cases 
as an option but was declined by the patients.  
Biomarker analysis. All biomarkers were assessed on formalin-fixed, paraffin -embedded 
(FFPE) samples. Βeta-catenin, mismatch repairs (MMRs), O6-methylguanine-DNA 
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methyltransferase (MGMT) and p16 assays were performed using immunohistochemistry 
(IHC). Four-μM sections of the tumour were cut on to coated slides and IHC was performed 
using standardised protocols for each antibody. The final step was visualisation of antigen-
antibody complexes by the addition of the chromogen, diaminobenzidine. The slides were then 
assessed (by SDC and JM) and scored for percentage of positive tumour cells and protein 
location (Figure 13-16). 
KRAS mutation analysis was performed on the same tumour samples. Haematoxylin and eosin 
(H&E) stained sections of the tumour were assessed and marked for tumour content and the 
tumour was then macrodissected using serial, unstained section from the non-tumour 
components, allowing for enrichment of tumour cells. DNA was then extracted from these 
samples using standardised protocols and quantified by Qubit analysis. Polymerase chain 
reaction (PCR) using primers either side of the regions of interest, codons 12 and 13 and codon 
61, was performed. After immobilisation of the resulting amplicons, single stranded DNA was 
prepared and the sequencing primer for each region was annealed. The samples were then 
analysed on a Qiagen Q24 pyrosequencer (QIAGEN Group®, PyroMark®, Pyrosequencing®, 
1061692 02/2010 © 2010 QIAGEN, all rights reserved) and the resulting sequence was 
analysed using the appropriate software (PyroMark Q24 Software, 1/2009 ©). The mutation 
status of each tumour was reported according to standard protocols (by SDC and JM).  
Appropriate positive and negative controls were included for all assays. 
 
Statistical analysis. Statistical analysis of our results was performed using IBM SPSS for 
Macintosh version 22 (IBM Corp., Armonk, NY, USA). We have performed bivariate 
correlations (Pearson’s and Spearman’s rho, as well as Chi-square associations) to identify any 
potential links between follow-up parameters and KRAS, BRAF, p16, β-catenin or MGMT.   
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7.4 Results  
The mean overall follow-up period was 32.83 months (SD=23.02, min=12.96, max=126.9). 
From 29 patients, 19 did not have recurrence (65.5%), whereas 10 did have local recurrence of 
the rectal lesion (34.5%). The mean recurrence time was 13.04 months (min=4.11, max= 42.28) 
(Table 11).   
From 29 patients, 79.3% (N=23) did not require further surgery, whereas 21.6% did (N=6). 
Twenty-five patients warranted TEMS procedure once (86%), whereas 1 patient required 
TEMS procedure twice (3.4%), 1 three times (3.4%) and 2 four times (6.8%). Decision to 
proceed with multiple TEMS was based on the fact that patients were unfit for radical surgery.  
Three patients (10.3%) received neoadjuvant radiotherapy (N=1 was pT1 and N=2 pT2), 
whereas 89.7% (N=26) did not receive.  N=9 received further course of radiotherapy, based on 
the histology findings of unsuspected cancer and individualised decision to proceed with 
radiotherapy was made by the Multidisciplinary Team meeting. Patients underwent short 
course radiotherapy; the regimen was 45-50Gy according to the local guidelines. All patients 
who had repeat TEMS surgery were elderly or unfit for major surgery and, therefore, the 
procedure was palliative (Table 11).  
All the 29 specimens were Stage I from which 62.1% were pT1N0 (N=18) and 37.9% were 
pT2N0 (N=11). This is based on radiological criteria. Completion of staging was performed 
with the rest of preoperative work up, including EUS, clinical assessment, CT abdomen-pelvis-
thorax (TAP) and MRI of the pelvis and rectum. Almost one third (31.0%) did not have 
confirmed clear resection margins (N=9), whereas in the rest 69% (N=20), the margins were 
confirmed to be clear. The remaining tumours had margins obscured by the energy device 
artefact (Harmonic Ace and electro cautery) and were declared uncertain. There were no 
positive margins. N=19 (65.5%) of the lesions were located in the lower rectum, 20.7% (N=6) 
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in the mid rectum and 13.4% (N=4) in the upper rectum. Two (6.9%) were poorly differentiated 
adenocarcinomas, whereas 62.1% (N=18) were moderate differentiated and 31% (N=9) were 
well differentiated. The mean circumference of the tumour was 40.80% (min= 20%, 
max=75%). Greater than 33% circumference was found to be linked with mutant KRAS 
(p=0.00) (Table 12). 
Nineteen of the specimens were KRAS wild type (65.5%) whereas 34.5% (N=10) were KRAS 
mutant (codon 12, 13 or 61). From the available BRAF results, 23 of the specimens were 
analysed and none was found to be positive for V600E mutation (wild type). From the MGMT 
point of view, 91% (N=23) were positive (preserved), whereas 8% (N=2) were negative (non-
preserved). Four patients did not have available MGMT status (Table 12). 
From 29 specimens, 25 had available β-catenin status. Almost half (48%) were found to express 
membranous (m) status of β-catenin (N=12) (Figure 13), whereas 28% was found to express 
membranous and 30% nucleus (n) (N=7) (Figure 14), 10.3% m+50% n (N=3) and 10.3% only 
nucleus (N=3).All KRAS mutant tumours were linked with membranous β-catenin (N=8, 
p=0.009), whereas wild-type KRAS were spread between β-catenin m (N=3, 23.1%), m+30%n 
(N=7, 53.8%), m+50%n (N=3, 15.2%) and 100%n (N=1, 7.6%). Also, membranous β-catenin 
was linked with more circumferential configuration of the tumour (p=0.028) but not with 
survival (p>0.05) (figure 18). 
From our primary analysis, there was an association between mutant KRAS and local 
recurrence (p=0.037). From 10 specimens, which recurred, 60% were mutant for KRAS (N=6) 
and 40% wild type (N=4). Also, from 19 specimens with no recurrence, 79% (N=15) were wild 
type and 21% (N=4) KRAS mutant (Table 13). There was no association between recurrence 
and p16 or β-catenin or MGMT status (p>0.05). Furthermore, local recurrence was not found 
to be associated with MRI pT stage, (p>0.05) or other morphological features of the tumour, 
including height, location, circumference and orientation (p>0.05). Local recurrence was not 
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found to be associated with histological features of the specimens, i.e. pT stage, clear margins, 
dysplasia or differentiation (p>0.05). Moreover, there was no association between recurrence 
and neoadjuvant radiotherapy (p=0.123) (Table 12). 
The overall mass was calculated from the dimensions documented on the histology report (size 
1 in mm x size 2 in mm x size 3 in mm). The overall mean mass of the specimens was 
13229,967 mm3 min=0.00 mm3, max=159.250,00 mm3, SD=28.706,9. The mean mass of the 
tumours that recurred was 25.776,00 mm3 (min= 3200,00 mm3 max= 159.250,00 mm3, 
SD=47.375,34) compared to 6626,78 mm3 (min=00 mm3, max=17.940,00 mm3, SD=5121,69) 
for those that did not recur. There was a statistical significant relationship between the mass 
and recurrence of the lesions (p=0.028).  
KRAS was found to be associated with β-catenin status (p=0.009) and, more specifically, 
mutant KRAS tends to be linked with membranous (m) β-catenin (N=12, 41.9%). Also, KRAS 
mutant status is associated with the increased number of total TEMS (p=0.02). All wild type 
KRAS (N=19) specimens have undergone a single operation, whereas 11.1% (N=1) of mutant 
had times 2 TEMS, 11.1% (N=1) times 3 and 22.2% (N=2) times 4. What is more, cancer-
related death was noted in 6.9% (N=2) and was linked with KRAS mutant status (p=0.045). 
Discovery of unsuspected cancer was noted in 41.3% (N=12) and linked with mutant KRAS 
(N=7, p=0.023). However, there was no link between KRAS and dysplasia or differentiation of 
the specimen or clear margins or mass or pT stage or orientation of the specimen (p>0.05 for 
all associations, Table 12). 
Mean p16 expression was 10.8% (min=0.0%, max=75%). P16 expression more than 5% was 
linked with recurrence within the first 11.70 months (N=7, p=0.04) (Figure 19), though no 
other histological, morphological or phenotype association was identified (p>0.05) (Table 12) 
(Figure 15-17). 
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Finally, MGMT status was found preserved in 92.0% (N=23) and non-preserved (negative) in 
8.0% (N=2). All patients with MGMT negative results were aged above 80 years at the time of 
diagnosis (p=0.024) and pT2 (p=0.030). There was no other association noted between MGMT 
and morphological, histological or follow-up parameters (p>0.05) (Table 12). 
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7.5 Discussion 
There has long been an effort to link molecular biomarkers with prognosis in colorectal cancer 
but it still remains a poorly understood field. From our data, there seems to be a link between 
mutant KRAS and the risk of local recurrence of early rectal cancer after endoscopic local 
excision surgery TEMS. This is a previously unreported finding. We discuss here whether there 
may be a sound biological basis of this finding. 
Kirstein rat sarcoma viral sarcoma oncogene (KRAS), is a proto-oncogene involved in cellular 
response to extracellular stimuli, i.e. mitogen-activated protein kinase (MAPK) and 
phosphoinositide-3-kinase / v-akt murine thymoma viral oncogene pathways (PI3K/AKT) [69, 
113]. Therefore, KRAS mutations can potentially lead to activation of downstream signaling 
pathways, i.e. MAPK and PI3K/AKT. The latter is thought to lead to a higher resistance to 
anti-epidermal growth factor receptor (EGFR) inhibitors and, hence, this could be the etiology 
for increased resistance to anti-EGFR chemotherapy agents [198, 199].  
KRAS mutations in codons 12, 13 and 61 are the most popular and tend to occur in 30-40% of 
CRCs. However, there have been noted 85 different KRAS mutations, many of which refer to 
a specific cancer pathway [56, 119].   
So far, the prognostic and predictive value of KRAS gene in CRC has been debated, though it 
still remains controversial. There have been studies, which mainly support KRAS predictive 
value in response to anti-EGFR chemotherapy agents [198]. More specifically, wild type KRAS 
is thought to be linked with better response to anti-EGFR agents, i.e. cetuximab, and this could 
be attributed to the relevant molecular mechanism described in the previous paragraph [199]. 
Nevertheless, there are emerging data that KRAS predictive value in response to anti-EGFR 
inhibitors is controversial when BRAF gene appears to be mutant (V600E mutation) [93, 142, 
179].  
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On the contrary, the prognostic value of KRAS in CRC remains equivocal. Most of the studies 
are inconclusive [70, 119] but there are some that associate KRAS mutant status with poorer 
prognosis [172].  
Our study concludes that mutant KRAS may create a higher risk of local recurrence of early 
rectal cancer following TEMS. In our data, there is no association between local recurrence 
and pT stage or any other histopathological features (p>0.05); however, we need to keep in 
mind this is a small study not powered enough to test all possible factors. A recent study [85] 
supports that the frequency of KRAS mutant colorectal carcinomas is 35-40%, where in our 
case is 34.5%.  
KRAS is also linked with some morphological features of the tumors and this can support its 
impact on the recurrence [85]. Given the fact that a change in the genotype can directly reflect 
on the tumor phenotype, we can support that KRAS is linked with more circumferential 
configuration (p=0.000) and height of the lesion (p=0.030), as well as bigger mass (p=0.029).  
BRAF V600E seems to be another valid prognostic biomarker in CRC. There is a link between 
BRAF V600E status and worse prognosis [122, 146] and BRAF V600E and more advanced 
cancer, being mostly present in right-sided tumours [93, 177]. As discussed before, BRAF 
V600E has been found to interfere with KRAS occasionally. There are studies supporting that 
mutant BRAF status can affect response to anti-EGFR chemotherapy agents even in the 
presence of wild type KRAS [76, 95]. All our specimens were BRAF wild type, where tested, 
and this could be explained by both the location, as well as earlier stage.     
Another interesting finding in our data, is that p16 and MGMT are associated with older age 
(p=0.01 and p=0.024, respectively). _ENREF_43Methylation of CpG islands (CpG island 
methylator phenotype (CIMP) and, specifically, O(6)-methylguanine-DNA methyltransferase 
(MGMT) gene promoter methylation) has been studied extensively in CRC [72, 80, 116] and 
seems to have a recognised impact on the carcinogenesis pathway, though there is no consensus 
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about its prognostic value [200]. Loss of MGMT expression is found in 30-40% of metastatic 
CRC and results in the inability of the alkyl base to be removed from the methylated guanine 
and, hence, preservation of the DNA is not achieved [200].  
With regards to the prognostic value of p16, there are studies correlating the methylation of 
p16 promoter with several clinicopathological features of CRC [93, 155, 201], i.e. TNM stage 
(p=0.006), lymph node metastasis (p=0.002), histologic grade (p<0.001), Dukes stage 
(p=0.002), tumour size( p=0.041) and location (p<0.001) Also, another study [202] shows that 
p16 methylation is found more in the serum of metastatic CRC patients. On our study, there is 
a link between p16 expression >5% and recurrence within 11.5 months (p=0.04). Furthermore, 
a recent cohort study [203] concludes that patients with advanced CRC, p16, human mutL 
homolog 1 (hMLH1) and MGMT methylation are associated with higher risk of recurrence, 
compared to patients with preserved unmethylated promoters. 
Another interesting recent study [204] concludes that approximately 70% of KRAS-positive 
tumors are thought to have a CIMP characterised by aberrant methylation of the DNA of 
multiple genes, including p14, p15, p16. Therefore, this could be used as a link between KRAS 
status and p16 expression, especially in different stages of the cancer pathway. 
In terms of the β-catenin significance, there seems to be a link between KRAS mutant status 
and membranous β-catenin (N=8, p=0.09). This is fairly interesting as it connects two different 
pathways of the carcinogenesis pathway together. Βeta-catenin seems to belong to a different 
signalling pathway (wnt/β-catenin) and its significance in CRC remains equivocal. Βeta-
catenin is a pivotal molecule involved in intercellular adhesion and some other oncogenic and 
developmental processes [205]. The same study links the up-regulation of β-catenin with the 
confrontation of tumour cells in the host microenvironment, whilst in metastatic process. 
However, its role in CRC remains unclear. In our study, membranous β-catenin is linked with 
higher circumference of the tumor (p=0.028, Figure 18). This supports again a joint role with 
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mutant KRAS status as the latter is linked with higher circumference as well. An interesting 
study [176] in lung cancer concludes that combinational activation of KRAS and wnt/β-catenin 
pathway leads to a significant increase on the lung tumour formation and, therefore, worse 
prognosis effect.   
With regards to the decision for further neoadjuvant radiotherapy, no relationship was 
identified between the decision for neoadjuvant radiotherapy and our potential biomarkers, i.e. 
KRAS, BRAF, MGMT, β-cateninand p16 (p>0.05 for all associations).  
In summary, our study has limitations of size, which does not allow clarification of all the 
contributing factors in recurrence. As recurrence of early rectal cancer after local excision is 
rare, with average numbers around 10%, it is not easy to form a much larger study than this.   
However, we consider our findings adequate to propose that KRAS, p16 expression and β-
catenin status should be looked further as a potential combined biomarker system to assess the 
risk of local recurrence. Mutant KRAS is found to be associated more with local recurrence and 
with unsuspected cancer in the specimen (p=0.023) (when the initial tumor was thought 
dysplastic). Membranous β-catenin tends to be linked with mutant KRAS as well. P16 
expression is associated with earlier recurrence, something that could re-direct the focus of the 
5-year postoperative surveillance protocol if confirmed. 
In conclusion, the biomarkers KRAS/p16/β-catenin could be used as a combined biomarker for 
prediction of local recurrence and stratification of the risk for further surgery, as well as to 
stimulate further larger studies to confirm these findings and increase our understanding of the 
factors causing recurrence after local excision of early rectal cancer. 
 
 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 113 
 
Figure 13: Beta-catenin membranous 
.  
Original photo from KCH lab (J. Moorhead). 
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Figure 14: Beta-catenin membranous and nuclear 
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Figure 17: P16 expression 
  




Patients’ characteristics (Table 11) 
Age 
(Diagnosis) 
Minimum=28.25, Maximum= 86.87, Mean age=67.92 years 
pT stage pT1N0, N=18 (62.1%) pT2N0, N=11 (37.9%) 
Recurrence YES, N=10 (34.5%) NO, N=19 (65.5%) 
Follow-up Mean follow-up=32.83months, SD=23.02, min=12.96, max=126.9  
Mean 
recurrence 
Minimum=4.11 months, Maximum=42.28, Mean= 13.04 Months 
Clear margins YES, N=N=20 (69%) Inconclusive, N=10 (31%) 
Location Lower rectum, N=19 
(65.5%) 
Mid rectum, N=6, (20.7%) Upper rectum, 
N=4 (13.4%) 
Differentiation Well dif., N=9 (31%) Moderately Dif., N=18 
(62.1%) 
Poorly Dif., N=2, 
(6.9%) 
TEMS (NOP) Times x1, 
N=25 (86%) 
Times x2, N=1 
(3.4%) 
Times x3, N=3 
(3.4%) 




Minimum= 20%, Maximum=75%, mean=40.80% 




YES, N=3 (10.3%) NO, N=26 (89.7%) 
Adjuvant 
radiotherapy 
YES, N=9 (31%) NO, N=20 (69%) 
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KRAS Wild type, N=19 (65.5%) Mutant, N=10 (34.5%)  
BRAF All analysed specimens (N=23) were BRAF wild type   
MGMT Preserved, N=23 (91%) Non-preserved, N=2 (9%) 






n, N=3, (10.3%) 
P16 Minimum= 0%, Maximum=75%, Mean expression =10.8% 
Table 11: Patients’ characteristics, specimens' morphology, biomarkers' profile 
NOP, number of procedures. 
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KRAS status Recurrence Significance 
 YES NO Total   
Wild type N=4 (13.8%) N=15 (51.7%) N=19(65.5%) p=0.037 
Mutant N=6 (20.7%) N=4 (13.8%) N=10(34.5% p=0.037 
Total N=10 (34.5%) N=19 (65.5%) N=29(100%) 
 
 








Figure 18: Circumference vs. β-catenin expression 
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8.1 Abstract.  
Background/Aim: Total mesorectal excision combined with neo-adjuvant chemoradiotherary 
(CRT) and adjuvant chemotherapy, has been the standard treatment of locally advanced rectal 
cancer (LARC). Although TNM (Tumor, Node, Metastasis) Classification for Malignant 
Tumors is still the cornerstone in rectal cancer staging, there has been an effort to identify 
molecular biomarkers with additional prognostic or predictive value. Materials and Methods: 
We retrospectively analyzed molecular biomarkers on prospectively collected histology 
specimens and clinical data from a cohort of 135 consecutive Rectal Cancer Cases who 
underwent radical excision in a tertiary center between 2011-2014 (M=87, F=48, age: 22-89, 
mean=64,67, SD=13.40). Radiological, histopathological, molecular staging, treatment 
stratification by the multidisciplinary team (MDT), as well as prognostic outcome data were 
compared with various biomarkers including KRAS, BRAF, p16, b-catenin, MSI, MMR and 
MGMT. Results: The mean follow-up was 39.21 months (range=5-83 months, SD=21.34). 28 
cases were Stage  (20.9%), n=30 Stage  (22.4%), n=45 Stage  (33.6%) and n=31 Stage V 
(23.1%). Forty specimens were KRAS-mutant (mt) (37.4%) while n=67 (62.6%) wild type 
(wt). KRAS mt status was associated with female sex (n=20, p=0.021) and older age (69.62 vs. 
62.27, p=0.005). Stage  Early Cancer Subgroup analysis showed that KRAS mt status is 
associated with distant recurrence of disease (n=4, p=0.045). Conclusion: KRAS mt status may 
affect the prognosis of early rectal cancer, as this is linked with distant recurrence.   
 
  





Treatments for rectal cancer have evolved significantly during the last decade [78]. Bowel 
cancer screening is starting to diagnose tumors at an earlier stage [206, 207]. This has 
significantly notably improved survival and made minimally invasive treatments more feasible. 
Neo-adjuvant Chemo radiotherapy (CRT), followed by total mesorectal excision (TME) and 
adjuvant chemotherapy, remains the gold standard in the treatment of Locally advanced rectal 
cancer (LARC) [196]. LARC generally refers to Stage  rectal cancer, and it represents 70% 
of the rectal cancers on presentation [208].  
Recent developments in the study of oncogenes and biomarkers, have raised hopes that they 
may of possible assistance in prognosis and treatment choices [70, 80, 119]. Molecular 
biomarkers are grossly divided into prognostic and predictive. The former Prognostic 
biomarkers refer to those molecules, that could potentially hold important information on life 
expectancy post diagnosis +/- treatment of disease, whereas the latter predictive biomarkers 
are used to predict response to a treatment plan [69, 70].  Although there is progress in the 
understanding of the significance of those biomarkers, the complexity and diversity of 
carcinogenesis pathways in Colorectal Cancer (CRC), makes it challenging to identify their 
impact on prognosis, and potential implications to treatment choice [86].  
KRAS is a proto oncogene which seems to be a well-recognized predictive biomarker in CRC 
[70]. Most of the studies comment on KRAS value expression as a tool to predict response to 
anti-EGF chemotherapy, though its prognostic value is still equivocal ambiguous [209]. BRAF 
V600E mutation has also been well studied and it seems to be associated with proximal tumors 
as well as poorer prognosis [103]. Microsatellite instability (MSI) is a part of the molecular 
phenotype of CRC, and hence has been widely studied in both hereditary as well as and 
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sporadic CRC [78]. Methylation products seem to play an increasingly significant role as well. 
Currently, many studies look at hypermethylation of CpG islands which are generally located 
at the promoters of various genes, the expression of which can affect CRC outcomes [72, 82, 
116, 202, 210]. For instance, p16 and b-catenin protein expression as well as MMR or MGMT 
preservation are currently tested routinely in our institution, for completion of the molecular 
staging of the CRC cases. Our aim in this study is to examine the significance of certain 
molecular biomarkers including KRAS, BRAF, MMR, MGMT, p16, MSI, b-catenin in the 
prediction of recurrence and survival. 
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8.3 Materials and Methods 
  
Samples. One hundred and thirty-five rectal cancer cases with prospective collection of clinical 
and pathological data (as part of the UK National Bowel Cancer Audit) were used for this 
study. Analysis of biomarkers was performed on stored tumor specimens. Our center offers 
treatment options to patients, based on the multidisciplinary team MDT approach. Intense 
follow-up on a 6-month basis, according to local guidelines. This protocol includes CT 
Abdomen, Thorax and Pelvis, colonoscopy, CEA, and occasionally EUS or MRI of the 
abdomen. Data on demographics, radiological, histopathology, molecular as well as follow up 
outcomes are prospectively collected as part of the UK National Bowel Cancer Audit.  
 
Molecular analysis: All biomarkers were assessed on formalin fixed, paraffin embedded 
(FFPE) samples. Β-catenin, MMRs, MGMT and p16 assays were performed using 
immunohistochemical analysis (IHC). Four-μM sections of the tumor were cut on to coated 
slides and IHC was performed using standardised protocols for each antibody. The final step 
was visualization of antigen-antibody complexes by the addition of the chromogen, 3-3’-
diaminobenzidine (DAB). The slides were then assessed (by SDC and JM) and scored for 
percentage of positive tumor cells and protein location. 
 
KRAS mutation analysis was performed on the same tumor samples. H&E stained sections of 
the tumor were assessed and marked for tumor content and the tumor was then macro-dissected 
using serial, unstained section from the non-tumor components, allowing for enrichment of 
tumor cells. DNA was then extracted from these samples using standardized protocols and 
quantified by Qubit analysis. PCR using primers either side of the regions of interest, codons 
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12(35G>A, 35G>T, 34G>T) and 13(38G>A) and codon 61 (182A>T), was performed. After 
immobilization of the resulting amplicons, single stranded DNA was prepared and the 
sequencing primer for each region was annealed. The samples were then analyzed on Quigen 
Q24 pyrosequencer and the resulting sequence was analyzed using the appropriate Qiagen 
software (Version 2.07). The mutation status of each tumor was reported according to standard 
protocols (by SDC and JM).  
Appropriate positive and negative controls were included for all assays. 
 
Statistical analysis: Statistical analysis of our results was performed using IBM SPSS for 
Macintosh version 22 (IBM Corp. Armonk, NY, USA). Univariate correlations (Pearson’s and 
Spearman’s rho as well as Chi-square crosstabs) were used to identify any potential links 
between various parameters and KRAS, BRAF, p16, b-catenin or MGMT.  Independent t-test 
associations were used to compare means in different groups. Statistical significant level was 










One hundred and thirty-five patients with confirmed rectal cancer were identified in our cohort 
(mean age at diagnosis was 64.67 years old, range=22-89 years, SD=13.32). Eighty-seven 
(64.4%) patients were male, and 48 (35.6%) were female. The mean follow-up was 39.21 
months (range=5-83, SD=21.34). 21 (16.3%) were ASA grade , 72 (55.8%) ASA grade , 35 
(27.1%) ASA grade  and 1 was ASA grade V (0.8%) (Table 14).   
 
Preoperative staging (MDT Stage): Twenty-eight were Stage  (20.9%), n=30 were Stage  
(22.4%), n=45 were Stage  (33.6%) and n=31 were Stage V (23.1%). Stage was defined 
during the MDT meeting based on either radiology or pre-op biopsy if available (Table 15).  
 
Neoadjuvant treatment: Seventy-one (52.6%) did not receive any neo adjuvant treatment and 
went straight to surgery. N=10 (7.4%) received neo-adjuvant radiotherapy only prior to 
surgery, from whom n=3 (30%) were radiological Stage  and n=7 (70%) were radiological 
Stage . N=38 (29%) received neo adjuvant chemo radiotherapy, from whom n=20 (52.6%) 
were radiological Stage V, n=15 (39.5%) Stage , n=2 (5.3%) Stage  and n=1 (2.6%) Stage 
. N=12 received neo adjuvant chemotherapy, from whom n=9 (75%) were radiological Stage 
V, n=2 (16.7%) Stage  and n=1 (8.3%) Stage . All decisions were based on MDT 
preoperative staging (Table 14). 
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Pathological staging (postoperatively): All the 135 cases were adenocarcinomas. N=23 
(17.4%) specimens were well differentiated, n=94 (69.6%) were moderately differentiated, and 
n=8 (5.9%) were poorly differentiated. N=10 (7.3%) were non-specified (Table 15). 
N=32 (23.7%) were Stage , n=38 (28.1%) Stage , n=33 (24.4%) Stage  and n=31 (23%) 
Stage V. This was because some of the patients were offered down-staging neo adjuvant 
therapy.  N=9 were pT1 (7.1%), n=34 were pT2 (26.6%), n=69 were pT3 (53.9%), n=16 
(12.5%) were pT4. N=78 were pN0 (61.9%), n=26 were pN1 (20.6%), n=22 were pN2 
(17.5%). In n=53 (67.1%) there was LVI negative, whereas, in n=26 (32.9%) it was LVI 
positive.  
In n=12 there was Perineural Invasion noted (PNI), whereas in n=67 there was negative PNI.  
In the rest of the cases there was no PNI or LVI status documented on the biopsy report. 
Finally, in n=77 the margins were clear (71.3%), whereas in n=31 (28.7%) histology was 
inconclusive. Regarding the rest n=27 of the cases there was no documentation on the biopsy 
report. The mean number of the lymph nodes (LN) was 15.08 (range=0-41, SD= 7.13), and the 
mean number of positive LN was 1.83 (0 - 24, SD=3.73). The mean ratio LN+ve/LN total was 
0.107 (range=0-1, SD=0.202).  
 
Molecular staging: Molecular analysis was performed in theatre specimens. All were BRAF 
wild-type (n=65). There was only n=1 MSI-H and n=95 MSS (MSI Stable). The mean p16 
expression was 12.63% (min=0, max=70%, SD=15.33). n=63 (94%) were MGMT preserved 
whereas n=4 (6.0%) were MGMT non-preserved. In n=94 cases MMR was preserved, whereas 
in n=1 MMR was not preserved. With regards to beta-catenin, in n=27 it was Membranous 
(M), in n=22 (34.8%) M and focal Nucleus (N), in n=10 (15.9%) mixed M+N and in n=4 
(6.3%) N (Table 16). Associations between molecular biomarkers and outcomes are shown in 
Table 17. 
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Adjuvant treatment: Seventy-six (58%) patients did not receive any adjuvant treatment, while 
n=49 received adjuvant chemotherapy (37.4%) based on the pathological staging. From those 
49 patients, n=4 were Stage  (8.2%), n=10 (20.4%) Stage , n=18 (36.7%) were Stage  and 
n=17 (34.7%) were Stage V. n=2 received some additional radiotherapy (1.5%) from whom, 
n=1 was Stage  and n=1 Stage V, as they both were not fit for further surgery. N=4 (3.1%) 
had adjuvant chemo radiotherapy, from whom n=1 was Stage , n=1 was Stage  and n=2 
were Stage V (Table 14).  
 
Outcomes: One hundred and two cancer cases (75.6%) did not recur (Table 18). In n=6 there 
was local recurrence (4.4%), whereas n=27 (20%) suffered distant recurrence.  With regards to 
local recurrence n=1 was pT1, n=1 pT2, n=3 pT3 and n=1 pT4. n=3 were pN0, n=1 pN1 and 
n=2 pN2. n=5 were pM0 and n=1 pM1. Overall n=1 was Stage , n=1 Stage , n=3 Stage  
and n=1 Stage V. Concerning distant recurrence, n=6 were Stage  (22.2%), n=5 (18.5%) Stage 
, n=4 (14.8%) Stage  and n=12 (44.4%) Stage V. The mean time to recurrence was 18.66 
months (min=17.00, max=22, SD=2.84) for local recurrence and 10.22 months (range=2-32, 
SD=8.63) for distant recurrence. In n=13 (9.6%) there was Cancer-related death. The mean 
time of Cancer-related death was 26.39 months (range=0-52, SD=17.60). No other association 
between KRAS status and histopathological features (pNI, +ve LN/LN, pTNM, LVI), follow 
up parameters (recurrence, adjuvant/neo-adjuvant chemo/radiotherapy) or radiological staging 
(uTNM), was noted (p>0.05) (Table 17). 
In the only MSI-H specimen, there was positive PNI (p=0.020), and similarly for the n=1 case 
with non-preserved MMR expression (p=0.021). What is more Furthermore, the mean age of 
cases with non-preserved MGMT was higher, compared to preserved MGMT (83.50 vs. 66.53, 
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p=0.005). No other significant association for MGMT status was noted (p>0.05 for all 
associations) (Table 17). 
Otherwise, recurrence was positively associated with positiveve LN [1.09 (for no recurrence) 
vs. 1.33 (for local recurrence) vs. 4.68 (for distant recurrence), p< 0.001], as well as the ratio 
+ve LN/LN [0.066 (no recurrence), vs. 0.722 (for local recurrence) vs. 0.278 (for distant 
recurrence) p<0.001] and pM Stage (p=0.005), as well as overall Stage of the disease as defined 
by the MDT (p=0.022). However, positiveve LN / LN ratio, seems not to be associated directly 
with any of the molecular biomarkers (p>0.05 for all associations) (Table 17).     
 
Stage I Cases - Subgroup analysis results: In the second part of our analysis we examined 
biomarkers in stage  rectal cancer exclusively. N=32 cases were identified, and n=20 were 
male (62.5%) whereas n=12 were female (37.5%). The mean age was 65.15 (min=40, max=85, 
SD=11.97). N=3 (9.4%) had neo-adjuvant chemo radiotherapy prior to surgery, n=1 (3.1%) 
chemotherapy and n=1 (3.1%) radiotherapy. N=1 received adjuvant radiotherapy (3.1%), n=4 
chemotherapy (12.5%) (Table 19). N=8 were pT1 (27.6%), n=21 were pT2 (65.6%). N=7 
(21.9%) were well-differentiated adenocarcinomas, n=20 (62.5%) were moderately (70.0%), 
n=1 (3.6%) poorly and n=4 were unspecified. The mean ratio +ve LN/ LN was 0.375 (min=0, 
max=1, SD=0.20). n=17 had no LVI +ve (94.4%), whereas n=1 had positive LVI (5.6%). All 
the specimens were pNI negative (n=20). N=21 had complete margins (87.5%), whereas n=3 
had inconclusive margins (12.5%), and in the rest n=8 there was no documentation (Table 19). 
The mean follow-up was 35.25 months (min=11, max=72, SD=20.046), and there was no 
cancer related death. In n=22 of the cases there was no recurrence (78.6%), n=1 was local 
recurrence (3.1%) and n=6 distant (18.8%). The mean recurrence time was 11.5 months (3 - 
25.00, SD=8.57) (Table 20). 
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With regards to molecular status, n=12 were KRAS wt (52.2%), and n=11 (47.8%) were KRAS 
mt. MSI was stable in all cases (n=20) and MMR expression was preserved as well (n=20). 
MGMT status was preserved in n=15 cases and non-preserved in n=1 from the specimens that 
were analyzed. The mean p16 expression was 16.85% (min=1.00, max=50.0, SD=14.40). b-
catenin was M in 53.3% of the cases (n=8), focal N and mainly M in 26.7% (n=4) and mixed 
N + M in 20.0% (n=3) (Table 20). 
KRAS-mutant status seems to be associated with distant recurrence (n=5, p=0.045). No other 
significant association was noted (p > 0.05). Membranous b-catenin seems to be associated 
with distant recurrence (n=3 distant recurrences / n=8 M expression), though this did not reach 
statistical significance due to low numbers (p=0.098). However, no association was noted 
between b-catenin status and any other histopathological, radiological or follow outcomes 
(p>0.05 for all associations). No other significant associations with regards to molecular 
biomarkers were noted (Table 20).  
 
There were no cancer-related deaths, therefore we cannot comment whether there is any link 
between KRAS and cancer related deaths (Table V). Distant recurrence of disease positively 
associated with the number +ve LN (p=0.049) as well as increasing ratio +LN/LN (p=0.05) as 
expected. There was no association between KRAS and +ve LN or the the ratio +ve LN/LN 
overall (p>0.05) (Table 20). 
  





The pathway of carcinogenesis in CRC is a complex multifactorial process [86]. Sporadic CRC 
pathway can result from the down regulation of tumor suppressor genes, or activation of 
oncogenes, or from various discrepancies in the mismatch repair genes (MSI), or even from 
chromosomal losses (CIN) [80, 86, 119], [211].  
KRAS is a proto-oncogene, that is involved in the mitogen-activated protein kinase (MAPK) 
and phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene pathways (PI3K/AKT). 
More specifically KRAS, regulates cellular response to extracellular stimuli. Its mutant status 
can lead to downstream activation of the latter pathways (MAPK, PI3K/AKT)[69, 199]. This 
is the potential mechanism, through which, mt KRAS can result in resistance against anti-
EGFR chemotherapy agents [199].  
The incidence of KRAS mutations is comprises around 35-40% of CRC cases, which is 
confirmed by our study as well (37.4%) [85]. Point-mutations in codons 12,13 and 61 are 
supposed considered to be the most common, though approximately 85 different mutations 
have been identified [119]. Rosty et al. [85] managed to define various distinct 
clinicopathological features, which are associated with KRAS mutant status i.e. mucinous 
differentiation, proximal location, certain MSI status, MGMT methylation, and presence of 
contiguous polyp (p<0.05 for all associations). The same study notes that mt KRAS is 
associated with female sex, which was the case for our study as well (p=0.021). Notably, in 
our study, there was also a significant association between older age in mt KRAS compared to 
wt (69.62 vs. 62.26, p=0.005), which could be attributed to the fact that carcinogenesis is a 
lengthy process, accumulating distinct mutations. 
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Despite the predictive value of KRAS in better response to anti-EGFR chemotherapy [198], its 
prognostic value remains debatable [70, 119], and there is not enough evidence with regards to 
KRAS prognostic value in purely rectal cancer. In our cohort of rectal tumors, KRAS wild type 
is linked with cancer related death for any stage (n=10, p=0.033). Colorectal cancer follows 
complex and variable pathways, and in this case, it seems that KRAS may not be involved in 
the carcinogenesis process.  
The most important finding of our study is that KRAS-mutant status seems to be associated 
with distant recurrence in Stage  rectal cancer (p=0.045). This seems to support the assumption 
that early cancer recurrence can represent the reflection of a specific carcinogenesis pathway 
where KRAS plays an important role, and it is involved at early stages. Similar findings were 
reported in one of our recently published study [104], where KRAS is linked with local 
recurrence in Stage  Rectal Cancer following Transanal Endoscopic Microsurgery (TEMS). 
On the other hand, if KRAS is found mutant in more advanced stages of rectal cancer, this may 
be a consequence of a different molecular pathway, where prognosis is defined by other 
molecular parameters. No other association was found between KRAS status and distinct 
histopathological features (pTNM, positive LN / LN, PNI, LVI, p>0.05 for all associations) or 
radiological parameters or survival outcomes (p>0.05).  
In a recent meta-analysis in 2017, Tosi et al, included 1833 patients [212] and concluded that, 
KRAS mutant status is negatively associated with overall survival (OS) and relapse-free 
survival (RFS) in patient who underwent liver resection for metastatic CRC. Brudvik et al 
[213], report similar findings in their meta-analysis of 1809 cases, published in 2015.  Jones et 
al [66] evaluated 392 cases of advanced and recurrent colorectal cancer from a UK Centre, and, 
concluded that codon 12 mutations are independently associated with worse overall survival 
after diagnosis. Similar findings are reported from another US study [88, 89], where KRAS 
mutations, seem to be independent risk factors for worse OS. Moreover, the same team, 
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reported in another study[87], that KRAS codon 13 mutation, is associated with higher risk for 
overall extrahepatic or lung specific recurrence.  
BRAF V600E mutation seems to be another valid biomarker in CRC. Its presence has been 
associated with poorer prognosis [122, 146], and is deemed more as feature of right-sided, 
advanced CRC [103, 177, 201]. In our study, BRAF was found wt and this is explained by its 
association with proximal colorectal cancer. Recently, there have been studies, which associate 
BRAF V600E mutation with resistance to anti-GFR inhibitors, regardless the presence of wt 
KRAS [76, 95].  
Methylation of CpG islands, and especially, O(6)-methylguanine DNA methyltransferase 
(MGMT) gene promoter methylation has been deemed to play a role in the CRC pathway, 
however, consensus regarding its prognostic value, has yet to be reached [72, 80, 200]. MGMT 
is a DNA repair enzyme, codified at locus 10q26, which removes alkyl groups from the O6 
position, and this leads to irreversible inactivation of the enzyme [200, 214]. Hence, loss of 
MGMT expression, via methylation of the CpG islands of its promoter, could be reflected, with 
alteration of normal DNA [210, 215, 216]. Non-preserved MGMT expression is found in 30-
40% of metastatic colorectal cancer [200].  
In our study, non-preserved MGMT expression was associated with higher age (66.53 vs. 
83.50, p=0.005), which should, again, raise a question, whether older age would be deemed as 
an independent factor to worse prognosis, exclusively based on the accumulation of more 
genetic events, resulting in a distinct molecular phenotype. 
B-catenin is considered an essential molecule, that belongs to Wnt-signaling pathway. Wnt/b-
catenin pathway is primarily involved in the regulation of oncogenic processes, as well as 
intracellular adhesion [205]. There is still little consensus on the role of b-catenin in CRC 
pathway. A recent study found that KRAS and Wnt pathway may interact in lung cancer [176]. 
In our study, there was a trend towards an association between M expression of b-catenin and 
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distant recurrence (n= 6 p=0.092). In Stage  subgroup analysis, there is a similar trend (n=3, 
p=0.096). However, these were only trends and none of them reach statistical significant 
values, therefore their interpretation value is limited. There was no association between b-
catenin and neo-adjuvant/adjuvant therapy, and any other histopathological features (pTNM, 
+ve LN/LN, LVI, PNI, p>0.05 for all associations). 
 
With regards to p16 expression, there is a recent meta-analysis [155], which associates various 
clinico-pathological features with the deregulation of its promoter via methylation. In our 
cohort, there is a trend towards higher p16 expression in M b-catenin (21.66 vs. 10.25 vs. 5.00, 
p=0.028). Interestingly, there was no association between the status of any of the biomarkers 
studied in our cohort (KRAS, BRAF, MMR, MGMT, p16, b-catenin) and the response to neo-
adjuvant therapy (p>0.05) or other pathological features.  
Finally, we recognize the limitations of this study which is predominantly the relatively small 
sample size, that does not allow to use multivariate statistics. However, our conclusions can 
raise interesting questions for further research. 
 
8.6 Conclusion  
Carcinogenesis of CRC is a complex and multifactorial event, in which various molecular 
events interfere. We found that when KRAS is mutant in early rectal cancer, this fact may be 
linked with higher chance of distant recurrence. This is an interesting finding that should be 
further examined with greater amount of research in hope that it may constitute an additional 
prognostic factor for early rectal cancer.     
 





Age Mean Age= 64.67, [22, 89], SD=13.32 (years) 
Sex Male 87(64.4%) Female 48(35.6%) 






















Complications n=78(57.8%) uncomplicated n=57(42.2%) minor 
complication 
 Received Received 
Neo-adjuvant 
treament 









 Received Received 
Adjuvant 
Treatment 
Chemotherapy Radiotherapy None ChemoRadio 
n=49 (37.4%) n=2 (1.5%) n=76 (58%) n=4 (3.1%) 
Table 14: Patient’s demographics and treatment. 
 
  




 Pre-operative Stage (-V) 




                                       Post-operative Stage (I-IV) 
Stage  32(23.7%)   38 (28.1%)  
33(24.4%) 
31 (23.0%) 
Histology 135(100%) adenocarcinomas 
Differentiation 23(17.4%) Well 94(69.6%) 
moderately 
8(5.9%) poorly 




pN Stage N1 78(61.9%) N2 26(20.6%) N2 22(17.5%) 
pM Stage M0 95 (77.3%) M1 28(22.7%) 
LN Mean 15.08 [0.0 -41], SD=7.13 
LN +ve Mean 1.83 [0.0- 24], SD=3.73 
LN +ve /LN Mean 0.107, [0-1], SD= 0.2020 
CRM Clear 77 (71.3%) Inconclusive 31(28.7%) 
LVI Positive 26 (32.9%) negative 53 (67.1%)  
PNI Positive 12 (15.2%) Negative 67 (84.8%) 
Table 15: Preoperative and pathological staging. 
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Molecular Staging (I-IV) 
KRAS Mutant n=40 (37.4%) Wild type n=67 (62.6%) 
BRAF Wild type n=65 (100%) 
MSI MSI-H n=1 (1%) Stable n=95 (99%) 
P16 Mean 12.63% [0-70] SD=15.33 
MGMT Non-preserved 4(6.0%) Preserved 63 (94%) 
MMR Non-preserved 1(1.1%) Preserved 94 (98.6%) 





Table 16: Molecular staging 
 M, Membranous; N=nucleic. 
  






Vs. Feature Total/p value 
 No Recurrence Local Distant  
Wild type 
Mutant 
47 3 17 67 
32 1 7 40 p=0.526 
 No PNI PNI  
Wild Type 
Mutant 
33 8 41 
20 2 22 p=0.242 
 No LVI LVI  
Wild Type 
Mutant 
25 17 42 
22 5 27 p=0.017 
 Male Female  
Wild Type 
Mutant 
48 19 67 
20 20 40, p=0.021 
 +LN / LN  
Wild Type 0.095  
Mutant 0.1141 p=0.658 
 Mean Age  
Wild Type 62.26  
Mutant 69.62 p=0.005 
 




Vs. feature Total/p-value 
 No Recurrence Local  Distant  
M 
M + focal N 
M + N 
N 
20 1 6 27 
19 0 3 22 
9 1 0 10 
4 0 0 4 p=0.092 
 No PNI PNI  
M 
M + focal N 
M + N 
N 
16 3 19 
6 2 8 
5 0 5 
1 0 1 p=0.504 
 No LVI LVI  
M 
M + focal N 
M + N 
N 
16 6 22 
13 3 16 
8 1 9 
2 2 4 p=0.952 
 Male Female  
M 
M + focal N 
M + N 
N 
16 11 27 
15 7 22 
6 4 10 
4 0 4 p=0.339 
 
Table 17: Biomarkers vs. outcomes. 
 






 Yes No  










14.8months [2-54], SD=13.44 
Cancer Related 
Deaths 
n=13 (9.6%) Mean Time 26.39 [0-53], 
SD=17.6 
Table 18: Outcomes (Recurrence, Cancer Related Deaths). 
 
  




Patient’s Demographics Stage  (n=32) 
Age Mean Age= 65.15, [40, 85], SD=11.97 (years) 
Sex Male 20(65.2%) Female 12(37.5%) 















 Pathological Stage  
Differentiation n=7 Well 20 moderately n= 1 poorly 
pT Stage T1 8 (27.6%) T2 21 (65.6%) 
LN +ve /LN Mean 0.375, [0-1], SD= 0.20 
CRM Clear 21 (87.5%) Inconclusive 3 (12.5%) 
LVI Positive 1 (5.6%) negative 17 (94.4%)  
PNI Positive 0 (0%) Negative 20 (100%) 
 








Outcomes for Stage  
 Yes No  














Molecular Staging  
KRAS Mutant n=11 (47.8%) Wild type n=12 (52.2%) 
BRAF  
MSI MSI-H n=0 (0%) Stable n=20 (100%) 
P16 Mean 16.85% [1-50] SD=14.40 
MGMT Non-preserved n=1 n=15, Preserved  
MMR Non-preserved 0 (0%) Preserved 20 (100%) 
B-catenin M 8 (53.3%) M + focal N 4 
(26.7%) 
Mixed N+M 3 
(20.0%) 
N 0 (0%) 
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KRAS Status I Vs. Feature Total/p value 





11 0 1 12 
6 0 5 11 p=0.045 
 
B-Catenin Status I Vs. feature Total/p-value 
 No Recurrence Local Distant  
M 
M + focal N 
M + N 
5 0 3 7 
4 0 1 4 
3 0 0 3 p=0.098 











Understanding the significance of molecular biomarkers for prognosis and treatment 
stratification remains an equivocal subject. Recent advances in molecular biology have greatly 
improved our knowledge of CRC, and significant progress has been made towards the 
identification of powerful prognostic as well as predictive biomarkers [78, 80, 119]. However, 
apart from a few well-studied genes or methylation products, identification of most of the 
current biomarkers remains controversial, which makes it challenging to implement them in 
clinical practice. 
Looking through the most recent literature [73, 79], we found that most studies divide CRC 
carcinogenesis pathways into 3 distinct categories: CIN, MSI, and CpG island methylation 
(CIMP) pathway. The mechanism of these pathways is to try to elucidate CRC biology 
background by simplifying certain molecular events that share the same concept. However, 
despite all the efforts to distinguish certain molecular characteristics of each tumour and create 
a unique classification model [78, 80-82, 115, 119, 125, 137, 141, 167], there is still a 
significant knowledge gap to fill, which is primarily attributed to the complexity of colorectal 
carcinogenesis. 
Currently, most studies divide biomarkers into prognostic and predictive categories. Prognostic 
biomarkers are those whose primary function is to delineate cancer-related survival, whilst 
predictive biomarkers refer to response to chemotherapy. For example, KRAS is a well-
established predictive biomarker, as  KRAS wild type is generally linked with a more 
favourable response to anti-EGFR chemotherapy [85]. On the other hand, BRAF V600E 
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mutation and MSI are gaining recognition in the literature as prognostic biomarkers, with the 
former indicating a poorer prognosis and the latter improved overall survival. 
 As discussed extensively in previous chapters, most of our work was based on a panel of 
biomarkers that was highlighted in the literature as the most influential in terms of its 
prognostic and predictive value [77, 78, 103, 104]. MSI has been extensively discussed in 
several papers, and its presence is linked with better overall survival, mucinous differentiation, 
and proximal tumour location [77, 78, 103, 126, 128, 133]. CpG island methylation (CIMP) is 
a promising family of biomarkers that are gaining more ground in CRC classification [75, 81, 
82, 116]. CpG islands are generally part of the promoter region of several genes, and their 
abnormal methylation results in transcriptional silencing of either tumour suppressor or DNA 
repair genes [81, 82, 115, 127]. A classic example of CIMP is the abnormal methylation of the 
MLH1 gene promoter, which results in MSI and subsequently links CIMP-positive phenotypes 
with MSI-high. In our cohorts, we did a thorough study of β-catenin, p16, and MGMT 
methylation products, which were part of the biomarkers panel run by the Advanced 
Diagnostics Laboratory at King’s College Hospital NHS Foundation Trust (KCH) [77, 104]. 
Despite the complexity in the understanding of molecular biomarkers, current advances in 
screening programs have made earlier diagnosis of CRC possible [206]. In that context, 
development of minimally invasive surgical techniques such as local excision is becoming 
more popular. Although local excision in the treatment of CRC is associated with reduced 
morbidity and mortality [41], the challenge of maintaining a similar recurrence rate compared 
to that of radical surgery remains a principal limitation for its application. Therefore, careful 
selection of patients is paramount for the achievement of optimal oncological outcomes. 
Transanal endoscopic microsurgery (TEMS) is one of the most favoured local excision 
techniques, initially introduced for the treatment of benign rectal tumours, for which it offers 
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the advantages of better technical and more complete excision in comparison to the older TAR 
technique [41, 104, 217-219].   
In the context of the increasing rate of diagnosis of rectal cancer at an earlier stage, and given 
the current trend for tissue-preservation surgical techniques, we explored the significance of 
those biomarker panels in an early stage I rectal cancer cohort [104]. We also compared the 
significance of the same biomarkers in a cohort that underwent radical surgery for rectal cancer 
from the same specialist centre (KCH) in a similar period of time [77].  
Furthermore, we performed a pilot study on 41 confirmed CRC cases selected from 1,500 
consecutive referrals from the 2-week-wait pathway to figure out whether any of those 
biomarkers is linked with certain clinical or biochemical features at diagnosis [103]. This 
would help us delineate the difference between left and right cancer biology and identify those 
biomarkers that are more applicable to rectal cancer. For example, unexplained IDA was 
flagged as a worrying right-sided CRC symptom which was associated with the BRAF V600E 
mutation. Our findings are in keeping with the current literature [93, 113, 184] and raise the 
possibility of inclusion of BRAF biomarkers in screening tools in order to stratify potential risk 
for advanced cancer, as reflected by their relationship with IDA. 
In a nutshell, we aimed to identify the prognostic significance as well as the predictive value 
of the most important biomarkers, based on the oncological outcomes of early cancer treatment 
with TEMS. However, along with TEMS, management of early-stage cancers involves 
neoadjuvant and/or adjuvant radiotherapy, which remain a cornerstone supplement either as 
downstaging (neoadjuvant) or as additional treatment (adjuvant). Therefore, the last chapter of 
this dissertation aims to determine the importance of neo+/-adjuvant radiotherapy in the 
oncological outcomes of TEMS and to delineate the possibility of a better treatment 
stratification protocol, along with biomarkers, in the context of an MDT  approach [63, 220].     
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9.1 Kirsten rat sarcoma viral oncogene homolog (KRAS) in early rectal cancer 
(Stage I) 
 
KRAS is a proto-oncogene involved in the cellular response to extracellular signals, and it is 
strongly associated with downregulation of mitogen-activated protein kinase (MAPK) and 
phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene (PI3K/AKT) pathways [69, 
70, 132]. This means that surface tyrosine kinase receptors such as epidermal growth factor 
receptor (EGFR) are becoming resistant to inhibition [119]. However, there is a large family 
of chemotherapy agents consisting of anti-EGFR agents that target these receptors. Hence, 
KRAS mutant status is directly associated with chemotherapy resistance, which in clinical 
practice is used as a predictive biomarker [70, 76, 134-136]. 
KRAS mutations refer to a frequent alteration of G>A, a mutation most likely found in codon 
12. Codons 12 and 13 in exon 2 constitute 90% of KRAS mutations [85], which has been the 
case with all our original cohorts [77, 103, 104]. In total, there have been 85 different mutations 
reported, many of which are pathway-specific [198].  Female gender is associated with KRAS 
mutant status tumours [85]. The Melbourne Collaborative Cohort Study concluded that KRAS 
mutations are associated with mucinous differentiation, and they appear in bimodal distribution 
along the proximal-distal axis, with the vast majority presenting proximally [85]. 
In the classic adenoma-carcinoma progression pathway, KRAS seems to appear early in the 
sequential neoplastic route. In 1988, Vogelstein et al. [221] stated that KRAS mutations appear 
after deregulation of the wingless-related integration site (WNT) pathway, most likely through 
APC mutation prior to TP53 gene inactivation. This theory has been accepted by recent studies 
[85] which delineated the distinct clinicopathological features that KRAS mutant tumours 
carry. In the same study, with one of the biggest original cohorts in the literature, KRAS mutant 
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status appears to affect 28% of the CRC specimens whilst generally the incidence fluctuates 
from 35−40%. 
Nevertheless, the prognostic value of KRAS still remains equivocal. Although some 
researchers associate it with poorer prognosis [90], the vast majority doubt its prognostic value 
[85, 177]. In that context, we were one of the first to report that KRAS mutant status is 
associated with a higher recurrence rate in an early rectal cancer cohort following TEMS [104]. 
This is in keeping with the molecular basic that KRAS appears early in the carcinogenesis 
pathway [166]. Further, we introduced morphological features that could explain its prognostic 
value, including higher circumferential configuration (p<0.0001), larger tumour mass 
(p=0.029), as well as height of the specimen (p=0.030). Similarly, another team in the US 
supported the finding that codon 13 KRAS mutation can predict recurrence in patients 
undergoing hepatectomy for colorectal liver metastasis. [87-89]. A series of papers have 
described the relationship of KRAS codon 12 or 13 mutation status with the possibility for liver 
metastases of colorectal origin, highlighting the prognostic value of KRAS status. A recent 
meta-analysis confirmed the negative association of KRAS and overall survival, including 
poorer disease-free survival for patients undergoing liver resection for metastatic CRC. 
Another meta-analysis focusing on the prognostic value of KRAS using cell-free DNA 
concluded that KRAS affects CRC survival with a hazard ratio (HR) of 1.67 (95% CI 1.25–
2.42, p<0.01) [91]. Finally, Rui et al. [222] in their meta-analysis link KRAS mutant status 
with worse overall survival. 
Along with this novel finding, our original cohort of TEMS [104] revealed some more 
interesting associations. There seems to be a link between aberrant methylation of CpG islands, 
especially hyperexpression of membranous β-catenin with mutant KRAS status. This is 
confirmed by a previous study which states that 70% of KRAS mutant tumours are thought to 
have aberrant methylation profiles, including hyperexpression of p14, p15, and p16 [204]. This 
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finding is also supported by the fact that, as part of the same study, hyperexpression of p16 is 
associated with earlier recurrence, and hence this draws an indirect link with KRAS mutant 
status as well as other methylation products in the context of early rectal cancer. 
To confirm our findings, we performed another original study in which we investigated the 
significance of the same panel of biomarkers. Focusing on KRAS status, we were gratified to 
confirm that there is still an association between early cancer specimens (Stage I) and distant 
disease recurrence when KRAS is mutant (n=4, p=0.045) [77]. Also, KRAS mutant status was 
associated with older age (69.62 vs. 62.27, p=0.005) and female gender (n=20, p=0.021) which 
is in keeping with reports in the current literature [85]. In the same study cohort, we did not 
find any further associations between KRAS status and distinct histopathological features, 
including LVI, the ratio of positive lymph nodes to lymph nodes, perineural invasion, and 
advanced stage of disease. 
Similarly, there was no association between KRAS mutant status and LVI or disease stage in 
our first original cohort [103]. In this pilot study, we screened 1,446 consecutive 2WW referrals 
and confirmed 41 cancer cases whose clinical, biochemical, and histological presentation were 
evaluated against the molecular profile for the same biomarker panel. KRAS was not associated 
with advanced disease stage, and this study primarily focused on exploring the effect of BRAF 
V600E mutation in cases of unexplained IDA. 
In conclusion, with our cohorts we delineated KRAS mutant status as a potential prognostic 
biomarker for early rectal cancer, since it was associated with a higher recurrence rate. This 
was supported by the fact that there is a link between aberrant methylation expression of p16 
and membranous β-catenin with the classic codon 12 and 13 point mutations. It is important to 
note that KRAS is currently a broadly used biomarker across several cancer units in the UK, 
primarily as a predictive biomarker for response to chemotherapy. Recent advances in cancer 
screening have made it possible for a vast majority of CRC cases to be diagnosed at an earlier 
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stage, and for local excision techniques to be a potential option. On this background, our 
findings may be promising and KRAS could be used in combination with methylation products 
as an early-stage cancer prognostic biomarker. 
  
9.2 v-raf murine sarcoma viral oncogene homolog B V600E mutation (BRAF 
V600E)  
As previously discussed, the BRAF gene is involved in the RAS/MAPK intracellular signalling 
pathway [78]. Because it encodes a serine-threonine kinase that inhibits the RAS/MAPK 
pathway; therefore, any mutation can cause upregulation of the aforementioned pathway. The 
BRAF V600E mutation accounts for approximately 90% of BRAF mutations, and it is 
classically associated with MSI-high phenotype [93].  Most studies have associated BRAF 
V600E with proximal tumour location and in most cases, it is associated with CIMP-high 
phenotype and subsequently with MSI-high [80, 82, 119].  
In their recent meta-analysis, Chen et al. [93] summarised all the clinicopathological features 
of BRAF-V600E based on those of 11,675 patients in 24 studies. Female gender (OR=1.71; 
95% CI=1.42−2.07) was associated with BRAF V600E. Age above 60 years [OR=2.29; 95% 
CI=1.13−4.61) was another characteristic of this mutation and this was based on a sample of 
2,982 patients. A very important aspect of BRAF mutation is its association with advanced 
disease stage at diagnosis (Stage III and above, OR=1.59; 95% CI=1.16−2.17). There is also 
an association with poor differentiation (OR=3.89; 95% CI=2.94–5.17), as well as with 
mucinous histology (OR=2.99; 95% CI=2.20–4.07) and proximal location (OR=4.85; 95% 
CI=3.59–6.56). 
This same meta-analysis [93] confirms the association between BRAF V600E and MSI-high 
(OR=8.18; 95% CI=5.08–13.17) as well as CIMP-high (OR=16.44; 95% CI=6.72–40.21) that 
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many previous studies had already reported, as highlighted in our review [78]. With regard to 
KRAS status, there was a link with wt-KRAS and BRAF V600E, underscoring the probability 
that they derive from different pathways. In summary, this meta-analysis validated the 
association of BRAF mutant status with MSI and CIMP. Given the fact that 85% of sporadic 
CRC includes features of CIN and that the other 15% include the MSI-phenotype [223], this 
finding can be used as a guide to further delineate the way in which CRC follows distinct 
molecular pathways. 
In our retrospective study [103], we tried to clarify the association between any of the current 
panels of biomarkers used by King’s College Hospital with a clinical presentation of 41 
confirmed cancer cases derived from a pool of 1,446 consecutive referrals from GPs. The main 
finding from this retrospective study was that BRAF V600E was associated with right-sided 
tumours and subsequent unexplained related iron-deficiency anaemia (IDA). BRAF mt 
tumours presented with a significantly lower Hb compared to those with BRAF V600E (89.0 
vs. 123.5g/dl, p=0.009). Overall, we examined 26 patients with a colonic primary and 15 with 
a rectal primary. All the rectal cancer cases were found to be BRAF wild type, which is in 
keeping with the current trend in the literature.  There was no significant association between 
presentation Hb levels and eventual disease staging (p >0.05 for all associations). Patients with 
right-sided tumours were found to have significantly lower Hb levels compared to those with 
rectal tumours (98.6 vs. 122.3 g/dl), a fact that is well known in the literature. 
One of the strengths of this pilot study was the comparison of patients’ symptoms at 
presentation, including CIBH, iron-deficiency anaemia (IDA), rectal bleeding (RB), family 
history of bowel cancer, and presence of an abdominal mass, with the biomarker profile and 
the histopathological features, e.g., LVI. Apart from the association between BRAF V600E 
and significantly lower Hb, we did not find any further associations. 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 157 
Summarising our findings and correlating them with the clinical practice, it is important to 
comment that although a lower Hb can be a feature of right-sided tumours and can be  
subsequently related to BRAF V600E, any case of unexplained IDA should be investigated 
and the possibility of advanced stage disease should be considered. This may affect the choice 
of treatment in cases of unexplained IDA, where BRAF status should be further examined. 
This corresponds to the current knowledge that BRAF is linked with advanced stage disease 
[93, 177, 179], and in our cohort, this was confirmed because all the BRAF V600E cases were 
T3b stage and above. However, there was no statistically significant association between 
BRAF V600E mutation and LVI, which could be due to missing data on the histopathological 
status of the specimens. 
Another interesting feature of that study is the suggestion that BRAF should be included in the 
newly introduced Cologuard screening test [185], which is a multi-target DNA stool test based 
on the faecal immunochemical test (FIT). It is considered a noninvasive alternative to 
colonoscopy due to a sensitivity of 92.3%, which could be increased if BRAF status were 
included in this FIT. 
With regard to the rest of our studies, both in the TEMS cohort as well as the rectal cancer 
cohort, BRAF V600E provided limited input in terms of a novel knowledge in the literature 
[77, 104]. This is primarily because BRAF-V600E is mostly found in proximal tumours, as 
discussed previously. All of our rectal specimens, both early and more advanced stage, were 
found to be BRAF wild type. The described relationship between BRAF V600E mutation and 
advanced disease stage could be due to the differing embryological origins and consequently 
the clinicopathological features of the right (midgut) and left (hindgut) colon [98].  
9.3 Hypermethylation of CpG islands (CIMP) as a colorectal cancer biomarker 
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Methylation of CpG Islands (CIMP) is a fundamental aetiologic factor for cancer progression 
in molecular biology [81, 82, 116]. Aberrant hypermethylation can be classified further as 
global or regional. A classic example of regional hypermethylation is the aberrant methylation 
of unmethylated areas, most of which are CpG clusters [92, 224]. Tumour suppressor gene 
promoter or DNA repair gene promoter methylation occur in typical cases of CIMP aberrant 
methylation. Most studies have developed a classification model based on CIMP status [81, 
116]. Generally, CIMP is defined as hypermethylation of CpG, which results in transcriptional 
silencing of the promoters of various tumour-suppressor and DNA genes [78]. A classic 
example of the latter is the silencing of the promoter of the mutS Homolog-1 (MLH-1) gene, 
which is a DNA repair gene. This is the pathway where CIMP and MSI meet, and hence the 
fact of their coexistence is fairly common in the literature. Simons et al. [82] suggest a 
classification model based on CIMP, MSI, and CIN. More specifically, according to the same 
study, MSI- and CIMP-positive tumours are proximally located, whereas CIMP-positive and 
CIN or CIN-only tumours are more distally located. Triple-negative tumours are those that are 
89% BRAF V600E positive.    
Prior to discussing our findings, we will focus on understanding the context and role of CpG 
as a mechanism in CRC both as a specific pathway, as well as in the complex context of the 
rest of the biomarkers. A recent meta-analysis [92] summarises the current evidence regarding 
CpG island methylation and its association with the rest of the molecular biomarkers. In this 
meta-analysis [92], 29 studies and 9,393 patients were involved. In the CIMP-high sub-type of 
CRC, there was a clear association between BRAF mutations (OR 34.87; 95% CI, 22.49–
54.06) and MSI-high (OR 12.85, 95% CI, 8.84–18.68). KRAS mutations were less frequent 
(OR 0.47; 95% CI, 0.30–0.75) compared to CIMP negative. Also, the CIMP-high CRC subset 
shows a clear trend to older age at diagnosis (WMD 2.77; 95% CI, 1.15–4.38); mucinous 
histology (OR 3.81; 95% CI, 2.93–4.95); proximal location (OR 6.91; 95% CI, 5.17–9.23); and 
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poor differentiation (OR 4.22; 95% CI, 2.52–7.08). CIMP was associated with shorter survival 
(HR 1.73; 95% CI, 1.27–2.37), although no clear association was identified with tumour stage 
(OR 1.10; 95% CI, 0.82–1.46). Hence, according to those findings, CIMP can be considered 
as a prognostic marker which can potentially overlap with BRAF mutant status.  
In our studies, we looked at the status of p16, β-catenin, MGMT, and MMR, all of which are 
methylation products that can be measured with IHC methods. In terms of p16, we measured 
the percentage of expression and correlated this with survival outcomes and 
clinicohistopathological features. Β-catenin can be found localised either as membranous 
status, mixed membranous and nucleus, or nucleus. Β-catenin status was further correlated with 
the same survival outcomes and clinicopathological outcomes. In the case of MGMT, we 




P16 encodes a tumour-suppressor gene whose role is to bind with CD4/6 to stop interaction 
with cyclin D [225]. This prevents the cell progressing from G1 to S phase. Hypermethylation 
of p16 causes downregulation of the gene activity and hyperproliferation of cancer cells.  
P16 seems to be a valid biomarker as 30−68% of sporadic CRC express hypermethylated p16 
[75]. Many studies [224, 225] associate p16 protein upregulation in a stepwise fashion with 
colorectal adenoma and colorectal carcinoma. Al-Ahwal et al. [225] note in their results that 
p16 was significantly higher in CRC compared to in adenomas (p=0.033) and normal colonic 
mucosa (p=0.005). A recent systematic review on DNA hypermethylation [75] correlated the 
presence of p16 as an advanced stage feature, where persistent elevation may be associated 
with recurrence.  This was one of the main findings from our TEMS cohort [104]. The p16 
expression trend was associated with a shorter time-to-recurrence. More specifically, p16 
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expression >5% was associated with recurrence within the first 11.70 months. This could be a 
very important finding because p16 would serve as a biomarker for treatment stratification in 
early rectal cancer, and its expression trend could be a prognostic marker for future recurrence. 
However, no other association between p16 and other clinicohistopathological features was 
found. With regard to the rectal cancer cohort who underwent radical surgery +/- 
chemoradiotherapy [77], we found an increased trend of p16 expression along with 
membranous β-catenin compared to membranous/nucleus and nucleus (21.66 vs. 10.25 vs. 
5.00, p=0.028). However, there was no association with any other biomarker or prognostic 
outcome. This could be justified by the fact that there were some missing data in the actual 
cohort, which made it harder to interpret the results. 
Overall higher trends of p16 can be a promising indicator of prognosis, especially when 
combined with other already established biomarkers.   
 
9.5 O6 methylguanine-DNA methyltransferase (MGMT) 
 
MGMT is a DNA repair protein which is thought to be involved early in the carcinogenesis 
pathway [226]. MGMT protein is coded at 10q 26 [200, 214], and it removes cytotoxic products 
from the O6-guanine by transferring the alkyl group to an active cysteine, which is part of the 
MGMT sequence [216, 227]. Following this fundamental enzymatic reaction, the MGMT 
protein cannot be used again [215]. This implies its very significant role in the protection of 
the colorectal epithelium from various mutagenic agents throughout the replication process. 
According to a recent meta-analysis [226], MGMT is involved at an early stage in the 
carcinogenesis pathway, and its expression is altered even in the case of adenomas. The way 
expression is regulated is through methylation of the promoter of MGMT gene. The normal 
colorectal mucosa holds low levels of methylated MGMT [228, 229]. Previous studies have 
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compared MGMT methylation status across various stages of the carcinogenesis pathway from 
adenoma to carcinoma. Their important conclusion is that MGMT methylation exists even at 
the adenoma phase, which makes it a potentially useful biomarker for early-stage cancer [228, 
230]. The outcome of the meta-analysis by Li et al. [226] was that MGMT protein expression 
precisely indicates its capacity to repair the DNA, and hence MGMT-preserved protein 
expression is a feature of the normal mucosa with good repairing potential. On the other hand, 
MGMT methylated status or loss of MGMT  are poor prognostic markers. Loss of MGMT 
status is found in 30−40% of metastatic CRC [80, 116, 200, 215]. Although the role of MGMT 
is fairly well understood, there is still a long way to go in delineating the exact prognostic value 
of preserved vs. methylated status and reaching a consensus across researchers [80, 116, 200]. 
The Advanced Diagnostics Laboratory at King’s College Hospital runs MGMT methylation 
status as part of its routine CRC molecular staging. Hence, as part of our studies we evaluated 
the status of MGMT against various clinicopathological parameters and survival outcomes, 
including recurrence. 
In our first study [104], which involved early Stage I rectal cancer specimens of cases who 
underwent TEMS, MGMT was preserved in 91% (n=23) and non-preserved in 9% (n=2). 
MGMT non-preserved status was associated with advanced age (p=0.024 for age >80 years) 
and pT2 stage (n=2, p=0.030), which correlates with what currently exists in the literature. 
However, MGMT status was not associated with any recurrence outcome (p >0.05), and this 
can be attributed to the limitations of the small cohort.  
In the second rectal cancer [77] cohort (2010-2014) who were treated with surgery +/- 
neo/adjuvant chemo/radiotherapy, MGMT was preserved in 63 cases (94%) and non-preserved 
in 4 cases (6%). Again, non-preserved MGMT status was associated with older age (83.50 vs. 
66.53, p=0.005). Other than that, there was no other significant association noted. In the Stage 
I subgroup analysis of the same cohort, MGMT was available only in 16 cases,  and in 1 case 
The significance of molecular biomarkers following Transanal Endoscopic Microsurgery (TEMS). 
 162 
it was non-preserved. Nevertheless, due to the size limitations we could not draw any further 
statistically significant associations. 
In conclusion, MGMT can be perceived as a promising biomarker, especially for early rectal 
cancer, based on its molecular background as well as on the studies that have been published 
in various countries. 
 
9.6 βeta-catenin 
βeta-catenin is a fundamental pivotal molecule which is involved in oncogenic pathways and 
mainly in intracellular adhesion [205]. Β-catenin is part of the Wnt-signaling pathway, which 
initially was thought to be regulated at the protein level; however, emerging data show that its 
regulation is at the gene promoter level [205]. To understand the role of β-catenin in CRC, we 
should focus on the “liver CRC metastasis” model. Initially, colorectal carcinomas appear to 
undergo a dedifferentiation process, and the actual result is a transition from epithelial to 
mesenchymal phenotype. This serves as a key mechanism for invasion and metastasis, known 
in the literature as epithelial-mesenchymal transition (EMT) [231-234]. The opposite 
phenomenon occurs in the inner parts of metastasis where cells are converting from 
mesenchymal to epithelial phenotypes, or in other words, re-differentiation. This process is 
known as mesenchymal-epithelial transition (MET) and implies that metastasis is a dynamic 
situation in which the tumour cells interact in their microenvironment via cytokines as well as 
matrix metalloproteinases (MMPs) and hypoxia. Coming back to the role of β-catenin, the 
dynamic EMT/MET transitions are thought to be regulated by β-catenin [231-234].  
Localization of β-catenin in the cancer cell is linked with the development of cancer growth 
[235]. More specifically, nuclear β-catenin acts as a transcriptional activator of various genes—
including the T-cell factor/lymphoid enhancer factor (TCF/LEF) family [74, 236]—and 
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therefore enhances tumour-promoting potential. Increased nuclear β-catenin is a feature of 
metastatic CRC and expresses the invasive potential of the tumour cells. 
A study by Bandapalli et al. [205] supports this finding: 55% of their tumour specimens 
revealed elevated β-catenin mRNA, suggesting that β-catenin has a transcriptional regulation 
mechanism, which is a subsequent event arising from the interaction between the cancer cell 
and the tumour microenvironment. Based on that observation, they proposed that there should 
a dynamic transcription mechanism pattern, where transcriptional activation of the β-catenin 
promoter results in increased nuclear concentration of β-catenin and transcriptional activation 
of β-catenin-TCF-4. This mechanism promotes the EMT transition mechanism and therefore 
successful invasion, as described previously. The Wnt pathway has been studied in various 
other cancer models,  including those for lung cancer [176]. 
In our early-cancer cohort who underwent TEMS [104], β-catenin was found to be 
membranous in 12 cases (48%); membranous and 30% nucleus in 7 cases (30%); membranous 
and 50% nucleus in 3 cases (10.3%); and nucleus in 3 cases (10.3%). All KRAS mutant 
tumours were associated with membranous β-catenin (n=8, p=0.009), whereas wild type KRAS 
were spread across various combinations of membranous/nucleus β-catenin. This may be 
attributed to the fact that early stage cancer has less potential for invasive spread and may 
follow different routes later on the carcinogenesis pathway. For example, nucleus β-catenin is 
a predominant finding of metastatic deposits of CRC in the liver [205]. In the case of early 
cancer, there is no clear timeframe when β-catenin transcription gets upregulated and the EMT 
pathway begins to work. Also, our study concluded that the KRAS mutant is linked with a 
higher local recurrence potential. However, although local recurrence itself is a poor prognostic 
marker, it does not represent a direct transition to metastasis, and there is still another branch 
of events that happen between recurrence and spread of disease. It would have been prudent to 
investigate the potential of distant recurrence and nucleus β-catenin. In that case, β-catenin 
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could have been a good predictor since distant recurrence can be an event which requires 
increased invasive potential.  
Another limitation of this study is the small cohort size. This does not allow for generalisable 
results, and potentially makes it difficult to compare the early rectal cancer context with the 
already existing literature on β-catenin, which primarily refers to metastatic CRC. On a 
separate note, membranous β-catenin was associated with higher circumferential configuration 
of the tumour. Again, it is difficult to delineate the significance of this finding in the context 
of a small cohort of cases. However, a higher circumferential configuration level was 
associated with KRAS mutant status. Putting this together, we may assume that early cancer 
can be more complex to interpret, in the context of the different potential mechanisms of cancer 
progression. There was no other association of β-catenin status with survival or 
histopathological outcomes. 
Hence, although it is clear that β-catenin plays a role in cancer invasion and progression, the 
stage at which altered localization can be a prognostic marker has not yet been identified, and 
further research focused on early cancer is essential.   
Moving forward to our second cohort of rectal cancer cases [77], β-catenin was available in 63 
cases (47% of cohort). Β-catenin was membranous in 27 cases (42.9%); membranous + nucleus 
in 10 cases (15.9%); membranous with focal nucleus in 22 cases (34.9%); and nucleus in 4 
cases (6.3%).  Interestingly enough, membranous β-catenin was associated with a higher trend 
of overall recurrence in the early rectal cancer subgroup analysis, although this did not produce 
a statistically significant result (n=3, p=0.096). However, in the overall cohort there is a slight 
trend for membranous β-catenin to be associated with distant recurrence (n=6, p=0.092) 
although this again was not statistically significant. Furthermore, membranous β-catenin was 
associated with higher p16 expression trends when compared to mixed localization 
(membranous or nucleus) and nucleus (21.66 vs. 10.25 vs. 5.00, p= 0.028). Finally, there was 
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no association between β-catenin status and any histopathological features (p >0.05 for all 
associations). 
This slight deviation of our results compared to the overall literature can be attributed to 3 main 
factors. First, the limitations of a retrospective study with limited data can be a confounding 
factor that makes it difficult for us to interpret the results. Second, our cohort was composed 
exclusively of rectal cancer cases, which differ compared to what exists in the overall literature, 
where most studies discuss β-catenin in CRC in general. The third point is the fact that the 
assumption that nucleus β-catenin is associated with a higher invasive potential is based on 
metastatic CRC, where the EMT/MET pathway is primarily studied. Hence, examination of 
metastatic cells using IHC techniques may give a different picture. Our results derive from the 
original theatre biopsies that were processed at the Advanced Diagnostic Laboratory of King’s 
College Hospital for completion of the pathology staging. 
In conclusion, β-catenin is an important prognostic marker in CRC. Its biological background 
involves this protein in cell adhesion and invasion. Nucleic localization can indicate a high 
invasive potential in metastatic cohorts. Further research to evaluate its significance in early 
cancer prognosis is essential. Despite the limitations of our cohorts, it is clear that β-catenin is 
a significant prognostic marker which needs to be taken into consideration for further treatment 
stratification.   
 
9.7 Microsatellite instability (MSI) 
 
Microsatellites (MS) are short, repetitive DNA sequences which are prone to frame-shift type 
mutations as well as base-pair substitutions during replication [70, 78]. The role of 
microsatellites in colorectal carcinogenesis has been extensively discussed in the literature, and 
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the first systematic review on their prognostic value was published in 2005 [237], confirming 
a significantly better overall prognosis when MSI is present. 
The DNA Mismatch Repair System (MMR) has been studied since the early 1990s, and it has 
been recognised as the primary cause of hereditary nonpolyposis colorectal cancer (HNPCC) 
syndrome[9]. The MMR system is primarily responsible for proofreading the replication 
sequence outcome and correcting and synthesising errors that arise from DNA replication [10]. 
MMR, therefore, has a DNA replication surveillance role and prevents recombination of non-
identical sequences [10]. Although MMR has been extensively studied in the case of HNPCC, 
it is also responsible for around 15−25% of cases of sporadic cancer. The remaining 85% of 
sporadic CRC arises from CIN patterns, which primarily involve aneuploidy, allelic losses, and 
translocations [237]. 
The eukaryotic DNA mismatch repair system resembles the one found in E. Coli; hence there 
may be a revolutionary process in between these two [9]. The primary difference is that E. coli 
has 3 series of MMR proteins, including MutL homologs, MutS, and MutH. The eukaryotic 
DNA mismatch repair system resembles this model, with the exception of the endonuclease 
MutH [9]. There are 6 MutS homologs (MSH1−MSH6) and 4 MutL homologs (MLH1-3 and 
PMS1). Each homolog has unique functionality and serves in several aspects of DNA safeguard 
[9]. In Lynch syndrome, the MutL/S homologs involved are MLH1, MSH2, MSH6, and PMS2 
[78]. Sporadic CRC is more likely to be associated with MLH1, and this is primarily through 
a mechanism of hypermethylation of CpG islands of its promoters, as described extensively in 
the previous paragraphs. 
Failure of the MMR repair system can result in microsatellite disorders [78]. The tumour-
suppressor genes are ideal targets for MSI-pattern mutations because they contain repeated 
hypermutable sequences that can contribute to MSI-related carcinogenesis [9]. Depending on 
the presence or absence of MSI phenotype, most studies divide CRC patterns into MSI-high or 
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MSI-low. Some authors divide MSI status into MSI-high, MSI-low, and MSS (stable), but in 
most instances, MSS and MSI-low fall into the same category [78]. 
With regard to the prognostic and predictive values of MSI in CRC, most of the studies 
conclude that MSI-high has a better prognostic value compared to that of MSI-low. This has 
been confirmed by a meta-analysis in 2005 [237] and has been extensively discussed and 
acknowledged [9, 78, 79, 125, 126, 170, 175]. However, its predictive value remains equivocal. 
Ribic et al. [178] state that MSI-H tumours are less likely to respond to fluorouracil-based 
adjuvant therapy. A recent meta-analysis [238] including 14 studies and 9,212 subjects showed 
that 5FU treatment for MSI-H tumours did not offer any statistically significant improvement 
in the overall survival [HR 0.66 (95% CI: 0.43, 1.03)]. However, the same meta-analysis 
showed overall improved survival in MSS cases who received 5FU treatment, both for disease-
free survival [HR of 0.62 (95% CI: 0.54, 0.71)] and for overall survival [HR of 0.65 (95% CI: 
0.54, 0.79)]. Hence, those results are in keeping with the fact that MSI holds a predictive value 
of response to 5FU, apart from its already-known prognostic value. Nevertheless, regarding 
MSI prognostic value, there have been 2 recent meta-analyses [239] [240] that doubt the 
prognostic significance of MSI status in stage II CRC. Gkekas et al. [239] state that MSI 
screening in stage II CRC cannot be routinely recommended as their meta-analysis concluded 
no overall benefit for disease-free survival or overall survival in general. 
MSI has been part of several CRC molecular classification models [80-82, 119], and it has 
been associated with several features. To start with, MSI-high CRC is primarily proximal, 
poorly differentiated, and has a higher incidence of female gender.  It also has mucinous 
differentiation, increased age of onset, and prominent nucleolus [69, 80-82, 127].   
With regard to MSI association with other biomarkers, MSI-high is paired with the CpG 
methylator phenotype (CIMP) [93] as well as BRAF V600E mutation, as indicated by a recent 
meta-analysis [93]. The association with CIMP is via the mechanism of hypermethylation of 
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MLH 1 homolog, as described previously. With regard to CIN, this is considered to be a 
different family with distinct features which will be discussed later on this chapter. According 
to Rosty et al. [85], KRAS mutant status is associated with more MSS (p<0.001, n=36). In 
contrary from 92 MSI-high cases, 83 were KRAS wild type (p<0.001). 
With regard to our findings, in both our cohorts who received radical surgery [77] or TEMS 
[104], MSI status played a limited role because both series were related to distally located 
specimens (rectal).  In the TEMS cohort, our specimens were microsatellite stable, which 
corresponds with other reports in the current literature; therefore, no further conclusions were 
drawn. In the second cohort of patients who received radical surgery +/- neo/adjuvant 
chemo/radiotherapy, only 1 case was MSI-High and 95 were MSS. Regarding associations, it 
was noted that MSI-H and overall preserved-MMR were associated with positive perineural 
invasion (p=0.021); however, this has limited value given the fact that it refers to only 1 case. 
On the subgroup Stage I analysis, all the cases demonstrated microsatellite stable phenotype 
and preserved MMR.   
In summary, MSI is a particular molecular pathway which is responsible for 15−22% of CRC 
cases [9, 119] because of its effect on the DNA repair system. Predominantly, MSI is a feature 
of proximal tumours, and its prognostic value seems to be accepted by the vast majority of the 
studies published in the literature. MSI-H is a favourable indicator of prognosis, and the 
absence of MMR defects is deemed as a poor prognostic feature. All but 1 of our specimens 
were MSS, which conforms to the current trend of the literature; therefore our contribution to 
novel knowledge on this particular biomarker was limited. MSI is known to be linked with 
BRAF V600E mutation, and in most cases it appears to coexist with wild type KRAS, although 
there have been many studies that link MSI-H with KRAS mutant. Finally, MSI is strongly 
related to CIMP-high, as the latter explains the molecular mechanism by which the MLH1 gene 
is affected in sporadic cancer.  
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9.8 Chromosomal instability patterns (CIN) − the hallmark of colorectal cancer 
CIN refers to a large proportion of colorectal tumorigenesis, and this is considered to be around 
85% [69, 80, 82, 130, 131, 169, 241]. The biological definition of CIN is any chromosomal 
losses or gains that result in aneuploidy or polyploidy, respectively [78]. A recent narrative 
review summarises all the evidence acquired during the last decade [241]. The background 
behind CIN is based on the somatic-copy-number-alterations (SCNA) that cancer cells display. 
SCNA includes any focal events that cause segmental instability or general aneuploidy. As a 
result, around 70% of colorectal tumours display significant internal heterogeneity and deviate 
from diploid karyotypes, and this phenomenon is explained by CIN mechanisms [241-243].  
Many studies consider CIN as a distinct mechanism of carcinogenesis [80, 82, 169], and 
tumours that do not encompass this mechanism are often classified as MSI-pattern tumours. 
As previously discussed, MSI involves all DNA repair mechanism failure, which includes 
mutations to DNA polymerase-ε and/or DNA polymerase-δ catalytic subunit 1 [241]. The MSI 
mechanism itself may cause the maximum instability that a cell can sustain before it drives to 
cell death.  
Understanding of this molecular mechanism includes the fundamental assumption that CIN is 
the reason for temporal and spatial diversification of tumour subclones via intratumour 
heterogeneity through SCNAs [241]. Also, CIN allows cancer cells to diversify their phenotype 
via segmental or whole-chromosome aneuploidy, and hence tumour cells can try different 
complex genetic makeups before they reach lethality [241]. On the other hand, this means that 
CIN aneuploidy can potentially concentrate a significant amount of DNA mutations, which 
convert the cancer cell to non-sustainable and cause tumour suppression. However, any 
chromosomal alteration leads to a variation in tumour cell potentials and therefore a poor 
predictive outcome of cancer treatments, as the cell may be resistant to the chemotherapy 
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agents [241]. CIN influences all immune-checkpoint inhibition, and a deeper understanding of 
this process will be a key factor in optimising cancer treatment in the future [241].   
In studies that delineate the CIN macroscopic features, CIN-positive tumours tend to have a 
poor prognosis and tend to be characterised as well or moderately differentiated [80]. Simons 
et al. [82] noted that CIN-only tumours occur slightly more frequently in males (54.7%) and 
76.5% are at least Stage II  when diagnosed. A study by Domingo et al. [80] makes the 
fundamental assumption that CIN is completely different from MSI cancer pathways. In our 
study, we have briefly explained the potential incompetence of the cell to accumulate both 
pathways. However, CIN+ tumours can be associated with TP53-mutant cancers to the CIN+ 
group. Domingo et al. did not find any negative association between KRAS or PIK3CA and 
CIN, and hence they divided the CIN group into KRAS/PIK3CA mutants and KRAS/PIK3CA 
wild type. Given the fact that TP53 has an inverse relationship with the KRAS pathway, they 
added the TP53 mutant to the KRAS wild type group and the TP53 wild type to the KRAS 
mutant group. 
A study by Simons et al. [82] describing 509 CRC tumours attempted to delineate the distinct 
types of CRC carcinogenesis. According to this study, 58.2% of the tumours followed the CIN-
only pathway and 13.4% adhered with CIN and CIMP. Increased poor survival rate was noted 
for CIN-only tumours, CIMP and CIN, triple-negative, and CIMP-only tumours. The 
maximum heterogeneity in terms of tumour groups was noted in CIMP, where there is a good 
mix of CIN (13.4%), MSI (12.6%), and CIMP-only (5.3%) cancers. 
In their meta-analysis, Walther et al. [242] conclude that CIN tumours have a worse prognosis 
compared to the other CRC subtypes. Exploring the way Walther et al. synthetised the 
evidence; 63 studies were included and 10,126 CRC cases were analysed. With regard to CIN+ 
subtype prognosis, a worse prognosis was reported for 54 of the 63 studies. The overall HR 
associated with CIN was 1.45 (95% CI 1.35−1.55, p<0.001. To emphasise the impact of CIN 
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on the prognosis itself, Walther et al. did a subgroup analysis comparing patients who had not 
received any treatment or studies before 1987 with non-metastatic cases who had rarely 
received any chemotherapy. The overall HR in this case was 1.66 (95% CI 1.41−1.95, p<0.001; 
Q=17.34, I2=36.6%, p=0.098), which shows robust evidence of poorer prognosis in CIN 
subtypes [242]. 
Another really important conclusion from the same meta-analysis is that there was no robust 
conclusion about the predictive (response to chemotherapy) value of CIN for 5-FU-based 
agents. 
In conclusion, CIN is a fundamental biomarker in CRC and a hallmark of oncology in general. 
Although we did not focus on CIN directly in our original cohorts, all our results were 
compared against the literature trends for the current classification models. 
  
9.9 Comparison of various clinicohistopathological data with the biomarkers 
panel (KRAS, BRAF, β-catenin, p16, MGMT, MMR/MSI) 
 
Although we have extensively discussed most of the biomarkers that we studied during our 
cohort analyses, it is interesting to see the impact of our biomarkers’ status on 
clinicohistopathological outcomes in a holistic way. In the first cohort of patients who received 
TEMS [104], our main biomarkers were KRAS, β-catenin, and p16. BRAF was wild type in 
all cases, so we did not draw any further conclusions. Similarly, all the specimens had MMR-
preserved and only 2 had MGMT non-preserved. MGMT non-preserved was associated with 
pT2 stage, although this can be attributed to sample limitations since it refers to only 2 cases 
(p=0.030). Therefore, there was no association between differentiation, dysplasia, tumour 
location, volume, or circumference, or excision margins with MGMT or MMR or p16 (p 
>0.05). Evidence across the literature is limited on these associations. A study by Chen et al. 
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[155] was one of the first to correlate clinicopathological data with methylation patterns and 
especially p16. More specifically, Chen et al. [155] associated the status of p16 promoter 
methylation with lymph node metastasis (p=0.002), histologic grade (p<0.001), tumour size 
(p=0.041) and location (p<0.001) as well as with stage of disease [TNM, (p=0.06)]. This is a 
promising finding that associates known histopathological parameters with the molecular 
background, from which significant conclusions can be drawn. 
Back to our study, the most important findings were based on KRAS status. The context of our 
cohort was 29 early rectal cancer cases (pT1 or pT2–Stage I) that received local excision 
treatment and only 3 cases additional neoadjuvant radiotherapy. The main associations between 
KRAS mutant status and histological features involving greater tumour circumference (30−80 
vs. 20−50%, p=0.000), pT stage, MRI pT stage, or tumour mass (cm3) were not associated with 
KRAS mutant status. However, the tumour’s mass (cm3) was higher in the case of mutant 
KRAS (159.250 vs. 17940, p=0.073), although this was not statically significant. 
With regard to the pilot study which consisted of 41 confirmed CRC cases [103] (any location), 
there was no statistically significant association between BRAF V600E mutation and LVI, 
although LVI positive  was associated with lower Hb (109 vs. 115.1g/dl). BRAF V600E 
mutation was found in right-sided tumours with advanced disease stage (T3b and above), which 
is the case described in the latest meta-analysis [93]. With regard to KRAS status, there was 
no evidence of any association between mutant (codon 12 or 13) status and disease stage as 
p>0.05 for any association. Currently, there is no clear evidence in the literature of any 
association of KRAS status and disease stage [85]. 
Finally, in the rectal cancer cohort who received neo/adjuvant chemo/radiotherapy +/- radical 
surgery [77], there was no clear association between KRAS mutant status and positive lymph 
nodes (LN) or ratio of positive lymph nodes/lymph nodes (+ve LN/LN). The latter (+ve 
LN/LN) was not associated directly with any of the biomarkers studies (KRAS, β-catenin, p16, 
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BRAF, MMR) as p>0.05 for any relationship. This study did not reveal any new associations 
between our biomarkers and the histopathological outcomes. There have been studies in the 
literature which associate histopathological features directly with KRAS, BRAF, p16, MGMT, 
or MMR status, as described previously. However, there is still very limited evidence on the 
relationship of those biomarkers with perineural invasion (PNI),  LVI, LN, or +ve LN/LN, and 
this is what we tried to delineate in this cohort. Further studies with larger cohorts may help in 
shedding light on the hidden link in the sequence of the events between molecular events and 
histopathological outcomes. A promising project towards this direction will be the 100K 
genome project, which will allow prospective gene mapping and a large, promising cohort of 
analysed cancer specimens across the UK [238, 244]. 
 
9.10    Conclusions 
As we are moving towards an era when screening and earlier diagnosis of CRC will have been 
achieved, understanding this particular cancer field will improve long-term survival outcomes 
and decrease morbidity. Furthermore, in the context of evolving surgical techniques and newer 
technology becoming available, local excision techniques have been greatly improved in the 
last 2 decades, allowing a “tissue-sparing” approach to be possible. There has also been rapid 
progression in oncology, and new chemotherapy or radiotherapy adjuncts and techniques are 
now available. In that context of rapidly evolving science, a multidisciplinary approach to 
rectal cancer becomes essential for optimal results. However, given the complexity of the 
cancer biology, specific and sensitive prognostic and predictive biomarkers in early rectal 
cancer become a real challenge. Although there are extensive studies on advanced cancer and 
the relevant biomarkers, there is still a long way to go in delineating the significance of the 
existing biomarkers in the case of early cancer stages. This will allow optimal stratification of 
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treatment and reduce recurrence risks, which are definitely higher in the case of local 
tissue−sparing techniques.  
One of our main findings is that KRAS mutant (codon 12 or 13) may be an important prognostic 
biomarker for early rectal cancer. This finding is something new, and definitely larger 
prospective studies are needed to evaluate how it can be useful and applied to clinical practice. 
KRAS is routinely tested in most of the cancer units in the UK for cases of positive histology. 
The question is whether early Stage I rectal cancers with mutant KRAS status follow a more 
aggressive pathway and whether they tend to reoccur either locally or distantly. Surprisingly 
enough, a similar finding came from the second cohort when we focused our analysis on early 
rectal cancer (stage I). Therefore, there is ground for a research hypothesis and a new, larger 
prospective study to take place in the future. 
Undoubtedly, aberrant methylation is one of the most promising hallmarks in the understanding 
of cancer biology. More and more sporadic cancers are explained by hypermethylation of 
several promoter regions of CpG islands, which affects various tumour suppressors and 
oncogenes. In our studies, β-catenin and p16 seem to be involved, and their expression deviates 
from normal. This underscores the fact that methylated protein products can be useful and 
important biomarkers even at the earliest stages. Although there are a few meta-analyses on 
this subject, a deeper understanding is required to reach robust explanations of their role. We 
found that a higher p16 expression trend is associated with higher chances of early recurrence 
after local excision, which is partially confirmed by the current trends in the literature. Β-
catenin expression can shift from membranous to nucleus; however, the time point at which 
this phenomenon occurs remains unclear. More recent articles state that this is the case early 
on in the disease process, and therefore attention to this biomarker must be given even for Stage 
I cancers. Our cohorts of early-stage tumours revealed that a predominantly membranous β-
catenin with an element of nucleus holds prognostic value. This may represent the beginning 
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of the process, and nucleus β-catenin is evolving as the predominant localization in later phases 
of carcinogenesis. 
Finally, we suggested that unexplained IDA in the case of suspected cancer can be associated 
with BRAF V600E and right-sided advanced cancer. As we are shifting into an era of non-
invasive CRC screening in which more DNA stool tests are becoming available, BRAF V600E 




However, we recognise the limitations in our studies; most of the limitations have been 
discussed in each chapter separately. In general, the size of the 3 original cohorts can be 
considered as small (cohort 1: 41 specimens, TEMS cohort 2: 29 specimens, Rectal cancer 
cohort 135 specimens); nevertheless, most of TEMS original series reported in the literature 
are limited in terms of number of specimens. 
Also, some of the studies incorporate retrospective collection. To optimize accuracy of data, 
most of the cases, especially in the TEMS cohort, were discussed both with the senior surgeon 
who performed the procedures (SP), as well as with the consultant histopathologist who 
interpreted the original histopathology. As this thesis was based on a single tertiary institution, 
we focused on samples from the local population. This can be a question for external validity, 
however, the representativeness of our population is adequate, given the fact that KCH is an 
international institution, and the geographic region cover a widely diverse population. Finally, 
with regards to statistical methodology, we focused on univariate inferential statistics as the 
sample size did not allow multivariate modelling. However, this was interpreted in the context 
of a deep understanding of the background (molecular biomarkers), which ensured that all our 
conclusions were drawn appropriately. 
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There were also some missing data in terms of molecular biomarkers, which unfortunately was 
attributed to cost implications. However, in most cases the data were available for analysis 
(either de novo lab-based work analysis, or some pre-analyzed biomarkers in the last cohort), 
and on top of that, the quality was extremely high, as all the results were double validated by 
JM who is an experienced senior scientist (Director of the Advanced Diagnostics Lab).  
 
9.12 Future work 
 
As in every other study in molecular oncology, this piece of work generates several and 
valuable questions. Further research is vital to delineate the significance of current biomarkers 
in early cancer cohorts. Also, identification of new biomarkers remains a hot topic in oncology, 
which may benefit from emerging evidence from miRNA molecular biology or metabolomics. 
Combining results from multiple centres, or equally retrospective synthetising of existing 
evidence using advanced statistics (individual Patients’ Data – iPD meta-analysis) will help in 
developing an ultimate prediction model in which cancer treatment will be personalised to 
optimise survival, minimise morbidity, and improve patients’ experience. Finally, as 
previously discussed, artificial intelligence and “big data” research methodology is rapidly 
evolving, allowing more questions to be answers via using advanced technology. 
We do not know how far this may lead; however, a rapidly evolving multidisciplinary 
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